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The gap in knowledge for pediatric mechanical ventilation (MV) management makes 
practice standardization difficult. The European Society for Pediatric and Neonatal Intensive 
Care (ESPNIC) was the first to establish consensus recommendations on pediatric MV 
management. In Canada, respiratory therapists (RTs) have a large role in MV management, but 
do not exist in Europe. The purpose was to determine Canadian RTs’ recommendations on 
common pediatric MV management.   
An e-Delphi study included n=56 participants from 15 Canadian pediatric facilities. All 
statements achieved consensus and this guideline consists of 59 recommendations, organized 
into 10 subsections: Non-invasive ventilation; tidal volumes and inspiratory pressures; 
respiratory rate and inspiratory time; PEEP and FiO2; Advanced Mechanical Ventilation; 
Weaning; Physiologic Targets; Monitoring; General MV practice and Equipment adjuncts. 
These commonly practiced pediatric MV techniques by RTs may be used as a standard 
for future clinical practice and studies to understand their clinical impact in critically ill children.    
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1.0 Introduction to Thesis 
1.1 Overview of Pediatric Mechanical Ventilation  
 Mechanical ventilation (MV) is a life-sustaining treatment, used to assist critically ill 
patients when they are in respiratory failure and unable to breathe on their own (1-3). Respiratory 
failure is a common cause for pediatric intensive care until (PICU) admission and is associated 
with increased mortality in the pediatric population (2, 4, 5). Children with difficulty or failure to 
sustain adequate spontaneous breathing require MV (1, 4). MV may be provided non-invasively 
(e.g. mask, nasal prongs) and invasively (e.g. endotracheal tube) (2, 4, 6) and can further be 
classified by the mode and settings delivered by different devices for different ranges of diseases 
(4, 6-8). MV management is quite sophisticated and dynamic; appropriate knowledge and skills 
are required to safely, efficiently and continuously treat patients using MV (9, 10). 
 Inconsistent use of MV may lead to negative consequences including ventilator 
associated pneumonia, ventilator induced lung injury, sedation complications, longer hospital 
stay and increased mortality (1, 3, 11, 12). Therefore, it is crucial that MV therapy is managed 
effectively using standardized approaches across patients, to improve safety and efficiency (2, 3). 
Standardization of practices is difficult because of the many components of pediatric MV 
management. In addition, there is limited evidence to determine the best pediatric MV practices 
as children vary in size, maturity and underlying conditions  (6, 7, 13, 14). Though limited, a few 
systematic reviews, meta-analyses and clinical trials have suggested that standardized pediatric 
MV practices may improve clinical outcomes (1, 9, 15).  
 
1.2 Statement of problem 
Currently, there is an evidence gap for pediatric MV management, making standardized 
practices difficult (6, 16). Often common clinical practices for pediatric MV management are 
adopted from clinical experience and evidence from neonates and adults (2, 4, 17). The European 
Society for Pediatric and Neonatal Intensive Care (ESPNIC)(6) is one of the first groups to 
establish consensus recommendations on many aspects of pediatric MV management. However, 
there are minimal studies to support the use of protocolized MV management in critically ill 
children and their associated outcomes. There are a few studies that report clinical outcomes on 
the different subtopics of MV, in different diseases (1, 7, 15, 18-22). Although protocols and 
guidelines are available, they vary across different centers and not integrated within the practice 
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culture (11, 23, 24). Potential barriers to successful implementation may include: not considering 
the social and cultural work environment, the intensivists’ level of acceptability to the protocol, 
and lack of large multicenter data to support the practice (11, 21, 23-25). This inconsistency of 
MV practices make it difficult to determine which method is best, and which are associated with 
adverse events. Therefore, minimizing practice variability may improve patients’ safety, 
treatment efficiency and clinical outcomes (9, 15, 18, 25).  
In Canada, RTs are considered one of the experts in MV management, whereas in 
Europe, they do not exist. The ESPNIC recommendations are from the perspectives of European 
physicians only. It would be of significance for Canadian RTs to compare their perspectives with 
ESPNIC’s to determine specific approaches to expedite the knowledge and standardization in 
pediatric MV practices in Canada.  
 
1.2 Purpose 
 The purpose of this study was to determine Canadian RTs recommendations on common 
pediatric MV management, based on the European (ESPNIC) (6) consensus guidelines. It is 
anticipated this information will guide future research to facilitate the standardization of MV 
management practices.   
 
1.3 Research Question 
What are Canadian RTs consensus recommendations on pediatric MV practice and 
management in critical care?  
 
1.4 Research Hypothesis  
It was hypothesized that by the end of Round 2 (26, 27), Canadian RTs would reach 
consensus (75% agreement) on pediatric MV recommendations.  
 
1.5 Impact and Significance 
This study highlights Canadian RTs’ perspectives on pediatric MV management, based 
on the consensus recommendations from Europe. These common practices can be used to inform 
standardized protocols, used in future studies to measure their efficacy and clinical impacts in 
pediatric critical care environments. 
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1.6 Methodology   
Not all questions can be answered by conventional quantitative research methods, and 
many times, limited conflicting data make it difficult to understand and guide practices (28, 29). 
Expert consensus group methods such as the Delphi technique is considered an appropriate and 
accepted approach to compile available information to address clinical problems and 
management in health sciences (28-30). There are several different versions of the Delphi 
techniques, with the Classical and Modified Delphi techniques as the most popular (27, 31-34). 
Any form of the Delphi study delivered in an electronic format is called an electronic Delphi (e-
Delphi) (27, 35). 
The Delphi technique is a well-recognized method used to identify solutions and 
priorities in medical and nursing research since the 1970s (27, 34). It is used as a tool to identify, 
understand and establish guidelines and priorities in speciality practices (e.g. mental health, 
palliative care, critical care), predict disease patterns, direct nursing education, and standardize 
practices and policies (27, 34, 36). It is based on the principle that combined intelligence is 
superior and reliable, compared to anecdotal experiences (26, 37, 38). The structured system for 
participant feedback specifically minimizes the effect of noise and bias by maintaining 
anonymity amongst participants (26, 39).  In contrast, other consensus gathering methods, such 
as focus groups or committees, are prone to bias and influence from dominating figures at 
meetings (40). Using a Delphi technique is time efficient, cost-effective and convenient when 
participants are geographically dispersed (27, 34, 38, 41, 42).  
The Delphi technique utilizes a series of surveys, referred to as Rounds, to gather 
controlled feedback (opinions and feedback) from a group of participants, identified as experts in 
the field (43). This technique enables discussions, and guides future approaches in areas with 
unknown or not well supported evidence (30, 40, 44); it combines existing information and 
experiences to address the lack of knowledge in a particular area (26, 27, 35, 42). The number of 
Round iterations vary across studies, but it is suggested that further Rounds are terminated once 
consensus is achieved or after a predetermined number of Rounds is met (26, 27, 39).  
A 3 Round Modified e-Delphi technique was used in this study (Figure 1). The ideas and 
topics for the Modified Delphi were derived from the literature (27) and existing ESPNIC 
consensus guideline. Round 1 used a qualitative approach, where participants were asked to 
provide open-text feedback on survey topics, in order to form the contents for the subsequent 
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Rounds (26, 35). Subsequent Rounds were quantitative in nature; participants were asked to rate 
their level of agreement or disagreement using a 5-point Likert scale (26, 27, 35). At the end of 
Round 2 and Round 3, descriptive statistics, measures of central tendencies and consensus for 
each item were reported. Items in Round 2 that did not receive consensus (75% agreement) 
were revised and included for Round 3 (33, 35, 39). Statements that achieved consensus in 
Round 2 were removed from Round 3 to minimize the length of the survey (27, 45). The study 
was terminated after completion of Round 3 as consensus was achieved across all survey items. 
An overview of the study was presented in a video presentation and the finalized 
recommendations and their consensus distributions were summarized in a report for participants 
to review for additional comments or remarks.  
 
1.7 Outline of Thesis  
This thesis provides an overview of the existing pediatric MV management literature, and 
the rationale and importance for undertaking the Modified e-Delphi study to establish Canadian 
pediatric MV management guidelines from the RT perspective. Chapter 2 highlights the existing 
knowledge gap in pediatric MV management, the known effects of protocolized MV 
interventions, clinicians’ engagement in providing protocolized MV and an overview of the role 
of RTs in MV practices. Chapter 3 elaborates on the Modified e-Delphi methodology, and 
Chapter 4 (4.2 Methods) describes its appropriateness to fulfill the purposes of this study. 
Additionally, Chapter 4 presents the details of this research project, including an in-depth 
discussion of the results and the implications of the Canadian RT-consensus MV management 
guideline. A finalized manuscript version of Chapter 4 will be revised and submitted to the 
Respiratory Care Journal and/or the Canadian Journal of Respiratory Therapists. Chapter 5, the 
final chapter provides an overview summary of this thesis. Chapters 6 to 8 provide the finalized 
guideline, supplementary data and study documents.  
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Figure 1: Delphi study process. 
 
 
Process derived from Hsu and Sandford, 2007 (26); Keeney, Hasson and McKenna, 2011 (27); 
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2.1 Introduction and Search strategy 
 
Defining the Key terms for literature search: 
Mechanical ventilation (MV) is an intensive life supportive treatment for patients who are 
critically ill and unable to sustain spontaneous breathing required for life (1-4). MV can be 
provided non-invasively or invasively, through different devices, modes, and settings (2, 3, 5).  
Invasive MV modes (delivered through an endotracheal tube) include, but are not limited to, high 
frequency oscillatory/ jet ventilation (HFOV/ HFJV), pressure control (PC)/ support (PS), 
volume control (VC), pressure regulated volume control (PRVC), synchronized intermittent 
mandatory ventilation (SIMV), proportional assist ventilation (PAV), airway pressure release 
ventilation (APRV), or neurally adjusted ventilatory assist (NAVA). Non-invasive MV 
(delivered through nasal or facial interfaces) includes interventions such as high-flow nasal 
cannula oxygen therapy (HFNC), bi-level positive pressure ventilation (PPV), continuous 
positive airway pressure (CPAP) or non-invasive NAVA. The term “MV management” includes 
management of all of these different components.  
The pediatric population is a group of children from infancy (greater than 28 days after 
birth) to 18 years of age (6, 7). Though the age limit of the pediatric population varies across 
studies, many studies use 18 years old as the higher limit (2, 8). However, this upper limit is 
arbitrary and may extend past 18, up to 21 years or older if a child requires special health needs 
from a pediatrician (as defined by the Canadian Pediatric Society and American Academy of 
Pediatrics) (7, 9). 
Standardized practices are harmonized approaches to ensure consistent treatment and 
management in specific medical conditions (2). To enforce standardized practices, protocols and 
guidelines may be developed through expert consensus, and using current evidence to inform 
care in specific patient populations (10).   
 
Search approach: 
The following approach was used to search and obtain relevant articles pertaining to the 
key terms defined previously. The first search was run on October 27 2019 and updated on 




Key terms used:  
Combinations of key terms were used to search for articles in a variety of databases. Search 
terms included controlled vocabulary e.g. Medical Subject Heading (MeSH) and keywords 
related to standardized pediatric mechanical ventilation. The following key terms were used: 
• Pediatrics, paediatrics, children (in critical care, intensive care) 
• Mechanical ventilation, mechanical respiration, artificial ventilation  
• Standardized guidelines, protocols, recommendations, consensus  
 
Databases: 
Articles were searched and selected from the following databases: 
• PubMed 
• Embase Classic and Embase (1947 to 2021) 
• Ovid MEDLINE 
• Cochrane library (Reviews and Trials) 
• Cumulative Index to Nursing and Allied Health Literature (CINAHL) 
 
Eligibility Criteria: 
Search results were screened manually via titles and abstracts. Articles were primary or 
secondary in nature, but only articles that satisfied the criteria outlined in below were included. 
Similarly, additional resources were screened for and selected through the references lists of 
eligible articles.  
 
Types of participants 
Only articles that identified children (of any age) receiving MV care in the PICU were 
included. Studies identifying neonates or newborns (birth to 28 days of age) as their primary 
population of interest were excluded as their MV management differs to older children (1). 





Types of interventions 
The intervention of interest was protocolized/ standardized MV management, including 
computer-driven protocols. Since MV includes many forms and settings delivered by different 
devices, studies that investigated any protocolized MV technique (e.g. mode, settings, strategies) 
were included (2, 3, 5, 8). Medical treatments that were not a form of MV were excluded, such 
medications, nutrition, and physiotherapy. 
 
Type of Comparisons 
Protocolized MV management were compared to non-protocolized invasive or non-
invasive MV management, which includes but were not limited to, physician-driven care or non-
protocol directed MV management.  
 
Types of outcome measures 
Trials were included if they evaluated clinical outcomes of standardized pediatric MV 
therapies and management e.g. number of adverse events, duration of MV, length of PICU stay, 
length of hospital stay, quality indicators, mortality etc. 
 
Study Designs 
Eligible articles were retrospective or prospective in design, interventional or 
observational, including systematic reviews, meta-analyses, randomized controlled trials, 
interventional trials, cohorts, case report, control and cross-sectional studies. Reviews and 
documents from working groups or conferences, consensus guidelines/ recommendations, or 
protocols on any aspect of pediatric MV management were acceptable. Articles of the 
commentary, editorial and newsletter nature were not included.  
 
Other requirements of eligibility 
Articles were in English, from peer-reviewed journals and published within the last 20 
years, 2000 until present day (to identify recent practices and research). The details of the 
inclusion and exclusion criteria for the articles included for this literature review are summarized 




To further identify relevant articles or studies, reference lists of screened and accepted 
articles were reviewed for eligibility.  
 
2.2 Search Results: 
The search generated a total of 1092 articles from the databases and 31 articles from 
other sources. Included articles (n=83) consisted of five systematic reviews (two with a meta-
analysis), five randomized controlled trial (RCTs), nine interventional (including pilot) studies, 
three observational studies, two retrospective analyses, 37 literature reviews (one with case 
studies), 13 survey studies, one thesis manuscript and eight consensus guidelines for different 
MV therapies of pediatric MV management in specific diseases. This information is displayed in 
Figure 2 and Supplementary table 1B. 
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Figure 2: Flow diagram of literature search 
 
2.3 Literature review: 
This section will provide background information and statistics for the topics of: 1) 
critically ill children, along with the challenges associated with their inclusion in research; 2) the 
indications and concepts of pediatric MV; 3) pediatric MV management and their associated 
health outcomes divided into subsections: (a) available modes and settings; (b) weaning; (c) 
management in specific disease groups, including pediatric acute respiratory distress syndrome 
(PARDS), bronchiolitis, and asthma; 4) clinician engagement and perceptions on the use of 
protocolized MV management; and 5) the role of respiratory therapists (RT) in MV management.  
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2.3.1 Topic 1 - Critically Ill Children  
The Canadian Pediatric Society (CPS) reports that children are traditionally an 
underserved population in health research (6). Children are considered a vulnerable population, 
and usually have additional safeguards that limit their participation in clinical studies, compared 
to adults (11, 12). Participants of research must have the cognitive capacity to make informed 
decisions to provide consent or assent(6, 12, 13). This raises ethical concerns, as children may 
not have the competence to make informed decisions and be at risk for coercion because they are 
cognitively undeveloped (13, 14). Therefore, consent or assent from children are usually taken 
with the agreement of their legal guardian (11, 12). Complications occur when a child has the 
cognitive ability to make a decision, but provincial laws prevent this by defining the minimum 
age required for children to make legal decisions without parental consent (11).  
Critically ill children are severely sick children who require PICU admission and 
complex care (12, 15). Although the overall PICU mortality has declined in recent decades, there 
are higher incidences of morbidity after PICU discharge (16-18). The Canadian Institute for 
Health Information (CIHI) reported that 171,786 children, under the age of 17, were hospitalized 
across Canada in 2018 (19). The CIHI estimates that around 12,000 children were readmitted for 
complications related to respiratory diseases, surgical interventions and newborn conditions. This 
data does not specify the number of children who require critical care attention; epidemiology of 
critically ill children is not well reported (18). A longitudinal study conducted by the Mayo 
Clinic Children’s Hospital reported that children under the age of one have the highest incidence 
of PICU admission compared to other ages, and a mortality of 3% (18). In the five year period at 
the Mayo Clinic Children’s Hospital, respiratory problems were the most common reason for 
PICU admission (2003-2007). Even after hospital discharge, children who were previously 
critically ill are at risk of developing complications. A cohort study by the National Institute of 
Child Health and Human Development Collaborative Pediatric Critical Care Research Network 
(CPCCRN) described the contributing factors to the morbidity and mortality of critically ill 
children (16). Out of the 292 children included in their cohort, 117 (40.1%) died, with 175 
(59.9%) presenting with new morbidities by discharge. The pathophysiological contributors in 
the cohort were low cardiac output, cardiac arrests and inflammatory complications from sepsis, 
respiratory failure, acute respiratory distress syndrome or multiple organ dysfunction.  
Research with critically ill children presents many challenges (11, 13, 14). The critical 
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care environment makes it difficult for researchers to approach family and guardians due to the 
extreme stress and lack of time (11, 17). These challenges are demonstrated in a RCT aimed at 
measuring the effect of protocol-directed weaning in infants (20). Only eight infants (age 2 to 8 
weeks) were successfully enrolled and randomized into the protocol-directed (n=3) or physician 
directed (n=4, with n=1 died) interventional groups. Although RCT is a gold-standard research 
design, the authors suggested that the restrictive eligibility criteria, ethical constraints and 
parental refusal were several potential barriers to successful recruitment in their study. Parents of 
the critically ill infants could not be approached until 24 hours after PICU admission, and this 
waiting period was enforced by the facility’s ethical committee to allow parents to become 
accustomed to the stressful PICU environment and to their child’s illness. However, the waiting 
period led to the loss of several potential participants and limited the opportunity for the 
researchers to build a positive relationship with the parents. This may have led to a lack of trust 
the parents had for the researchers who were not their child’s physician, but study consent 
obtained by the physician poses several ethical concerns. Therefore, poor patient enrollment and 
small sample size prevented the authors from reporting any study outcomes. They suggested 
future studies were needed to evaluate the best research approach to ensure successful 
recruitment to measure the effectiveness of protocolized weaning or any MV intervention. 
Because of these challenges presented above, many of the treatment options for sick 
children are not evidence based (17). Many of the practices in place are based on the 
extrapolation of animal or adult data, which is inappropriate as children do not share the same 
physiological maturity as adults (17, 21). Furthermore, children vary greatly in size, maturity and 
underlying conditions across a large age range, making it difficult to recommend the best 
treatments for all critically ill children (6, 14). Therefore, it is necessary to continue to research 
in critically ill children to improve the quality of data and enhance treatments (17).  
   
2.3.2 Topic 2- Pediatric MV  
Respiratory failure is a common cause of PICU admission and mortality in the pediatric 
population (4, 5, 18). In comparison to adults, children have a higher risk of developing 
respiratory failure, as they are physiologically immature (3, 4, 22). Children presenting with 
breathing difficulties or impending failure require MV (1, 5), and about 30% (3)of children 
admitted into the PICU require it to manage respiratory distress and resolve pulmonary disorders 
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(3, 4, 22, 23).  
MV can be described as a respiratory life-support therapy, used to provide patients with 
adequate gas exchange for the function of vital organs, and to alleviate respiratory distress for 
different respiratory etiologies (4, 22). MV is an umbrella term to describe a variety of 
respiratory support treatments, settings and modes that are provided across different devices and 
ventilator models (2, 5, 8, 24). Children may be provided non-invasive and/or invasive options to 
resolve their underlying respiratory issue during their PICU care (25) (see also Section 2.3.3c 
Topic 3c - MV in Specific Diseases). 
MV use and management are sophisticated and dynamic; appropriate and standardized 
knowledge and skills are required to safely, efficiently and continuously treat patients without 
generating complications (26, 27). Over the last few decades, the optimal risk and benefits 
associated with using MV are better understood, but there continues to be minimal or conflicting 
data on their use and impact in the pediatric population (3-5, 22, 26). A widely accepted 
guideline detailing all the available modes and settings to treat and support critically ill children 
is not available (2, 5, 28). Therefore, uncertainties exist about the best MV practices for their 
management, and variabilities exist across centers due to adopting practices from adult data or 
clinicians’ experiences (3-5, 29-31).  
Inconsistencies in pediatric MV management can be explained by several factors. First, 
the vulnerable nature of this population; they are usually protected and excluded from studies 
due to the difficulty in obtaining consent (see 2.3.1 Topic 1 - Critically Ill Children) (17, 21). 
Children also vary greatly in size, maturity, anatomy, physiology and underlying conditions at a 
given age, limiting the applicability of study interventions (2, 7, 9, 14, 32). Secondly, there is a 
broad variety of devices, settings and mode options available for a wide spectrum of pediatric 
diseases (4). The choice of MV therapy to manage a child will also differ across critical care 
teams (3, 4, 8, 33, 34). Even when facilities have protocols and guidelines in place, they may not 
be integrated within the practice culture, resulting in variation in practice (29, 35, 36). Despite 
these limiting factors, more research is required to understand the optimal MV management 




2.3.3 Topic 3- Pediatric MV management and Patient Outcomes 
The different types of pediatric MV management techniques (across various disease 
groups) are mainly presented in narrative literature reviews, surveys and case studies (29, 32, 33, 
37-46). These only offer a broad summary of different MV treatments, settings and modes for all 
children and do not provide clear practice recommendations (5, 23, 40, 47, 48). There are 
recommendation guidelines available, but they are limited in numbers and for specific diseases 
(24, 49-51). Guidelines for specific practices such as managing particular modes or settings (e.g. 
indications, initiation time, level of support, weaning time) are required across all critically ill 
children (29, 32, 40, 42, 52).  
The following subtopics sections will describe studies for different components of 
pediatric MV management including different modes, settings and adjunct therapies (e.g. NIV, 
HFNC), weaning techniques and MV management in specific pediatric diseases. 
 
2.3.3a Topic 3a- MV Modes and Settings 
A systematic review and meta-analysis published in 2011 (421 critically ill children, five 
clinical trials) evaluated the impact of different MV mode on the length of stay, oxygenation, 
ventilation duration and mortality (8). Six specific ventilation modes were used across these 
studies, which were high frequency ventilation modes (HFOV, volume diffusive respirator) and 
four conventional ventilation modes (PC, PS, VS and bilevel positive airway pressure). 
Participants included in these studies ranged from 0 to 23 years of age, and were diagnosed with 
air leak syndrome, acute hypoxemic respiratory failure, inhalation injury and/or weaning failure. 
There were no significant differences between the high frequency ventilation and conventional 
ventilation modes on mortality (three studies, odds ratio [OR] 0.7, 95% confidence interval [CI] 
= 0.33 to 1.47). Conventional ventilation was found to have significantly lower length of 
ventilation compared to HFOV (four studies, weight mean difference -2.3 days, 95% CI= -3.63 
to -1.04). HFOV was associated with improved oxygenation after 72 hours compared to other 
methods of ventilation, but heterogeneity between the three studies limit definitive conclusions. 
Limited evidence prevented a recommendation on the best MV mode in critically ill children 
immediately after the newborn period. They suggest future studies should investigate the best 
ventilation strategies for age specific ranges and disease pathologies, measuring the same 
outcomes. 
In a pre and post intervention study by Smith et al (53), a NIV protocol for children 
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presenting with respiratory failure in the intermediate care unit (IMCU) was created to help with 
clinical decision making and optimize patient outcomes. It included 207 children with an average 
age 8.3 years (range 2.4 to 14.5), with the most common diagnosis of pneumonia. Data for the 
study was collected for 4.5 years following NIV guideline implementation, and was compared to 
the data 3.25 years before guideline introduction. There was a decrease in overall hospital stay (-
49.52 days, p=0.03), and a decrease in intubation rates (3 vs. 0 patients, p=0.035) post-
intervention. Although the study showed a NIV protocol improved patient outcomes, it may not 
be applicable in the PICU as it took place in an IMCU where traditionally MV is not initiated. 
The purpose of their guideline was meant to guide NIV use in the IMCU to reduce PICU 
resource and bed use. Nonetheless, Smith et al (53) demonstrated that the use of a NIV protocol 
was safe, and provided positive health outcomes with reduced resource use.  
In a retrospective study, a total of 848 children (age range 4.1-4.8 years) presenting with 
respiratory failure in 2006 to 2009 were separated into three cohort groups: cohort 1- prior to 
HFNC availability, cohort 2- pre-HFNC guidelines and cohort 3- after HFNC guideline 
implantation (54). The cohort groups were compared to determine whether HFNC plus the use of 
a HFNC guideline made a difference to health outcomes. There was an 83% decrease in 
intubation rates in cohort 3 compared to cohort 1 (OR 0.17, 95% CI=0.06 to 0.5, p<0.001). There 
were no significant changes in the health outcomes between cohort 2 and cohort 1 (OR 0.98, 
95% CI= 0.39 to 2.45, p=0.97). When comparing the intubation rate across different respiratory 
illnesses, there were decreases in cohort 3 compared to cohort 1 in patients with asthma (0.6% 
vs. 5%, p=0.03) and bronchiolitis (10% vs. 21%, p=0.05). In addition, there was a decrease in the 
ventilator-utilization ratio (proportion of ventilator days to total patient days) after HFNC 
guideline implementation, seen in the difference between cohort 1 (0.41) and cohort 3 (0.21, 
p<0.001). Although the results did not show changes in the length of stay or mortality, guideline 
implementation showed promising effects on intubation rates in certain disease groups.  
There are a large number of narrative literature reviews, surveys and case studies on 
pediatric MV. A guideline from the Japanese Respiratory Society (49) detailed the indications 
and settings of NIV across various clinical conditions and diseases for adults and children; 
however, there were only a few sections dedicated to its use in children. Another guideline 
described prevention and treatment options for skin lesions caused by NIV interfaces, but did not 
focus on MV management (55). A narrative review (plus case report) on NIV provided an 
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overview of the indications (pathophysiology) for  NIV, along with different modalities to 
consider for MV management (42). Other NIV narrative reviews have provided overviews of 
current evidence, and information on the contraindications, indications, interfaces, monitoring 
parameters and modalities available for children across various diseases (4, 23, 47, 48, 56-61). 
Several others present details about the goals, and mechanism of action of NIV therapy and the 
different interfaces (55, 58, 59, 61). Like NIV, there are various case studies and literature 
reviews describing different invasive MV modalities (4, 22, 23, 46). Several of these narrative 
reviews provide suggestions for MV techniques including monitoring equipment, weaning 
options, lung protective strategies, lung recruitment, or modalities such as PC, PS, NAVA, 
HFJV, HFOV, and APRV  (4, 25, 44, 62, 63). Two topic-specific narrative reviews looked at 
MV protective lung strategies to minimize lung injury in children (62, 63). These reviews and 
case reports all provide valuable overviews, but verifying the impact of different MV therapies 
with larger clinical studies is needed (4, 25). Descriptions for all the articles discussed in this 
subtopic are found in the table below (Table 1).   
 
Table 1: Articles and reviews discussed in Chapter 2, Subtopic 3a - MV modes 











across 5 trials 




HFOV, PC, PS, 
VS, VDR, NIV 
• no difference in the length of stay, mortality 
or survival rate associated with any 
particular MV mode 
• pool analysis for the mortality rate between 
HFOV vs. conventional MV (3 studies) OR 
0.7 (95% CI=0.33-1.47)  
• Conventional MV vs. HFOV for length of 
stay (4 studies) for weight mean difference  -
2.3 days (95% CI=-3.63 to -1.04) 
• HFOV may have provided improvements in 
oxygenation, but heterogeneity in the studies 
made the conclusions inconclusive  
• there was limited evidence to suggest which 
MV mode was the best to minimize 
mortality, survival rates and length of stay  







(8.3 years, range 




• a NIV protocol was introduced to guide 
clinical decisions and optimize patient 
outcomes in children presenting with 
respiratory failure in intermediate care unit  
• data from 3.25 years prior and 4.5 years 
following the NIV protocol implementation 
were collected  
• overall decrease in hospital stay (49.52 days, 
p=0.03), and intubation rates (3 vs. 0 
patients, p=0.035)   
• this study suggested that a NIV protocol to 
guide clinical decisions may provide 
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positive health outcomes and reduce 
resource use 
• one limitation was that the protocol was 
trialed in an intermediate care unit, where 
NIV is not traditionally used 







Analysis of 3 
cohort groups: 








• children presenting with respiratory failure 
were separated into 3 cohort groups to 
compare their effects on health outcomes  
• improved health outcomes in cohort 2 and 3 
(when HFNC was available) 
• 83% decrease in intubation rates in cohort 3 
compared to 1 OR 0.17 (95% CI=0.06 to 
0.5), p<0.001 
• no differences between cohort 1 and 2, OR 
0.98 (95% CI=0.39 to 2.45), p=0.97 
• decreased intubation rates in children with 
asthma (6% vs 5%, p=0.03) and 
bronchiolitis (10% vs. 21%, p=0.05) in 
cohort 3 compared to 1 
• decreased in ventilator days/ total patients 
day in cohort 3 (0.21) vs. cohort 1 (0.41), 
p<0.001 
• no significant changes in mortality or 
median PICU stay 
Akashiba et al, 
2017 (49) 
Guideline - - • 24 recommendations of NIV use in adults 
and children, supported by existing evidence  
• recommendations for children in acute 
respiratory failure and neuromuscular 
diseases  
Raurell-Torredà 
et al, 2017 (55) 
Guideline  - - • Recommendation guide on prevention and 
treatment of skin lesions for patients using 
NIV 
• not specifically written for children, but the 
principles outlined may be applied  
• overview of the pathophysiology involved in 
skin damage from NIV interfaces, 
preventative measures, interface selection 
and treatment  




- • a case report of an infant (day 15 of life) that 
presented with nasal congestion, cough and 
apnea; the infant was treated with HFNC 
• described the pathophysiology involved in 
acute respiratory illnesses in children and 
infants, NIV, their initial settings and 
complication prevention 
• author elaborated on the potential 
treatments, which were NIV (i.e. CPAP, 
bilevel) and HFNC  
• evidence and review of the literature on the 
use of NIV and HFNC were discussed  
• literature review revealed these forms of 
NIV can be used in children with asthma, 
bronchiolitis, pneumonia, PARDS, 
respiratory failure, post-operatively and in 
neuromuscular diseases, with varying levels 
of evidence  
• emphasis on the interprofessional 
management required to successfully 
monitor any children on NIV therapies 
• recommendations on the initial settings 
could not be made 
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- -  • presented the views and efficacy on NIV use 
in children with respiratory failure due to 
different conditions  
• based on the reviewers’ experience, NIV use 
depended on the physician, disease severity, 
risk of PARDS, oxygen requirements, 
comorbidities and NIV response 
• NIV may be provided in the early stages of 





- - • evaluated the use of NIV in children with 
respiratory failure, cystic fibrosis, sleep 
apnea, upper airway obstruction, and chronic 
respiratory distress 
• important factors to consider are the 
indications for NIV, monitoring parameters, 
interface selection, initiation settings, 
ventilator/ mode selection and 
humidification  
• for initial settings, bilevel pressures should 
be set to offload respiratory muscles yet 
optimize comfort (2-4 cmH2O above PEEP) 
• NIV in children is a promising therapy, but 
lacks high quality clinical data to support its 






- - • assessed pediatric MV publications and 
adult studies that may be applied in children  
• NIV may be used for children with 
appropriate level of consciousness  
• lower tidal volumes (lung protective) were 
used in adults, but their protective effects 
were not confirmed in children 
• lung recruitment maneuvers were adjuncts to 
lung protective strategies, and may provide 
benefits in certain clinical situations  
• HFOV should be considered a rescue 
therapy for patients who continue to fail 
conventional MV 
• APRV is relatively new and more studies are 
required to understand their benefits   
• MV weaning protocols may reduce MV time 
(adult studies) compared to physician 
directed weaning but there were minimal 
randomized controlled trials to demonstrate 







- - • provided the details of NIV objectives, 
indications, contraindications, advantages, 
interface selection, management and failure 
• described the available types of NIV modes 
(i.e. CPAP, bilevel, spontaneous assisted, 
controlled assisted, controlled mechanical), 
but did not indicate which is best  
• the authors provided suggestions for initial 
setting parameters, but they must be 
individually tailored  




- - • summary of NIV including the description, 
mechanism of action, interface selection, 
goals of therapy, benefits over invasive MV, 
and an overview of the available modes  
• comparison between CPAP vs. bilevel use, 
their indications, and initial settings  
• NIV may reduce work of breathing, improve 
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cardiac output, increase functional residual 
capacity, reverse hypoventilation and 
maintain airway patency 
Fedor 2017 (57) Literature 
Review  
- - • review on the use of NIV in infants and 
children and different indications for NIV, 
including asthma, bronchiolitis, PARDS, 
cystic fibrosis, obstructive sleep apnea, 
neuromuscular disorders, cardiac diseases  
• other factors to consider when initiating NIV 
were interfaces, delivery devices and 
challenges with comfort and adherence  
• description of monitoring, NIV management 
and alternatives to ensure safe use  




-  -  • describe the use of NIV from RT perspective  
• indications (signs and symptoms) in children 
with respiratory failure  
• highlighted the key features to consider 
when selecting interfaces (e.g. nasal vs. 
mask, skin integrity, comfort)  






- - • discussed the applications and advantages 
between conventional NIV (i.e. CPAP, 
bilevel) compared to HFNC in children with 
acute respiratory failure  
• elaborative discussion on the mechanism of 
action, clinical indications, interface choices, 
monitoring and their benefits in 
conventional NIV (and HFNC therapy  
• NIV and HFNC may have similar effects on 
patients’ work of breathing and are safe 
• HFNC may be reserved for children with 
milder forms of respiratory distress 
compared to conventional NIV. 
• greater use of NIV may reduce the number 





- - • overview of NIV and HFNC to provide 
respiratory support children with acute 
respiratory distress 
• with the introduction of HFNC therapy, 
there had been an increase in their use and as 
an alternative to CPAP 
• indications and management of NIV and 
HFNC were briefly summarized, along with 
failure criteria to warrant invasive MV  
HFNC-focused Reviews and studies are summarized in  
Table 4: Articles and reviews discussed in Chapter 2, Topic 3b Bronchiolitis 





- - • overall summary of the different types of 
invasive and non-invasive MV modes, and 
specific settings to optimize MV 
management (i.e. low tidal volumes, 
inspiratory flow patterns, patient-ventilator 
interactions, weaning to extubation) 
• either invasive or non-invasive MV are 
indicated when children are unable to 
breathe on their own; the primary objective 
for either is to improve gas exchange, work 
of breathing and comfort  
• provided a comparison between NIV and 
invasive MV (indications and epidemiology) 
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• discussed the available literature and 
potential of using protocolized MV weaning; 
adult data shows benefits but their effects 
are unknown in children 
• regardless of the settings, it is most 
important to monitor and optimize patient-
ventilator interactions to minimize the 











7 year old girl, 4 
year old girl, 3 
year old boy 
- • presented 3 different cases and described the 
MV management for each  
• the approaches for each clinical case differed 
in the diagnostic tests and MV modes 
• there were multiple factors to consider when 
initiating any form of MV and clinicians 
should follow an algorithm to determine the 
next steps when providing MV  




- - • described the available MV modes and 
supportive treatments in children 
• a combination of strategies should be used, 
including recruitment maneuvers, low-tidal 
volumes, and higher PEEP 
• modes such as HFOV, PRVC, PS, and VS 
are several potential modes to use  
• other adjunctive therapies/ solutions such as 
permissive hypercapnia, prone positioning, 
surfactant and nitric oxide may be important 
in certain pathologies  







- - • summarized the pathophysiology of 
PARDS, initial MV settings, review of the 
therapies and other rescue treatment options  
• discussed about target tidal volume, driving 
pressure and oxygen concentration 
• data for alternative support modes including 
NAVA or PAV were sparse and the authors 
were unable to comment on their use  
• reviewed adjunct therapies including prone 
positioning and ECMO; these may be 
considered, but there is limited data 
• there was an overall improvement in 
children’s mortalities over the years; 







- - • reviewed the evidence of the different lung 
recruit maneuvers for children  
• provided background information, 
indications and purposes of lung recruitment 
• heterogeneity of the studies prohibited 
pooled analyses  
• evidence did not suggest the best method to 
perform lung recruitment 
Jauncey-Cooke 
et al, 2010 (63) 
Literature 
Review  
- - • overview of the pathophysiology of VALI 
and the lung protective strategies to 
minimize the risk 
• lung protective strategies included lower 
tidal volumes of 6-8ml/kg, PEEP of 8-
12cmH2O, lung recruitment maneuvers, 
prone positioning and permissive 
hypercapnia  
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• alternative strategies such as HFOV, NIV, 
early MV weaning, and biological variable 
ventilation may reduce the risk of VALI 
• though there is minimal data available, 
clinicians should consider the use of lung 
protective strategies when ventilating 
children, to minimize the risk of VALI  
Conti and 
Piastra, 2016 (5) 
Literature 
Review 
- - • assessed the data on MV practices in 
PARDS and the overall literature on the 
optimal management of NIV and invasive 
MV in children 
• discussed the PALICC recommendations, 
ARDSNet considerations, conventional MV, 
HFOV and nitric oxide use in PARDS 
• elaborated on the role of NIV in children, 
the indications, interface selection and other 
settings to consider to maximize comfort  
• descriptive analysis and overview of patient-
ventilator synchrony in different modes 
(e.g., HFOV, NAVA, PC/ PS) 
• despite the improvement in treating 
respiratory failure in children, more studies 
are required to determine the best methods 






- - • overview of APRV, its indications, 
perceived benefits and complications  
• available studies on APRV and its 
associated outcomes demonstrated variable 






- - • summarized pediatric MV studies published 
June 2017 to December 2018 
• contrasted the pathophysiologic similarities 
between adults and children with PARDS 
• described the different MV strategies 
including PEEP titration, target tidal 
volumes using ideal body weight, nitric 
oxide therapy, NAVA, weaning and MV for 
other populations (e.g. post-cardiac surgery) 
• discussed RT driven weaning protocols, and 
the lack of significant improvements in 
outcomes; but this may be explained by poor 
protocol adherence 
• knowledge gaps in the use of certain modes, 







- - • due to variable effects and poor compliance 
with written protocols, this review suggested 
the use of computerized protocols for MV 
management 
• overview of computer-based protocols, how 
they are designed and the available ones 
• closed-loop systems were available in the 
market with some preliminary data to 
suggest their benefits i.e. decreased MV time  
Abbreviations: APRV-airway pressure release ventilation; CI-confidence interval; CPAP-continuous positive airway pressure; 
ECMO-extracorporeal membrane oxygenation; HFJV-high frequency jet ventilation; HFNC-high flow nasal cannula; HFOV-
high frequency oscillary ventilation; MV-mechanical ventilation; NAVA-neurally adjusted ventilatory assist; NIV-non invasive 
ventilation; OR-odds ratio; PALICC-Pediatric Acute Lung Injury Consensus Conference group; PARDS- pediatric acute 
respiratory distress syndrome; PAV-proportional assist ventilation; PC- pressure control; PEEP-positive end expiratory 
pressure; PICU-pediatric intensive care unit; PRVC-pressure regulated volume control; PS- pressure support; RT- respiratory 
therapist; VALI-ventilatory associated lung injury; VDR- volume diffuse respiration; VS- volume support   
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2.3.3b Topic 3b- MV Weaning 
A component of MV management is the process of weaning MV to liberate children from 
life support (65, 66). Weaning children off of MV as early as possible is essential as it has 
beneficial effects for their functionality and quality of life, but little evidence exists to suggest 
the best weaning method (66-71). A Cochrane systematic review published in 2013 (1) included 
three clinical trials with 321 children, and assessed the effects of protocolized compared to non-
protocolized weaning. The authors defined protocolized weaning as the use of an algorithm to 
direct weaning while non-protocolized weaning was defined as usual care or clinician-led care. 
The largest trial (n=260 children) included in the systematic review found protocolized weaning 
(daily screening and spontaneous breathing test [SBT]) significantly reduced MV time by 32 
hours (95% CI= 8 to 56 hours, p=0.01). Similarly, protocolized weaning significantly reduced 
the weaning time in the two smaller trials (n=61 children) by 106 hours (95% CI= 28 to 184 
hours, p=0.007) and 21 hours (95% CI= 9 to 32 hours, 0<0.001). However, reduced weaning 
time in these two trials did not significantly decrease total MV time, PICU or hospital stay. The 
majority of the studies (2 of the 3) in that systematic review had small sample sizes and the 
weaning protocols differed across studies, thus the evidence can only cautiously suggest that 
protocolized weaning may reduce MV duration. Overall, the authors concluded that larger multi-
center, interventional studies are necessary to understand the effects of protocolized weaning and 
determine whether they are associated with reduced MV time. 
The systematic review performed by Rose et al (65) compared automated weaning 
systems with weaning protocols executed by clinicians (both attempt to standardize the weaning 
process across patients). Within that review, automated weaning was defined as computerized 
systems that were capable of weaning without the presence of clinicians. It included 21 studies 
totaling 1,676 participants, of which 48 were children from two studies. They found that 
automated weaning systems reduced ICU stay by 8% (0% to 15% reduction in geometric mean;  
-0.08 mean log days, 95% CI= -0.16 to 0.0, p=0.05) and MV duration by 10% (3% to 16% 
reduction in geometric mean; mean hours log hours -0.11, 95% CI= -0.18 to -0.03, p=0.005). 
Duration of hospital stay, incidence of adverse events, and mortality were not significantly 
different between the weaning groups. The results of that systematic review may have limited 
generalizability in the pediatric population, as a very small proportion of children were included 
in the overall analysis.  
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There are several RCT and interventional studies that compared the differences in 
outcome measures between protocol-directed versus traditional, non-protocolized weaning. Two 
RCTs showed that a protocolized weaning method, extubation readiness evaluations, and SBT, 
may have reduced MV duration and PICU length of stay, and increased extubation success (72, 
73). In one RCT, 294 children (range 28 days to 15 years old) were randomized into the standard 
weaning practice (no protocol, n=139) or SBT group (n=155) (72). In their SBT group, children 
were evaluated daily for their readiness for extubation, and were trialed on PS (10cmH2O) with 
positive expiratory end pressure (PEEP) (5cmH2O) for two hours. The control group received 
physician-directed weaning on any of the following MV modes: PS, PC or SIMV. The SBT 
group had a significantly lower average MV duration of 3.5 days (95% CI= 3.0 to 4.0) compared 
to the control group of 4.7 days (95% CI= 4.1 to 5.3) (p=0.0127). In a 2019 RCT conducted in 
Brazil (73), the recruited children (average age of 8 months) received the same SBT parameters 
outlined in the RCT by Foronda et al (72). Their control group performed weaning using PC, 
SIMV with PS, or PS alone, directed by the physician. The results demonstrated that the SBT 
group (n=56) had shorter PICU length of stay and greater extubation success compared to the 
control group (n=54) (85 vs. 367 hours, p<0.01; 83% vs. 68%, p=0.02, respectively). There were 
no significant differences in the hospital length of stay, ventilator-associated pneumonia or 
mortality. Although both RCTs used the same SBT intervention, there were differences in their 
outcomes, indicating that larger interventional studies are required to verify whether the outlined 
SBT parameters are beneficial  (72, 73). 
In a RCT by Schultz et al (74), 223 children were randomized into either protocol-
directed weaning (n=107; average  standard deviation [SD] age, 5.1 5.71 years) or physician 
directed weaning groups (n=116; 4.195.4 years). The protocol-directed weaning group outlined 
the eligibility criteria the children must meet before weaning to SIMV with PS. There was a 
significant decrease in the average weaning time (5.9 vs. 25.2 hours, p<0.001) and extubation 
time (16.2 vs. 30.1 hours, p<0.004) in the protocol group compared to the control group. 
However, there were no significant differences in MV duration, reintubation rates, or adverse 
events such as pneumonia, new onset of tracheitis or subglottic stenosis.  
In a RCT across 10 pediatric hospitals in North America from 1999 to 2001, 182 children 
under the age of 18 years old on invasive MV over 24 hours and had failed an extubation 
readiness test, were recruited to study the effect of two different types of MV weaning protocols 
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(10). The children were randomized into three groups: PS protocol (n=62), VS protocol (n=60) 
or no protocol (n=60). The primary outcome measures were the duration of MV and extubation 
success. Across the three groups, there was no significant difference in extubation failure (PS 
15%, VS 24%, no protocol 17%, p=0.44) or median weaning duration (PS 1.6 days, VS 1.8 days, 
no protocol 2 days, p=0.75). The compliance to these protocols was 66% in both the PS and VS 
groups, and its poor adherence may have been the reason there were no significant differences in 
the outcomes. 
Other smaller interventional studies suggested protocolized weaning may improve 
clinical outcomes (68, 70, 75). A quasi-experimental time series over two years compared MV 
duration, length of stay and quality indicators before and after a weaning guideline 
implementation in 220 patients aged 0 to 16 years old (n=107 pre-, n=113 post implementation) 
(70). There were no significant differences in the MV duration (median difference -15.8 hours, 
p<0.067), length of stay (-23.75 hours, p<0.089), or quality indicators (weaning failures 12% vs. 
7.9%, p=0.371; reintubation 6% vs. 3.5%, p=0.743) after the weaning guideline was 
implemented. In two pilot studies, computer-driven protocols were evaluated for their 
effectiveness in weaning children off of MV (68, 75). The first pilot study compared 20 children 
(aged 1 to 17 years old) using a computerized PS mode (68), with a historic cohort of 20 children 
weaned by clinicians. There was no significant change in MV duration in the computerized 
weaning group (mean±SD; 5.1±4.2 days) compared to the clinician-directed group (6.7 ±11.5 
days) (p=0.33). In the other pilot study (75), 30 children (aged 2 to 17 years) were randomized to 
receive a computer driven protocol (n=15) compared to weaning techniques directed by 
physicians (n=15). The computerized weaning group in that RCT had a significantly lower 
weaning time (time from weaning initiation to extubation) at 21 hours (range 3 to 142 hours), 
compared to the control group at 90 hours (range 4 to 552 hours) (p=0.007).  
A recent guideline by the German Respiratory Society outlined the physiology, 
importance, and techniques to wean children and adult patients off MV (50). That guideline 
summarized the rationale, evidence, indications, MV modalities and techniques for maximizing 
weaning success. As weaning studies were heterogenous, direct comparisons between weaning 
techniques across centers were difficult. As a result, that guideline was informed by various 
health care professionals, including intensivists, pediatricians, anaesthesiologists, surgeons, 
cardiologists, neurologists, respirologists, intensive care/chronic care nurses, respiratory 
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therapists, physiotherapists, speech therapists and ventilator manufacturers. These consensus-
based recommendations aimed to provide MV weaning approaches and strategies in acute 
medicine and chronic MV in adults and children.  
In summary, the literature on protocolized MV weaning in critically ill children may be 
associated with positive outcomes, such as decreased MV time, weaning time, PICU stay, 
hospital stay, and improved extubation success (43, 66, 67, 70) (Table 2). However, the results 
may not be generalizable because studies were heterogeneous, including their patient population 
(ages, characteristics, underlying conditions), design and delivery of the interventions (some 
studies used computerized protocols (68, 75), while others used practitioner directed protocols) 
and the specified weaning settings (different studies used different modes) (10, 70, 72-74). 
Although the results from the presented studies are promising, conclusions cannot be drawn from 
the limited data as more high-quality studies in investigating the clinical outcomes of 
standardized pediatric MV weaning is necessary (1, 43, 65).  
 
Table 2: Articles and reviews discussed in Chapter 2, Topic 3b- MV weaning 






al, 2013 (1) 
Systematic 
review  








• largest trial included in the systematic 
review (n=260 children) showed reduced 
MV time by 32 hours (95% CI= 8 to 56 
hours, p=0.01) 
• in the 2 small studies, there was decreased 
weaning time (n=61 children) by 106 hours 
(95% CI 28 to 184 hours, p=0.007) and 21 
hours (95% CI 9 to 32 hours, 0<0.001) 
• there was heterogeneity across the trials 
where protocols differ, small sample sizes 
• more clinical trials were necessary to 
evaluate whether protocolized weaning was 
associated with reduced MV time  












their effect on 
health outcomes  
• compared the effects of automated weaning 
(computerized systems) and protocolized 
weaning  
• 21 studies included, 2 on children (48 
children/ 1,676 patients) 
• automated weaning reduced ICU stay by 8% 
(95% CI= 0% to 15%; -0.08 mean log days, 
95% CI=-0.16 to 0.0, p=0.05) and MV 
duration by 10% (95% CI= 3% to 16%; -
0.11 mean hours, 95% CI= -0.18 to -0.03, 
p=0.005) 
• reduced weaning only in mixed medical ICU 
patients (42%, 95% CI= 10% to 63%) 
• hospital stay, incidence of adverse events, 
and mortality not significantly different 
between weaning groups 
• limited applicability of the data in children 
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since the analyses included adult data  
Foronda et al, 
2011 (72) 
RCT 294 children 
(age 28 days to 




practice groups  
• 294 children in the SBT protocol group 
(n=155) or standard care (n=139) 
• SBT protocol included an assessment 
(readiness for extubation) and PS trial 
(10cmH2O) with PEEP of 5 cmH2O for two 
hours 
• significant decrease in the average MV 
duration of 3.5 days (95% CI= 3.0 to 4.0) in 
SBT protocol compared to the control group 
of 4.7 days (95% CI=4.1 to 5.3), p=0.0127 
• SBT group had non-significant decrease in 
the risk of post-extubation NIV, 
reintubation, ventilator associated 
pneumonia and accidental extubation  
Ferreira et al, 
2019 (73) 
RCT 110 children 





practice groups  
• 110 children in the SBT group (n=56) or 
control group (n=54) 
• SBT protocol entailed PS trial (10cmH2O) 
with PEEP of 5 cmH2O, oxygen ≤ 0.5 for 
two hours 
• no-protocol group received MV weaning 
based on clinical judgement 
• significant decrease in PICU stay in the 
protocol vs non-protocol groups, 85 vs. 367 
hours, p<0.01; and greater extubation 
success 83% vs. 68%, p=0.02 
• no significant differences in the length of 
stay, ventilator-associated pneumonia or 
mortality 
Randolph et al, 
2002 (10) 









• 182 children in PS protocol (n=62), VS 
protocol (n=60) or no protocol (n=60) 
• no significant differences between the 3 
groups in extubation failure (PS 15%, VS 
24%, no protocol 17%, p=0.44) or median 
weaning duration (PS 1.6 days, VS 1.8 days, 
no protocol 2 days, p=0.75) 
• protocol compliance was 66% in both 
protocol groups 
Schultz et al, 
2001 (74) 







• 233 children enrolled; n=107 in the protocol-
directed weaning (average  SD age 5.1 
5.71 years) or n=116 in the physician 
directed weaning groups (4.195.4 years) 
• in the protocol group, patients met a list of 
eligibility criteria before receiving the 
weaning settings (SIMV with PS) 
• decreased average weaning time (5.9 vs. 
25.2 hours, p<0.001) and extubation time 
(16.2 vs. 30.1 hours, p<0.004) in the 
protocol group 
• no differences in MV duration, reintubation 
rates or adverse events between groups 
Rushford 2004 
(20) 
RCT 8 infants (age 2 







• 8 infants, n=3 in protocol group and n=4 in 
physician directed group 
• No differences between the two groups 
• true effects are unknown due to the limited 
recruitment, strict eligibility criteria, ethical 










220 patients  Weaning 
protocol 
implementation 
• pre-intervention n=107 and post intervention 
n=113 
• no significant differences in the MV 
duration (median difference -15.8 hours, 
p<0.067), length of stay (-23.75 hours, 
p<0.089), or quality indicators (weaning 
failures 12% vs. 7.9%, p=0.371; reintubation 
6% vs. 3.5%, p=0.743) 
Jouvet et al, 
2007 (68) 
Pilot  40 children (1 to 






• n=20 in each interventional group 
• closed loop system (protocol) decreased PS 
in 16 children; n=14 were extubated with no 
adverse events  
• no significant change in mean MV duration 
in the closed loop system group (5.1±4.2 
days) compared to the physician-directed 
group (6.7 ±11.5 days), p=0.33 
• no difference between reintubation or NIV 
post-extubation  
Jouvet et al, 
2013 (75) 
Pilot 30 children (age 







usual care  
• n=15 in the protocol group and n=15 in non-
protocol group  
• significant decrease in MV weaning in the 
protocol group, 21 hours (range 3-142 
hours) compared to non-protocol group, 90 
hours (4-552 hours), p=0.007 
• reintubation in 2/15 in the protocol group 
and 1/15 in the non-protocol group; NIV 
post-extubation was 2/15 in both groups  
• computer-driven protocols for children 
younger than 2 years may be beneficial in 
reducing MV weaning time  
Schonhofer et 





 - - • not specific to children  
• elaborated on the definitions, epidemiology 
and pathophysiology to weaning and 
weaning failure  
• reviewed the different weaning strategies 
including NIV, HFNC, PS, SIMV, NAVA, 
PAV, automated weaning and controlled 
ventilation  






- - • detailed the approaches to weaning children 
from MV in a post-acute setting  
• Described strategies to wean children in 
post-acute setting were different from PICU 
as most children in a post-acute setting have 
tracheostomies from failed weaning  
• the Weaning Severity Index can be used to 
assess the severity of ventilatory 
requirements and whether they are ready to 
be weaned  
• an algorithm may aid pediatric weaning in 






- - • overview of MV assessment, weaning 
techniques, extubation readiness tests and 
post-extubation management  
• two common predictive indexes for weaning 
described: rapid shallow breathing index 
(RSBI), Compliance, resistance, 
oxygenation, pressure (CROP)  
• weaning modes include SIMV or PS, but 
there was no universal mode of choice 
• the leak test, negative inspiratory force, and 
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SBTs were common tests to assess for 
extubation readiness  
• ventilator liberation in children has 
improved but there is limited evidence on 







- - • summary of weaning techniques, protocols, 
indications of weaning failure and the use of 
NIV for weaning purposes  
• most common weaning mode was SIMV 
• SBT may be used to assess and test for 
weaning and extubation success  
• daily assessment of clinical and functional 
parameters with SBT may identify patients 
ready for MV weaning  




- - • described weaning recommendations to 
achieve extubation success in adults and 
children including factors that impact 
weaning, predictive tests and modes 
• SBT, ERT and criteria for readiness for 
extubation were common assessment tools 
• protocolized weaning was safe and lead to 
earlier and faster weaning in adults 
• the best predictive test to indicate successful 
extubation was unknown 
• t-piece or PS trials for extubation assessment 
were effective in adults, though it is 
inconclusive for children 
Abbreviations: CPAP-continuous positive airway pressure; ERT- extubation readiness test; HFNC-high flow nasal cannula; 
MV-mechanical ventilation; NAVA-neurally adjusted ventilatory assist; NIV-non invasive ventilation; PAV-proportional assist 
ventilation; PC- pressure control; PEEP-positive end expiratory pressure; PICU-pediatric intensive care unit; PRVC-pressure 
regulated volume control; PS- pressure support; RCT- randomized controlled trial; SBT-spontaneous breathing test; SIMV-




2.3.3c Topic 3c - MV in Specific Diseases  
Pediatric acute respiratory distress syndrome (PARDS) 
PARDS is described as an acute onset (within seven days) of parenchymal lung disease 
seen on chest radiographs, and presenting with pulmonary edema (not explained by cardiac 
failure or fluid overload) (22, 76). PARDS’ severity is classified by the oxygenation index (OI), 
a formula used to calculate the usage of inspired oxygen concentration in the body (4, 51, 76-78). 
Prior to guidelines by the Pediatric Acute Lung Injury Consensus Conference Group (PALICC) 
in 2015, PARDS was described using the adult diagnostic criteria (acute lung injury [ALI] with 
ARDS) (78). The definition and management of ARDS in adults was extrapolated to children, 
due to the lack of high-quality studies in children with ALI/ARDS (77, 79). For example, the 
National Heart, Lung, and Blood Institute’s (NHLBI) ARDSNet protocol included a lung 
protective MV (LPMV) strategy that demonstrated decreases in mortality in adult studies (35, 
80).  Experts followed the same adult guidelines for children with ALI/ARDS, because pediatric-
specific standards had not been developed (34, 76). This subsection will describe three stages of 
evidence on the MV management for PARDS. First, studies published prior to the development 
of PALICC guidelines. Second, a broad description of the PALICC guidelines will be provided. 
Finally, studies published after will be described. 
An observational study from 2011 to 2012 that included 120 PICU patients (aged 17 days 
to 18 years) with PARDS, assessed whether a pediatric MV protocol, adapted from the LPMV 
strategies from the ARDSNet protocol, would reduce variability in MV management (35). 
Several types of MV modes were used, including PC (60%), VC (19%), PRVC (18%) and 
HFOV (3%). Despite its wide acceptance, changes in settings were rarely done in accordance 
with the protocol (followed 29% of the time), with decisions in MV management varying 
considerably. The findings suggest that a collaboratively created, well accepted protocol was 
required to successfully implement into the practice culture.  
The LPMV strategies in the ARDSNet protocol includes lower tidal volumes and higher 
PEEP to minimize atelectrauma, and lung injury caused from opening and closing of the alveoli 
(81, 82). A retrospective analysis evaluated whether children were managed according to the 
ARDSNet recommendations and measured its effect on mortality (82). Data was collected from 
four time periods from 2000 to 2016 across multiple hospitals, on 1,134 children with PARDS 
(average age 46.6 months [IQR 13.2 -137.6]). It was observed that children receiving lower 
PEEP compared to protocol-directed (higher) PEEP, demonstrated higher overall mortality by 
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18.6% (p<0.001), even after adjusting for hypoxemia, inotrope use, comorbidities, severity of 
illness, ventilator settings, and nitric oxide (OR 2.05; 95% CI= 1.32-3.17). The authors suggested 
that LPMV may reduce mortality in this pediatric population. Similarly, in a separate study, a 
secondary analysis of four multi-center studies from 2000 to 2010 included 315 children with 
PARDS (median age 3.3 years, [IQR 0.4-10.8]) and reported poor adherence to maintaining low 
tidal volumes of 6-8ml/kg ideal body weight (81). The authors found that 58-60% of children 
on MV received tidal volumes 8ml/kg, indicating a large proportion of children were still 
receiving tidal volumes greater than recommended (>8ml/kg). However, the study did not assess 
or address the impact of poor protocol adherence and its influence on the measured health 
outcomes. Both analyses emphasized a need for clinical studies focussing on LPMV strategies in 
children with PARDS, and their associated outcomes (81, 82).  
An adjunct to MV therapy is inhaled nitric oxide (iNO) therapy, a potent vasodilator to 
treat refractory pulmonary hypoxemia common in PARDS (25, 79). A quality improvement 
project evaluated whether implementing an iNO therapy protocol would minimize practice 
variability, iNO utilization and impact health outcomes (83). The project included a total of 63 
children separated into two groups, n=30 (median age 2 years [IQR 0.79-12.5]) in the pre-
guideline group, and n=33 (median age 4 years [IQR 0.96-14]) in the post-guideline 
implementation group. Significant changes between pre- and post-guideline occurred in the total 
median MV hours from 359 (IQR 283-846) hours to 304 (IQR 141-551) hours, p=0.03; mortality 
15% to 7%, p=0.02; and iNO therapy duration of 62 (IQR 87-290) to 76 (IQR 48-124) hours, 
p=0.0004, with a median iNO cost savings of $4600 (USD). Unfortunately, there were no 
significant differences in the median PICU length of stay (pre 443 [IQR 324-895] vs. post 477 
[IQR 181-761] hours, p=0.08) or hospital length of stay (pre 726 [IQR 447-1114] vs. post 592 
[IQR 310-1203] hours, p=0.25). However, the data suggests that implementation of a protocol 
may improve health outcomes and iNO utilization in children with PARDS. Therefore, more 
clinical trials will help verify the beneficial effect of an iNO guideline by clarifying the role of 
iNO as an adjunctive therapy. 
A 2008 PARDS case scenario survey distributed across American and European PICUs 
(12 countries) assessed and provided different MV management strategies (34). The authors 
found that even though many respondents endorsed the widely accepted ARDS guidelines in 
adults, and understood their associated benefits, these strategies were rarely translated into 
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clinical practice for critically ill children with PARDS. The data revealed that large tidal volumes 
(>10ml/kg) were used to ventilate over 25% of pediatric patients, possibly from the lack of strict 
MV protocols. In contrast, a 2012 questionnaire about MV strategies for children (one month to 
six years of age) was sent to 21 Nordic ICUs that treated children with PARDS (84). That survey 
revealed that 44% of the ICUs (three PICUs, five mixed ICUs) had written protocols, and the 
majority (n=18) had similar MV management (89% of units used PC setting) for children with 
PARDS. Though each survey demonstrated different practice patterns in different geographical 
locations, both authors concluded that an international MV guideline for PARDS would be 
beneficial to emphasize LPMV strategies to optimize compliance and limit variabilities (34, 84).  
A few narrative literature reviews have focused on the characteristics and management 
options for children with PARDS (25, 48, 63, 85). For example, an evidence-based review used a 
series of Delphi surveys, conference meetings and subgroup meetings to formulate 
recommendations on the use of specific MV options including NIV, LPMV strategies, APRV, 
iNO therapy, proning, and weaning protocols in sepsis induced PARDS (79). Another review 
discussed LPMV strategies (e.g. the control of tidal volumes, PEEP, lung recruitment), weaning, 
monitoring targets and alternative MV strategies to reduce risk for ventilator induced lung 
injuries (VILI) in PARDS (63). Some reviews did not explicitly focus on PARDS, but PARDS 
was mentioned as an indicator for MV strategies or techniques (23, 85). This included an 
overview of various MV techniques and adjunctive therapies with clinical experience summaries 
(many of these techniques mentioned were for PARDS). Indications, mechanisms and clinical 
data were described for different techniques, which included NIV, pressure-limited MV, high 
frequency ventilation, heliox, and extracorporeal membrane oxygenation (85). Similarly, two 
other reviews provided a summary of different MV options (e.g. PRVC, PS, VC, HFOV, iNO, 
LPMV strategies) to minimize the risk of VILI in PARDS and children in general (25, 48). 
In 2015, PALICC created three consensus recommendation documents on MV strategies 
and management of PARDS that included the characteristics, diagnostic criteria and overall 
management (51, 78, 86). The first consensus recommendation document provided an overview 
of PARDS and listed possible pediatric-specific MV management options (78). The second 
focused on the use of NIV and HFNC, and described the indications, contraindications, mode 
selection, duration of therapy, and ideal interfaces (86). The third focused on the use of invasive 
MV, including the indications, contraindications, initiation, mode selection and lung protective 
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strategies (51). PALICC strongly encouraged clinicians to use the recommendations as a guide to 
direct medical discussions and decisions. These practice guidelines were re-iterated by several 
review articles that provided an overview of the pathophysiology, potential strategies and MV 
management for PARDS (4, 22, 62, 77, 87). There were very few studies investigating specific 
components of the recommendations, and their impact on patient outcomes. 
In a before-after pilot by Wong et al (88), the PALICC PARDS consensus guideline was 
used to qualify children with diagnosed PARDS into their study. Data was collected from 2016 
to 2019 and in 2018, a PARDS LPMV protocol approved by the medical and nursing staff, was 
implemented for their 16 bed PICU. A total of 132 children (median age 2.4 years [IQR 0.5-
0.77]) were included, n=69 in the no-protocol (prior to protocol implementation; median age 1.8 
years [IQR 0.4-7.7]) and n=63 in the protocol groups (median age 2.8 years [IQR 0.59-9.6]). The 
PARDS LPMV protocol had 5 essential target components: 1) peak inspiratory pressures 
<28cmH2O, 2) tidal volumes 3-6ml/kg, 3) an incremental PEEP to FiO2 table, 4) permissive 
hypercapnia for moderate/ severe PARDS and 5) permissive hypoxemia (mild PARDS pulse 
oximetry 92-97%, moderate/ severe 88-92%). After implementing the LPMV protocol, there 
were no significant differences in mortality (15% vs. 26.1%, p=0.152), ventilator-free days (16.0 
vs. 19.0, p=0.679) or PICU-free days (13.0 vs. 16.0, p=0.233). After adjusting for severity of 
PARDS and illness, there was a significant decrease in mortality risk (adjusted hazard ratio = 
0.37; 95% CI= 0.16-0.88) in the protocolized LPMV group. After protocol implementation, 
authors observed a significant decrease in median tidal volumes (pre 6.4ml/kg [5.4-7.8] vs. post 
6.0ml/kg [5.1-7.6], p=0.005), higher PEEP levels (pre 8cmH2O [7-9] vs. post 8cmH2O [8-10], 
p=0.002), higher acceptable arterial carbon dioxide (PaCO2) (pre 44.9mmHg [38.8-53.1] vs. post 
46.4mmHg [39.4-56.7], p=0.033), lower acceptable arterial oxygenation levels (PaO2) (pre 
78.1mmHg [67-94.6] vs. post 74.5mmHg [59.2-91.1], p=0.001) and oxygen saturation (SpO2) 
(pre 97% [95-99] vs. 96% [94-98], p=0.007). When categorized into PARDS severity, at-risk / 
mild PARDS did not have significant improvements in their median tidal volumes (pre 6.4 ml/kg 
[5.5-7.8] vs. post 6.1 ml/kg [5.1-7.6], p=0.153), PEEP (pre 8cmH2O [7-9] vs. post 8 cmH2O [7-
9], p=129), PaO2 (85.9 mmHg [74.5-103.5] vs. post 83.5 mmHg [69.7-98.7], p=0.072) or SpO2 
(98% [96-100] vs. post 98% [95-98], p=0.273) even after protocol implementation. Although 
each of the five elements in the LPMV protocol had non-significant improvements in 
compliance, when SpO2 targets were separated into PARDS severity, there was a significant 
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improvement in clinicians complying to a SpO2 target of 88-92% in moderate to severe PARDS 
(pre 17.4% vs. post 29.3%, p=0.031). The pilot study suggests a PARDS protocol may improve 
compliance to LPMV strategies and potentially reduce mortality. Larger trials on LPMV 
strategies are needed to understand their impact on clinical outcomes, including the association 
of protocol compliance and PARDS severity (88). 
In summary, MV management for PARDS is complex and involves various MV 
modalities, strategies and adjunct therapies. Table 3 summaries all the articles reviewed in this 
section). LPMV strategies appear to be common in managing PARDS, though different studies 
report different outcomes including mortality, MV duration and length of stay (81, 82, 88). In the 
small number of studies, children varied greatly in their age, and protocol adherence was not 
high (81, 88). Larger high-quality clinical trials are needed to validate the effects of various 
PARDS and MV management strategies (e.g. LPMV), rather than literature reviews and 
summaries.    
 
Table 3: Articles and reviews discussed in Chapter 2, Topic 3c - Pediatric Acute Respiratory Distress 
Syndrome 











(age range 17 to 
18 years old) 
with PARDS 
from  
8 tertiary PICU 
in USA (2011 
to 2012) 
- • assessed MV changes on blood gases, pulse 
oximetry, and end-tidal CO2 
• PARDS MV protocol based on the 
ARDSNet protocol and data from the 
Pediatric Acute Lung Injury and Sepsis 
Investigators and the Collaborative Pediatric 
Critical Care Research Network 
• MV modes were either PC (60%), VC 
(19%) PRVC (18%) or HFOV (3%) 
• PEEP settings 10cmH2O  
• overall MV management varied 
considerably across different sites even 
when a protocol was available  






(2010 to 2013) 
Implementation 
of iNO protocol 
• iNO is an expensive therapy and this study 
aimed to see if a guideline would decrease 
practice variability, utilization and costs 
• 63 children into two groups, n=30 (median 
age 2 [IQR 0.79-12.5)) in the pre-guideline 
group, and n=33 (median age 4 [IQR 0.96-
14]) in the post-guideline implementation 
group 
• Significant changes between pre- and post-
guideline in total MV hours from 359 (IQR 
283-846) to 304 (IQR 141-551) hours, 
p=0.03; mortality 15% to 7%, p=0.02; and 
iNO therapy duration from 62 (IQR 87-290) 
to 76 (IQR 48-124) hours, p=0.0004, with a 
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median iNO cost savings of $4600 (USD) 
• no significant differences in PICU length of 
stay 
• implementing an iNO protocol may reduce 
the cost, MV duration and mortality in this 
population of children 
Jensen et al, 
2015 (84) 








- • explored MV strategies for PARDS and 
how it differed from international guidelines  
• a survey for children 1 months to 6 years  
• 18/21 (86%) units participated, 50% PICU  
• MV was mostly achieved by PC (89%) 
compared to VC (11%); NAVA was only 
used in some units (44%) 
• only 44% of the units had a protocol in 
place for MV management, 44% had 
ECMO, 94% had nitric oxide therapy and 
HFOV available 
• 67%  used low tidal volumes, 72% used 
PEEP between 10-15 cmH2O, 89% used 
prone positioning and 50% used cuffed ETT 
• MV practices across the countries were 
similar and follow international guidelines 
Kissoon, 
Rimensberger 




- - • overview of the indications, mechanisms 
and clinical experience for HFOV, NIV, 
nitric oxide, heliox, and ECMO 
• no single approach was appropriate and 
therefore, therapies should be given when 







- - • question-directed recommendations, and an 
overview of existing evidence on the MV 
management in sepsis-induced PARDS 
• described recommendations for the 
indications for NIV, invasive MV, and MV 
strategies such as low tidal volume 
(<6ml/kg with plateau pressures <30 
cmH2O), APRV, HFOV prone positioning, 
and weaning protocols/ SBT 
Jauncey-Cooke 
et al, 2010 (63) 
Literature 
Review  
- - Described in Table 1: Articles and reviews 














Haut, 2015 (42) Literature 
review 
- - 





PALICC consensus guidelines in 2015 
PALICC, 2015 
(78) 
Guideline  27 experts  - • Consensus conference to evaluate and create 
151 recommendations on the practices in 
acute lung injury/ PARDS  
• included 1) definitions, prevalence, 
epidemiology; 2) pathophysiology, 
comorbidities, and severity; 3) ventilatory 
support; 4) pulmonary-specific ancillary 
treatment; 5) non-pulmonary treatment; 6) 
monitoring; 7) NIV support and ventilation; 
8) ECMO support; 9) morbidity and long 
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term outcomes  
• recommendations took 2 years to finalize 
and were intended to optimize and 






Guideline  - - • Total of 11 recommendations on the NIV 
management in children with PARDS 
• NIV may be most beneficial in children with 
milder forms of PARDS  
• choice of interface, environment, and 
available clinicians were important in the 





Guideline  - - • Total of 27 recommendations on the MV 
management in children with PARDS 
• 17 recommendations reached strong 
agreement and 10 reached weak agreement  
• guideline should be used to encourage 
discussions when managing the care of 
children with PARDS 
After PALICC consensus guidelines were available  
Wong et al 
2020 (88) 














• assessed whether a lung protective MV 
protocol is associated with improved health 
outcomes in the PICU 
• n=69 in non-protocol group (usual care) 
compared to n=63 protocol group (lung 
protective MV protocol)  
• decrease in median tidal volume after 
protocol implementation, pre-6.4ml/ kg 
(5.4-7.8ml/kg) vs. post- 6.0 ml/kg (4.8-
7.3ml/kg), p=0.005; PaO2 pre- 78.1 mmHg 
(67-94.6) vs. 74.5mmHg (59.2-91.1mmHg), 
p=0.001 and SpO2 pre 97% (95-99) vs. post 
96% (94-98), p=0.007 
• increase in PEEP settings in the protocol 
group, pre- 8cmH2O (7-9) vs. 8 (8-10), 
p=0.002; permissive hypercapnia PCO2 44.9 
mmHg (38.8-53.1) vs. post- 46.4mmHg 
(39.4-56.7), p=0.033,  
• no differences in mortality, ventilator free 
days or PICU-free days 
• the protocol group was associated with 
decreased mortality (adjusted hazard ratio, 
0.37 (95% CI 0.16-0.88) (when adjusted for 
disease severity, organ dysfunction and OI) 








- • determined whether children are managed 
with the appropriate PEEP level as 
suggested by the ARDSNet 
• 26.6% of the 1134 children were managed 
with lower PEEP than suggested, p<0.001, 
and was associated with increased mortality 
(OR 2.05; CI=1.32-3.17) 
• after covariate adjustment, lower PEEP still 
associated with increased mortality  





patients from 26 
PICU (median 
age 3.3 years, 
IQR 0.4-10.8) 
 • evaluated the use of low tidal volumes in 
children with PARDS, and suggested 
methods to improve compliance to this 
practice  
• patients were included in this study if there 
was data to calculate the IBW  
• 2 thresholds for low tidal volumes were 
assessed: ≤6.5ml/kg IBW and ≤8ml/kg 
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• with threshold ≤6ml/kg, the adherence rate 
was 32%, with ≤8ml/kg, adherence was 
56% 
• overweight children were less likely to 
receive low-tidal weight practices (≤6ml/kg 
at 11% and ≤8ml/kg at 38%) 
• low-tidal volume practices were underused 






Survey  54 pediatric 
intensivists, 
from 47 PICU 




Survey with 3 
case scenarios 
to assess MV 
strategies 
• assessed pediatric intensivists’ knowledge 
and MV practices in children with PARDS  
• most (88-96%) intensivists used target tidal 
volumes 5-8ml/kg, upper pressure threshold 
of 35 cmH2O, and permissive hypercapnia/ 
mild hypoxemia 
• additional therapies such as nitric oxide, 
prone positioning, ECMO, or medications 
were considered if patient’s condition 
worsened  
• participants reported compliance and 
agreement to using lower tidal volumes and 
pressure limits, but over 25% of centers 
actually tolerate higher tidal volumes and 
pressure limits 
• a comprehensive decision support tool or 
protocol was necessary to enhance 






- - • described PARDS and its epidemiology, 
mortality and standards of care (which were 
consistent with ARDS network protocol) 
• emphasized using lung protective strategies, 
with reference to the PALICC guidelines 
• other adjunctive therapies were reviewed, 
such as HFOV, recruitment maneuvers, 
prone positioning, nitric oxide and ECMO 




- - • summary of PARDS pathophysiology, and 
available diagnostic tests and treatments 
(not MV focused)  
• MV management of PARDS is complex, 
and respiratory support may be provided as 
NIV or invasive ventilation  
• was a particular focus on using protective 
lung strategies in lower tidal volumes, 
higher PEEP, and prone positioning 
• other considerations for PARDS 
management included fluid management, 








 - - • review of MV protocol and the advantages 
of computer-based protocols  
• computer-based protocols may improve 
medical care and patient outcomes 
• described the process in developing, 
initiating and managing a computer-based 
protocol, along with challenges in 
implementation  
• even though decision support tools are 
shown to be beneficial, MV management 





- - • review of PARDS and the available MV 
therapies, adjunctive treatments, and 
weaning options  
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• PALICC guidelines for MV management 
were recommended for lower tidal volumes, 
limited peak inspiratory pressures, higher 






- - • summarized the pathophysiology of 
PARDS, initial MV settings, review of the 
therapies and other rescue treatment options  
• discussed target tidal volume, driving 
pressures and oxygen concentration 
• alternative support modes included NAVA 
or PAV, with limited use in children  
• review of other therapies included prone 
positioning, HFOV, and ECMO; these may 
be considered, but there was limited data 
• an overall improvement in children’s 






- - • overview of MV strategies for children with 
lung inhalational injuries 
• causes, pathophysiology and diagnosis of 
lung inhalational injuries were explained in 
depth, including the grade classification of 
lung injuries 
• MV strategies covered in this review 
included Conventional MV Lung protective 
strategies, HFOV, HFPV, APRV, NIV and 
HFNC 
• since lung inhalation injury may involve 
complications such as airway edema, and 
bronchoconstriction, PC mode may be the 
most beneficial in avoiding more damage 
• HFPV and HFOV may provide improved 
ventilatory and gas exchanges, but there is 
limited evidence 
• there is limited evidence to support the use 
of APRV, especially in children with lung 
inhalation injuries   
• limited data on NIV use, as it is problematic 
to apply any interface on facial burns  
• no HFNC studies were found in children 





- - Described in Table 1: Articles and reviews 













Abbreviations: APRV-airway pressure release ventilation; CO2- carbon dioxide; CPAP-continuous positive airway pressure; 
ECMO-extracorporeal membrane oxygenation; ETT-endotracheal tube; HFJV-high frequency jet ventilation; HFNC-high flow 
nasal cannula; HFOV-high frequency oscillary ventilation; HFPV-high frequency percussive ventilation; MV-mechanical 
ventilation; NAVA-neurally adjusted ventilatory assist; NIV-non invasive ventilation; OI-oxygenation index; PARDS- pediatric 
acute respiratory distress syndrome; PAV-proportional assist ventilation; PC- pressure control; PEEP-positive end expiratory 
pressure; PICU-pediatric intensive care unit; PRVC-pressure regulated volume control; PS- pressure support; RT- respiratory 






Bronchiolitis is a respiratory infection common among younger children and can be 
treated with CPAP, and/or with HFNC oxygen therapy (24, 89). HFNC is of particular interest, 
as it is relatively new and may be a preferred option to CPAP in children (24, 90). 
A 2011 systematic review evaluated the use of CPAP and its effect on the clinical 
outcomes of children with acute viral bronchiolitis (89). A total of eight studies (five CPAP and 
three CPAP-Heliox (He) studies) were included, with a total of 221 children (under 2 years old). 
In the five CPAP studies, four were before-after designs and one a RCT-crossover. CPAP levels 
from 4 to 8cmH2O, and the impact on PaCO2 and work of breathing was investigated. One of the 
RCTs using CPAP levels of 5-6cmH2O showed a decrease in PaCO2 by 6.9mmHg compared to 
standard oxygen therapy (nasal prongs/ mask) at 0.3mmHg (p<0.015). In two of the CPAP 
before-after trials, PaCO2 decreased from a range of 7mmHg to 11.7mmHg (p<0.001) after 2 
hours of 4-8cmH2O CPAP. In the quasi-RCT crossover with 1-2 month old infants, 5-12cmH2O 
CPAP was delivered with or without heliox (a mixture of helium-oxygen,70%/30%). There was 
a greater decrease in PaCO2 in the CPAP-He group by 9.7 mmHg compared to the CPAP group, 
5.4mmHg (p<0.001) after 30 minutes (similar to two before-after studies that demonstrated a 
decrease of PaCO2 9.7mmHg in the CPAP-He group after 1 hour of use, p<0.05). One before-
after trial with children under 3 months old (n=12), noted a decrease in respiratory distress 
(measured by the modified Wood clinical Asthma score [mWCAS]), by 2.2 points after 1 hour of 
6cmH2O CPAP (p<0.01). Two other before-after studies with children 0 to 2 years old (n=75), 
showed a significant decrease in the respiratory rate by 12-16 breaths/min (p<0.01), after 2 hours 
on 5-8cmH2O CPAP. In comparison, the quasi-RCT CPAP-He trial with 12 children (1-2 years 
old) showed a decrease in nWCAS by 2.12 in the 5-12cmH2O CPAP-He compared to the 5-
12cmH2O CPAP only group, 1.08 (p<0.001) (89). The other two before-after trials of CPAP-He 
with 23 children (0-2 years old) showed a decrease in respiratory rate by 8 to 13.7 breaths/min 
after 1 hour of 5cmH2O CPAP-He use (p<0.05). The overall evidence to support the use of 
CPAP at any pressure level, with or without heliox, for children with bronchiolitis, included 
studies using CPAP at various levels and measured different outcomes. Variability across studies 
make it difficult to provide a definitive conclusion, thus stronger evidence is required before 
recommendations can be made on the best CPAP pressure levels, in conjunction with heliox.  
A prospective physiologic study from 2011 evaluated the different levels of nasal CPAP 
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(nCPAP) to treat acute bronchiolitis in 10 infants (27 to 94 days old) (91). The infants’ 
respiratory pattern and gas exchange were recorded during spontaneous oxygen therapy (nasal 
prongs), 4cmH2O nCPAP, 7cmH2O nCPAP and 10cmH2O nCPAP. In all infants, the greatest 
reduction in respiratory rate and transcutaneous CO2 (compared to spontaneous oxygen therapy) 
occurred at 7cmH2O nCPAP: average (range) 78 (41-96) vs. 56 (39-108) breaths/min, p<0.05; 
61.5 (50-78) vs. 49 (35-65) mmHg, p<0.05 (respectively) (91). It is suggested that nCPAP of 
7cmH2O may be sufficient in unloading respiratory distress and improve breathing patterns in 
infants with bronchiolitis.    
In a protocol implementation study by Riese et al (36), a pre and post intervention study 
investigated the use of HFNC in children with bronchiolitis outside the PICU (general floors) 
and their associated health outcomes. In the period of 2010 to 2014, there were a total of 1937 
patients, 936 children (median 4 months [IQR 1.75-10]) in the pre-protocol phase and 1001 
children (median 5 months [IQR 2-11]) in the post-protocol phase. Overall, there was an increase 
of HFNC use in children with bronchiolitis from 23.9% to 35.2% (p<0.001). However, after 
using an interrupted time series analysis, there were no statistical differences in total hospital 
stay (0.48), PICU length of stay (0.06), PICU transfer (p=0.97), intubation (p=0.7) or 30 day 
readmission (p=0.37). Overall, the possible explanation for increase HFNC use in bronchiolitis 
may be because of its ease of use and tolerance in children. Though the protocol was not 
implemented in the PICU, the associated benefits demonstrated may still apply. Therefore, more 
research is required to determine the relationship between a HFNC protocol in and outside of the 
PICU and their associated benefits.  
A retrospective observational study described the care received by children with 
bronchiolitis in a PICU, during two separate time periods, 2014 to 2015 and 2015 and 2016 (92). 
A hundred and thirty-eight children were included, 75 children (median age 1.49 months) in the 
first time period, and 63 children (median age 1.89 months) in the second. NIV modalities 
(CPAP and Bilevel) were less frequently used in the second period (38% vs. 56%, p=0.036), 
while HFNC use increased, especially in children less than 1 month (25% vs. 63%, p=.035) and 
less than 1 year old (32% vs. 53%, p=0.021). This study demonstrated a shift from NIV to HFNC 
practices, warranting the necessity of clear guidelines on its use and outcomes.  
A survey from 2017 to 2018 in France collected information on the use of HFNC in 
infants with bronchiolitis outside PICU (93). A total of 217 pediatricians from 135 hospitals 
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responded, providing details on the characteristics to initiate, wean and discontinue HFNC. 
HFNC practices were not standardized across centers, and clinical outcomes were not reported. 
The authors highlighted the urgency to establish comprehensive guidelines on HFNC for 
children with bronchiolitis, especially given its increase in popularity.  
In a retrospective cohort study evaluated the effectiveness of using HFNC outside the 
PICU in 80 children (median 4.6 months [IQR 2.0-10.4]) with bronchiolitis from 2013 to 2015 
(94). Children that required HFNC received a median minimum flow of 3 (IQR 3-5) L/min with 
the median maximum flow of 8 (IQR 6-8) L/min; the maximum flow was 10 L/min with median 
maximum oxygen FiO2 0.4 (0.3-0.5). Children who stayed on the general floors received a 
median maximum flow of 7 (IQR 6-8) L/min and children who were transferred to PICU 
received a median maximum flow of 8 (8-10) L/min, which was shown to be significantly 
different (p<0.001). A total of 33 children (41%) were transferred to PICU, and 58% of these 
children required higher respiratory support options. None of the children recruited required 
intubation, or experienced any complications such as aspiration, pneumothoraces or death. These 
results indicate the safe use of HFNC as a respiratory support for children with bronchiolitis 
outside the PICU using this wide flow range. However, it was observed that children who 
required HFNC on the floors were commonly admitted to the PICU (41%) within 24 hours, 
which indicated that HFNC use still requires close monitoring.  
There are a few guidelines for bronchiolitis management, but they are limited in scope. 
The American Academy of Pediatrics (AAP) guideline focuses on diagnostic and pharmaceutical 
management, with minimal suggestions on respiratory support therapies for children with 
bronchiolitis (95). Similarly, the CPS (96) clinical practice position statement describes the 
background information, indications, safety concerns and brief suggestions for the initiation and 
management of HFNC. Milési et al (24) presented a HFNC recommendation guideline but it was 
not bronchiolitis-focused (though it did mention bronchiolitis as a strong indicator for this form 
of respiratory therapy). Other literature reviews only highlighted the potential of HFNC for 
children with bronchiolitis, including the indications, mechanism of action and suggested 




Table 4: Articles and reviews discussed in Chapter 2, Topic 3b Bronchiolitis 
Authors Study type (or 









(under 2 years) 




• eight studies (five CPAP and three CPAP-
Heliox (He) studies) were included 
• one RCT using CPAP levels of 5-6cmH2O 
showed a decrease in PaCO2 by 6.9mmHg 
compared to standard oxygen therapy (nasal 
prongs/ mask) at 0.3mmHg (p<0.015) 
• in two CPAP before-after trials, PaCO2 
decreased from a range of 7mmHg to 
11.7mmHg (p<0.001) after 2 hours of 4-
8cmH2O CPAP 
• one quasi-RCT crossover with 1-2 month 
old infants, compared 5-12cmH2O CPAP 
with or without heliox; greater decrease in 
PaCO2 in the CPAP-He group by 9.7 mmHg 
compared to the CPAP group, 5.4mmHg 
(p<0.001) after 30 minutes  
• Definitive conclusions cannot be made from 
the available data as further research is 
required to understand the benefits of CPAP 
and CPAP-He 




1937 children HFNC protocol  • assessed the implementation a HFNC 
protocol outside the PICU and impact on 
health outcomes 
• 936 were in the pre- (median age 4 [1.75-
10]) and 1001 were in the post (median age 
5 [2-11]) groups 
• increase in HFNC use for bronchiolitis from 
23.9% to 35.2%, p<0.001 
• significant decrease in HFNC therapy time, 
average 2.5 days ± 1.5 in pre and 2.0 ± 1.4 in 
the post implementation, p<0.001; and PICU 
stay, with median 2.3 days (1.5-3.4) before 
compared to after 1.7 days (1.0-2.6), 
p<0.001 (significance lost after an 
interrupted time-series analysis) 
• no significant differences in hospital length 
of stay, rate of PICU transfer, intubation rate 
or readmission  





10 infants with 
bronchiolitis (27 
to 94 days old) 
Nasal CPAP at 
4, 7 and 10 
cmH2O 
• a significant reduction in respiratory rates 
with nasal CPAP 7cmH2O, average (range) 
78 (41-96) vs. 56 (39-108) breaths/min, 
p<0.05; and transcutaneous CO2 
measurements 61.5 (50-78) vs. 49 (35-65) 
mmHg, p<0.05 
• nasal CPAP at 7 cmH2O may be sufficient in 
offloading respiratory muscles and 
improving breathing patterns  
Marcos-Morales 





138 children  
(Median age 1.8 
months, IQR 











• no changes in management between the two 
periods except for an increase use of HFNC 
in 2nd time period (p=0.036) 
• the PICU did not follow the AAP guideline 
but followed routine clinical care 
• non-recommended treatments were familiar 
to the primary physician, and the staff were 
not extensively educated on the AAP 
guideline nor was it enforced 
 50 





(Median age 4.6 
months, IQR 
2.0 to 10.4) 
HFNC 3 to 
10L/min 
• examined the safety in HFNC use outside 
PICU after protocol implementation 
• median minimum flow of 3 (IQR 3-5) L/min 
with the median maximum flow of 8 (IQR 6-
8) L/min; the maximum flow was 10 L/min  
• median maximum oxygen FiO2 0.4 (0.3-0.5)  
children on the general floors received a 
median maximum flow of 7 (IQR 6-8) 
L/min vs. children transferred to PICU 
received a median maximum flow of 8 (8-
10) L/min, (p<0.001)  
• 33 (41%) children required transfer to PICU, 
19 (24%) required higher respiratory support 
therapies, no incidences of intubation, 
pneumothoraces, aspiration or death 
Bradshaw et al, 
2018 (40) 
Survey study 57 PICU 
physicians from 
13 PICUs in 
Canada  
- • assessed practices in treating bronchiolitis 
across Canadian PICU  
• survey contained 2 case studies 
• the response rate was 55% (57/ 103 invited 
physicians, 13/15 PICU) 
• in patients that required MV, HFNC was the 
most common respiratory support therapy 
(57%) compared to CPAP (29%) 
• NIV was a standard of care for children with 
bronchiolitis in Canada, despite the lack of 
robust data to support its use  
• pediatric intensivists did not follow North 
American guidelines for bronchiolitis; as 
data for all the therapies were lacking 
• unique considerations in different cases were 
necessary; guidelines did not address the 
management of severe bronchiolitis 
Panciatici et al, 
2019 (93) 




- • assessed practices in HFNC in the 
emergency department and general floors 
• 135/ 217 (81%) responded (96 general 
hospitals, 39 university hospitals) 
• HFNC was commonly used in acute 
bronchiolitis outside the PICU (59.4% 
general hospitals vs. 38.5% in university 
hospitals)  
• HFNC initiation, settings and withdrawal 
were not standardized  




- - • review on the use, indications and 
management of HFNC in children  
• an overview of the machinery, mechanism 
of action and settings  
• descriptions on the use of HFNC in certain 
clinical conditions, including bronchiolitis, 
asthma and withdrawal of care  
• much of the information were drawn from 
evidence in infants  
• HFNC therapy should be initiated in the 
emergency rooms and PICU early to 
evaluate the severity of disease/ respiratory 
failure and the need to escalate respiratory 







- - • described the mechanism of action in HFNC 
therapy and its role in treating respiratory 
distress (especially bronchiolitis), including 
its advantages, limitations and complications  
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• provided suggestions for initial settings, 
signs of failure and escalation in settings  
• HFNC therapy may reduce work of 
breathing and reduce the risk of children 






- - • described HFNC use in children, including 
mechanism of action, clinical effects and 
indications in children after the newborn 
period (particularly bronchiolitis) 
• HFNC was a safe, well tolerated and feasible 
intervention and may reduce work of 
breathing 
• other benefits may the potential to reduce 
the need of CPAP and invasive MV  
• though there are no international guidelines 
on how to use HFNC, flow rates may be set 






- - • reviewed the knowledge, evidence and use 
of HFNC in children with bronchiolitis in 
the emergency department and acute floors 
• a summary of the HFNC initiation settings 
from different hospitals in USA  
• HFNC in children and infants may be safe, 
and more centers were using HFNC as an 
initial therapy for bronchiolitis 
Abbreviations: CPAP-continuous positive airway pressure; HFNC-high flow nasal cannula; MV-mechanical ventilation; NIV-
non invasive ventilation; PICU-pediatric intensive care unit 
 
Asthma 
Children presenting to the hospital with severe asthma exacerbation may require 
respiratory support (41, 42, 97). NIV options, such as BiPAP, CPAP and HFNC, are the most 
common (41). A methodological review with case scenarios highlighted one case of a 3-year old 
child presenting in the emergency room in severe respiratory distress, as a result of status 
asthmaticus, complicated with pneumonia (46). The article provided a general review of 
pediatric respiratory physiology, and the possible MV modes (e.g. PC, VC, PRVC) and initial 
settings (e.g. inspiratory time, respiratory rates, PEEP, PIP, tidal volumes). The child was 
initiated on HFNC for his respiratory distress but required imminent intubation for invasive MV 
due to impending respiratory failure. Once intubated, the child was started on SIMV PRVC 
settings, and shortly after the ventilator alarmed for high peak pressures. The review created and 
described an algorithm to troubleshoot this clinical situation.   
Other literature reviews also provide descriptions on the pathophysiology, diagnosis, 
medications and respiratory options to treat children with asthma (41, 97). This includes HFNC, 
NIV BIPAP, and if necessary, invasive modes of MV (41, 97). Jones et al., aimed to provide 
additional evaluation and management options for pediatric acute asthma exacerbations, not 
outlined in the guideline by the National Asthma Education and Prevention Program (NAEPP) 
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(97). The authors acknowledged there was limited evidence to provide recommendations on 
when or which MV option should be used, but HFNC, BiPAP and/or intubation should be 
considered. If a child requires invasive MV, no specific MV mode is considered superior to 
another, but clinicians must be careful to minimize risk of VILI and air trapping. There are 
generic HFNC recommendation guidelines available, but they do not explicitly review and 
comment on the use in children with asthma (24). Collectively, these only provide potential 
guides in MV management for children with asthma (Table 5). Therefore, more studies are 
required to inform evidence-based guidelines.  
 
Table 5: Articles and reviews discussed in Chapter 2, Topic 3c- Asthma 
Authors Study type (or 







Review - - • review on asthma management, including 
medications, HFNC, NIV and heliox  
• NIV indications included significant work of 
breathing, hypercapnia or hypoxemia  
• NIV mode should be selected based on the 
support required, either Bilevel or CPAP 
• a brief summary of HFNC was provided, 
and suggested that it may be used but there 
are limited studies to support its use 
Jones et al, 2016 
(97) 
Review  - - • overview of the available treatment options 
in acute asthma exacerbation in children  
• compared to National Asthma Education and 
Prevention Program guidelines  




- - See Table 4: Articles and reviews discussed in 







- - See Table 1: Articles and reviews discussed in 
Chapter 2, Subtopic 3a - MV modes 
Abbreviations: CPAP-continuous positive airway pressure; HFNC-high flow nasal cannula; NIV-non invasive ventilation; 
PEEP-positive end expiratory pressure; PICU-pediatric intensive care unit  
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2.3.4 Topic 4- Clinician Engagement in Protocolized MV 
Use and management of different MV options are often based on clinicians’ experience, 
due to the lack of national or international guidelines and protocols (33). Clinicians support the 
use of protocols (to limit variability in MV management), however, they acknowledge there are 
several barriers to successful implementation of protocols from recommended guidelines (3, 40). 
There are a few surveys and studies that explored the consistency of MV management across 
different centers and how protocol compliance may be improved.  
A systematic review evaluated 11 studies (with 267 participants) to understand the 
barriers and facilitators in the use of MV weaning protocols (98). Only one of the included 
studies was performed in the PICU, which the authors acknowledged is a different clinical 
environment compared to adult ICU. This systematic review showed protocols are generally 
accepted, but must take the social and cultural environment into account. To facilitate 
implementation, providers must be involved in the protocol development, and be familiar with 
the protocol (98). 
In a protocol implementation study by Duyndam and colleagues (28), an invasive MV 
management algorithm (targeted towards two different groups: with and without lung disease) 
assessed physicians’ adherence before protocol implementation, and after at two different time 
periods (t1=May to November 2009 and t2=May to November 2010). Prior to protocol 
implementation, 178 children (median age 4 months [IQR 0-211]) were included for the 
comparison and were divided into two groups, children with (n=67) and without lung disease 
(n=62). The compliance to the protocol for each were 79% in the lung disease group and 66% in 
non-lung disease group before the implementation. The protocol was designed by a 
multidisciplinary team, and included elements of LPMV strategies, with a specific MV mode for 
each group (lung disease group, PC vs. non-lung disease group, PRVC). The protocol was 
implemented in October 2008, and children thereafter were either included into the protocol 
group with lung disease (t1 n=51; t2 n=46) or without lung disease (t1 n=79; t2 n=85). In the first 
time period, t1, after protocol implementation, there were a total of 173 children (median age 8 
months [IQR 0-233]) and the reported compliance was 71% in the lung disease group and 78% 
in the non-lung disease. In the second time period, t2, a year after protocol implementation 
(n=156; median age 4.5 months [0-21]), there were noted improvements in protocol adherence 
(84% in both lung and non-lung disease group). Between the two groups, only the non-lung 
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disease group showed a significant increase in compliance (pre 66% vs. t1 78% vs. t2 84%, 
p=0.015). For successful protocol implementation, the authors gained staff approval, provided 
reminders, continuous education and safety reports. Furthermore, a well-organized 
implementation plan addressing the potential barriers and facilitators may have influenced the 
success of protocol adherence. Overall, with the proper education, resources and support, 
protocol adherence can be sustained and may translate to positive clinical outcomes.  
In a cross-sectional survey across Europe, 101 facilities from 23 countries responded to a 
survey that gathered information on the diverse use of NIV (30). The study revealed that NIV 
was initiated across different diseases and clinical circumstances. About 99% of the PICUs used 
NIV as a respiratory support therapy immediately after extubation, 77.5% for palliative care; and 
for respiratory failure caused by bronchiolitis (95%), pneumonia (97%), pulmonary edema 
(84%), upper airway obstruction (76%) and ARDS (91% in mild, 53% in moderate, 5% in 
severe) (30). Only 48% of the respondents had NIV protocols in place, suggesting variable NIV 
practices across Europe . Though this study did not provide clinical outcome measures, it 
demonstrated that NIV can be used for various applications, but availability of protocols were 
limited.  
With the increase in HFNC use as a NIV option for children in critical care, Hosheh and 
colleagues (33) used a cross-sectional survey to describe the current practices of HFNC use on 
the general floors and high dependency units (HDU). A total of 218 pediatricians from 81 
hospitals participated; 75 (91%) of the hospitals provided HFNC and 47 (58%) hospitals had 
HDU. The pediatricians were responsible for HFNC management 75% of the time, and 
responses for flow rates varied in different diseases and scenarios. One hundred and eighty-seven 
pediatricians (85%) supported the idea of developing national HFNC guideline for children on 
the general floors. And HFNC failure and HFNC length of use were identified as the most 
important outcome measures to include for future research. The results from this survey indicates 
that more research to is required to provide guidance in developing a national guideline.  
A survey collecting information on the airway management of children in burn units 
across North America, reported differences in MV practices (38). A total of 25 burn centers 
completed the survey, nine large centers (>50 ventilated patients in 5 year period) and 16 small 
burn units (<50 ventilated patients in 5 year period). There were no differences in the MV mode 
of choice, ranging from PC, SIMV, HFOV, or combination of settings. It did appear that HFJV 
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was used the least (p<0.05) compared to the others. Larger centers used SIMV more frequently 
compared to smaller centers (p<0.05). Therfore, MV management varied across centers and 
future studies should identify the benefits and limitations for each MV mode for burn patients. 
There are no guidelines for the use of NIV in cystic fibrosis (CF), a genetic disease, that 
is characterized by respiratory complications including airway obstructions, mucus plugging, 
inflammation and destruction of the parenchyma (99). A nationwide survey in France evaluated 
the NIV practices in CF patients, including their indications, MV modes, settings and interface 
options to develop a guideline (99). Thirty-six centers (15 pediatric, 13 adult, 8 adult and 
pediatric centers) for a total of 4,416 CF patients, were involved in the study. There were 
multiple indications for NIV reported across all centers, including CF exacerbations, lung 
function, sleep disturbances, insufficient long-term oxygen therapy, or lung transplantation. 
Bilevel pressure targeted ventilation was the preferred mode of MV compared to VC (p=0.18) or 
CPAP (p=0.9). Furthermore, the respondents provided a list of the perceived NIV benefits, but 
many were not backed up by evidence. This survey included NIV practices for both adults and 
children with CF (children were not separated out). The study concluded that NIV practices 
appear to be relatively similar across centers, but further studies are required to investigate the 
benefits of NIV in CF patients. 
Extracorporeal membrane oxygen (ECMO) is a life-support treatment specifically for 
supporting the heart and lungs in critically ill patients who are also intubated (29). The 
Extracorporeal Life Support Organization (ELSO) provides broad guidelines on the use of 
ECMO and MV. MV practices may vary across centers because there are no specific 
recommendations offered (29). A hundred and forty-four responded (34.2%) out of the 421 
centers invited, with representation from North America, Europe, Latin America, Asian-Pacific 
and Southwestern Asia/ Africa (29). Centers provided ECMO to children or adults, or both, with 
37.2% of respondents from pediatric-exclusive facilities, and 17.6% from mixed facilities. The 
MV strategy at the pediatric centers varied in regard to the mode of choice, with PC (74.5%) 
setting as the most common, compared to the others (e.g. PRVC 10.9%, VC 1.8%, HFOV 9.1%, 
NAVA 1.8% and Bilevel 1.8%). Additionally, indications for bronchoscopy, when to initiate 
MV weaning, lung recruitment techniques, tracheostomy and when to extubate, differed across 
pediatric sites. The authors noted an increasing trend in bronchoscopy use, tracheostomy and 
extubation across the adults and pediatric centers, but concluded that the change in respiratory 
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care and MV practices required further research to determine if this change translates to 
improved outcomes.  
A prospective postal survey in the United Kingdom aimed to describe the responsibilities 
involved with pediatric MV weaning in the PICU (100). Seventeen out of the invited 28 PICUs 
(61%) responded. Only 35% of the units had MV protocols, including specific topics such as 
weaning and NIV. Decision criteria in MV and weaning were collaboratively decided between 
nurses and doctors. The authors suggested that other health care provider directed protocols and 
automated weaning systems may minimize delays in MV weaning. Similarly, a European cross-
sectional survey with 65 participating facilities, from 19 countries aimed to determine the 
responsible personnel for MV management and the use of protocols in the PICUs (101). The 
most responsible person for MV management was usually the physician (>75% of facilities), and 
protocols for MV (31%), weaning (22%) and NIV (33%) were uncommon.  
An online questionnaire evaluated the acceptability of using a MV management protocol 
in a PICU for children with PARDS (31). A hundred and twenty-two physicians assessed the 
MV recommendations for 50 clinical case scenarios, with 80% of those recommendations 
deemed acceptable. In general, the recommendations for different MV modes were accepted, 
with HFOV at 83%, PRVC at 82% and PC at 75% (p=0.002). With respect to recommendations 
for specific parameter changes, all were widely accepted, including FiO2 86%, PIP 88%, HFOV 
frequency 74%, HFOV Amplitude 78%.  PEEP changes was the least accepted at 66% 
(p<0.001). When physicians were asked about their MV management practices, there was 
variability in some decision criteria. This included when children should be re-evaluated for 
weaning, whether the actual weight or ideal body weight for target tidal volumes should be used, 
the OI threshold to consider HFOV, or if VC should be used as the primary MV mode. Although 
many recommendations were accepted, this survey demonstrated that MV practices still varied 
greatly across centers. Therefore, MV management protocols may be necessary to reduce 
variability, and future research should evaluate the effects on patient outcomes.  
A multi-phase study explored the necessity and impact of MV weaning guidelines in an 
Australian PICU (69). In phase 1, a national survey revealed that SIMV with PEEP and PC or PS 
was the most popular MV weaning mode in PICU. For phase 2, a guideline with a descriptive 
algorithm was developed and evaluated by medical staff for its validity and safety. The MV 
weaning guideline was piloted on 10 patients for one month prior to implementation in Phase 3. 
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Phase 3 used a quasi-experimental time series design to measure the impact of the guideline on 
113 patients (historical control group before guideline implementation included 107 children) 
over two years at a tertiary PICU. There were no significant changes to the length of stay, but 
quality measures were slightly improved and a reduction in fluctuation of outcome variables, 
suggesting improved adherence to the guideline. In the final phase, a qualitative methodology 
(survey and interviews) was executed to understand the medical staffs’ perceptions on using the 
proposed guideline. Overall, staff perceived that the guideline implementation improved patient 
outcomes as it provided a framework and improved interdisciplinary collaboration for their 
weaning practice. However, several barriers in guideline use included resistance to practice 
change and the concern of withholding their clinical judgement. In summary, staff feedback on 
the use of a MV weaning guideline was positive and the barriers identified were associated 
clinicians’ autonomy and comfort. Though the author emphasized that the weaning guideline 
should not replace clinical judgement.  
Overall, it is important to include clinicians to not only develop optimal MV management 
protocols for different pediatric diseases, but to also help facilitate its implementation in practice 
(31, 33-35). This is especially important given MV practice varies across centers (32, 33, 100, 
101). Much of the current available information are overviews and broad guidelines for NIV and 
HFNC (2, 24, 50), or specific diseases, such as PARDS, asthma or bronchiolitis (76, 89, 91, 102) 
(summarized in Table 6). However, these only describe a few types of MV delivery mechanisms 
for certain diseases out of the many that require MV management.  
 
Table 6: Summary of articles discussing clinician engagement in protocolized MV management 
described in Chapter 2, Topic 4 
















- • evaluated the barriers and facilitators 
of using protocolized weaning  
• one study was conducted in the PICU 
• protocols were generally accepted, but 
must take into account for social and 
cultural environment  
• broadening the understanding and the 
application of the protocol may 
improve their use 




implementation;   
507 children 
(median age 5 
months, 0-50) 
MV protocol for 
children with or 
without lung disease 
• assessed physicians’ adherence to MV 
protocol prior (before October 2008) 
and after implement (measured in 2 
time periods; t1 =May – November 
2009; t2 = May – November 2010)  
• for children with lung disease, there 
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was a slight increase in adherence; pre 
79%, post t1 at 71% and post t2 at 84%, 
p=0.092 
• for children without lung disease, there 
was an improvement from pre 66% and 
post t1 78% and post t2 84%, p=0.015 
• education, reminders, and protocolized 
nursing care, may improve MV 





Survey’s objective Results 
Mayordomo-
Colunga et al, 
2018 
(30) 
101 units from 






To describe NIV use 
in Europe  
• 99% of the countries used NIV as a 
respiratory support post extubation 
(95.5% prophylactically, 99.1% 
therapeutically) 
• 77.5% used it for palliative care  
• NIV was used 15.5% on the floors, 
20% in the emergency department, and 
36.4% during transport  
• indications for NIV included 97.4% for 
pneumonia, 94.6% bronchiolitis, 
75.2% bronchospasm, 84% for 
pulmonary edema, 76.1% for upper 
airway obstruction and 91% for 
PARDS 
• NIV was given using oronasal mask 
(44.4%) and CPAP using nasal cannula 
(39.8%) 
• bilevel mode of preference is PS 
(62.3% in infants, 74.5% in older 
children) 
• authors concluded that NIV use varied 











To describe HFNC 
use, weaning 
practices, and ideal 
outcome measures (for 
future research)  
• 93% of the hospitals used HFNC 
• 75% of the decision to initiate HFNC 
was the responsibility of the physician 
• about 68% of the physicians used 
HFNC instead of CPAP (HFNC was 
seen more effective with less 
complications)  
• failure rate and length of HFNC 
therapy were deemed as the most 
important outcome to measure  
• pediatricians supported the 
development of national HFNC 
guideline  
Silver et al, 
2004 (38) 
25 pediatric 
burn centers  
North America To examine the 
patterns of pediatric 
airway management  
• North American pediatric burn centers 
listed by the American Burn 
Association were invited 
• no specific MV mode used; PC, SIMV, 
HFOV, HJFV or combination of 
different modes were used 
• large centers used SIMV more than 
small (p<0.05)  
• large centers usually used cuffed 
endotracheal tubes compared to small 
centers  
Faroux et al, 
2008 (99) 
36 centers  France  To determine NIV 
practices for treating 
cystic fibrosis  
• a total of 36 centers (15 pediatric, 13 
adult, 8 mixed)  
• NIV was used for various purposes, 
including cystic fibrosis exacerbations, 
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lung function, sleep disturbances, 
insufficient long-term oxygen therapy, 
or lung transplantation 
• bilevel was the most preferred mode 
and nasal masks to deliver therapy  














Asian Pacific  
Descriptive cross-
sectional 22 item 
survey  
• Described changes in MV strategies, 
use of tracheostomy, bronchoscopy 
practices at ECMO centers  
• Increased extubation at all ECMO 
centers (27% pediatric, 41% mixed, 
52% adult); increase use of bilevel for 
lung recruitment, bronchoscopy and 
tracheostomies 
• MV modes varied across centers, with 
PC as the most common (95% for all 
centers, 74.5% in pediatric, 50% in 
mixed centers) 
• other MV modes included VC, PRVC, 
bilevel, CPAP, HFOV, VDR, NAVA 
and assist control 
• weaning MV modes varied, with PC as 
the most common (34% for all centers) 
followed by bilevel, PRVC, HFOV and 
manual ventilation  
• significant variation in ECMO MV 
modes internationally (even though PC 
is the most commonly reported) 
• other MV considerations such as 
PEEP, rate, initiation of weaning and 
lung recruitment modes differed = 
Blackwood et 
al, 2013 (100) 
One nurse 
manager from 




To describe clinicians 
responsible for MV 
weaning, protocol use 
and education on MV 
• reported the characteristics of 
clinicians responsible for MV weaning, 
the use of protocols and automated 
weaning options and perception on MV 
management education 
• 17/28 PICU invited (14 PICU, 3 
mixed) 
• weaning initiation, method, 
management and assessment were the 
collaborative responsibility of 
physicians’ and nurses’ responsibilities 
• 35% of the units had MV protocols in 
place, 18% for weaning, 35% for NIV 
• 18% used closed loop systems  
• protocol-directed and close looped 
























To evaluate MV and 
weaning practices in 
Europe 
• this study described: 1) the 
responsibility for MV management and 
weaning; 2) use of protocols, SBT, 
NIV, HFNC, automated systems; 3) 
nurse-to-patient staffing ratios and their 
autonomy and influence in making MV 
decisions  
• 65 out of 102 centers responded 
• >75% physicians and fellows had key 
responsibility for MV management  
• guidelines/ protocols were available 
but uncommon for respiratory 
management; for MV (31%), weaning 
(22%), and NIV (33%)   
• HFNC (53%) and NIV (52%) were 
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used often to avoid intubation 
• SBT were used in 44% of the PICUs 
• large variability in the interprofessional 
team involvement and MV 
management responsibility across the 
centers  









network, USA  
Survey with 50 
clinical scenarios with 
suggested MV 
strategies  
• assessed the acceptability of the MV 
strategies outlined in clinical scenarios 
• about 80% of the scenario 
recommendations were accepted 
• acceptance varied by the MV mode: 
83% in HFOV, 75% in PC and 82% in 
PRVC (p=0.002) 
• PEEP recommendations were the least 
accepted (69%)  
• lack of consensus in MV practices 
demonstrated that a protocol may be 
necessary for lung protective strategies  
• though many of the recommendations 
were accepted, it did not translate to 
successful implementation/ adherence  
Keogh, 2004 
(69) 
PICU Australia Identify weaning 
practices and staff 
perceptions to 
weaning protocol 
• This thesis manuscript described a 
multi-phase study: 1) national survey 
on the practices of pediatric MV 
weaning methods; 2) protocol 
development and pilot study; 3) 
pre/post protocol interventional study; 
4) qualitative study on the staff’s 
perceptions and feedback of guideline 
use  
• phase 1: the most common method for 
pediatric weaning was SIMV with 
PEEP and PS/ PC  
• phase 2 and 3: the protocol was 
trialled, with no significant 
improvements in outcome measures 
including length of stay and ventilation 
time (70) 
• phase 4: staff responded positively to 
the protocol as it provided them with a 
framework and guide to collaboratively 
wean patients and may have improved 
clinical outcomes   
• barriers were clinicians’ discomfort 
and restrictions on their clinical 
judgement 
• use of a protocol is meant to guide 
practices, not to replace clinical 
judgement 
Abbreviations: APRV-airway pressure release ventilation; CPAP-continuous positive airway pressure; ECMO-extracorporeal 
membrane oxygenation; HFJV-high frequency jet ventilation; HFNC-high flow nasal cannula; HFOV-high frequency oscillary 
ventilation; MV-mechanical ventilation; NAVA-neurally adjusted ventilatory assist; NIV-non invasive ventilation; PARDS- 
pediatric acute respiratory distress syndrome; PAV-proportional assist ventilation; PC- pressure control; PEEP-positive end 
expiratory pressure; PICU-pediatric intensive care unit; PRVC-pressure regulated volume control; PS- pressure support; RT- 
respiratory therapist; SBT- spontaneous breathing triarl; VDR- volume diffuse respiration; VS- volume support  
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2.3.5 Topic 5- Respiratory Therapists 
RTs are health care professionals who assess and provide therapies to support people’s 
breathing, across all age groups, in a variety of practice settings, and in an assortment of diseases 
(58, 103-105). They are specially trained to provide care in acute and long-term MV, airway 
management, cardiopulmonary resuscitation, diagnostics, oxygen therapies, and pulmonary 
rehabilitation (PR) (105-107). Specialized RT driven protocols in acute care have been shown to 
reduce direct and indirect costs in healthcare (58, 108). Currently, RTs are known to practice in 
Canada, Qatar, United States of America (USA), Taiwan, China, Philippines, India, Saudi 
Arabia, Singapore, Liberia, Ghana, Yemen, Puerto Rico, Kuwait and United Arab Emirates 
(https://twitter.com/MikaRT/status/1298664147010359297?s=20). 
When RTs are most responsible for identifying and treating patients on MV (through the 
use of standardized protocols), patient outcomes improve (109), evidence-based practice and 
standardization of care is enhanced, and compliance to best-practices and interprofessional 
teamwork is improved (27, 110-112). RT-driven evidence-based and standardized protocols on 
MV management have been shown to be feasible and associated with positive patient outcomes 
(27, 103, 109, 111, 112). RT-driven protocols have been associated with decreases in mean MV 
duration by 58 hours (p<0.001) and hospital length of stay by 1.77 days, compared to historical 
physician-directed protocols (113). Similarly, Wood et al  (114) demonstrated a shorter median 
MV duration when RTs weaned patients from MV, compared to physicians. This included 
weaning patients after stable elective and emergency coronary artery bypass surgery, 16.8 
vs.18.6 hours (p=0.02); and with the addition of patients on intra-aortic balloon pumps, with 
prior history of cardiac surgery, and cardiac valve surgery: 17.8 vs. 19.7 hours (p=0.04), 
respectively (114). A prospective cohort study with 271 adult patients were weaned by 
respiratory care practitioners using a weaning protocol, which decreased the median time to 
wean from 29 days to 17 days (p<0.001) (115).  
Health professional/allied health directed protocols, particularly by RTs, can decrease 
duration of MV, length of stay and optimally wean patients from MV (110, 112, 113). 
Furthermore, RT specialized care through protocols, may reduce direct and indirect healthcare 
costs and resource allocation by providing specialized care, protocol-directed interventions and 
decision making (58, 108). Though RT-driven MV protocols have shown success, the majority 
were performed in the adult population (103, 114, 115). The outcomes of RT-driven protocols 
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for pediatric MV management is scarce, and one study from the Penn State Children’s hospital 
(219 children, median age 33.7 [IQR 3.5-157.7]) indicated there were no changes in SBT 
initiation, MV duration, hospital or PICU stay (109). That pre and post protocol implementation 
study developed a RT-driven protocol to guide SBT screening, initiation and initial PS level. 
However, although implementation was successful, RTs screened 56.4% of the eligible patients, 
30.7% completed the screening within the protocol’s timeline and only 42.1% set the PS level as 
indicated in the protocol. The authors acknowledged that there were difficulties in maintaining 
compliance over time and poor protocol compliance may have been the reason their RT-directed 
protocol yielded minimal benefits. Overall, more research is required to understand the impact 
RT-driven protocols have on pediatric MV management. 
 
2.4 Summary and Conclusions  
There is sparse literature informing the best approaches for standardized and 
comprehensive pediatric MV management (17). Much of the evidence was based on adult, 
neonatal and/or practitioner personal experiences (1, 2). Many trials were small, and described 
pediatric MV management for single diseases, or smalls component of MV management such as 
weaning. When protocols were available, compliance was usually low across studies (31, 34, 40, 
88). Many of the included studies in literature review were not conducted in Canada. Only two 
surveys (34, 40), one study in a systematic review (98) and one pilot study (75) were found. 
Therefore, adherence and impact of protocolized MV in Canadian PICUs less known. Larger 
clinical studies in the Canadian context are required to understand the impact of standardized 
pediatric MV management on patient outcomes (8, 34, 40, 75, 98, 102). 
In response to the overall lack of standardized and comprehensive pediatric MV 
practices, the ESPNIC (2) organized a consensus conference for European physicians with 
expertise in pediatric MV management. The premise of this conference was to collectively 
determine the best approaches to pediatric MV management for clinical practice and future 
research. ESPNIC outlined 142 recommendations, which detailed many aspects of pediatric MV 
management including MV modes, monitoring, targets of oxygenation and ventilation, weaning 
and extubation (termination of MV) readiness in children with various diseases. ESPNIC were 
the first group to establish consensus recommendations on the many components of pediatric 
MV management, across different disease groups. The consensus conference found insufficient 
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to no evidence on all aspects of MV weaning and extubation processes for critically ill children. 
This led the group to challenge healthcare providers to “embark on local or global initiatives to 
fill this huge knowledge gap” (2). Additionally, the authors repeatedly mentioned the need to 
minimize variability in practice to facilitate the understanding of their impact on clinical 
outcomes. Standardized protocols for overall pediatric MV management across a wide range of 
diseases would support this cause.  
ESPNIC were the first to outline comprehensive recommendations for many aspects of 
pediatric MV management across many disease states. These were based only on European 
physician expertise. Reinforcing the recommendations outlined by ESPNIC with Canadian RT 
expertise, may expedite the standardization of pediatric MV practices in Canada. This may 
enhance clinical practice by minimizing interventional variability and help inform future studies 
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3.1 Introduction to the Delphi technique in Health Sciences  
The Delphi technique was originally developed in the 1940s, and has been modified over 
the years to satisfy the unique goals of different disciplines, but its overall purpose remains the 
same (1-4). In health sciences, this technique is used to identify, discuss and guide future health 
approaches in the areas with unknown or not well supported evidence (5-8). It is important to use 
empirical evidence to guide medical practices and education but not all questions can be 
answered by conventional quantitative research methods (2, 9). The Delphi can be used to 
understand and establish guidelines and priorities in speciality practices (e.g. mental health, 
palliative care, critical care), predict disease patterns, direct nursing education, and standardize 
practices and policies (2, 7, 10, 11). Other applications of the Delphi technique include 
diagnostic criteria development, indicators for medical quality, assessment for medical 
interventions, and establishment of research agendas (12).  
The Delphi technique utilizes a series of surveys, referred to a Round, to gather 
controlled feedback from a group of participants, identified as experts in the field (13). The 
process generates ideas and seeks consensus from these experts to resolve problems or clarify 
information (1, 2, 14). Details of the process is outlined in Sections 3.4 Preparing for a Delphi 
Survey and 3.5 Sequential steps of the Delphi survey. This chapter aims to provide the 
background information about the Delphi survey technique; the specific application of this 
technique to the outlined study are described in Chapter 4– The Pediatric Mechanical Ventilation 
in Canada (PeMViC) Study: A Delphi Survey of Pediatric Mechanical Ventilation Practices by 
Canadian Respiratory Therapists.  
 
3.2 Other Consensus Methods 
The consensus conference, nominal group technique, and the Research ANd 
Development (RAND) / University of California, Los Angeles (UCLA) appropriateness method 
are several other consensus methods that aim to generate new ideas, problem solve or 
collaboratively form solutions in topics lacking sufficient data (15, 16). Each technique builds 
consensus differently, yet they share fundamental features including some level of anonymity, 
systemic controlled feedback, and statistical group responses (15).  
However, these consensus groups have several disadvantages compared to the Delphi 
technique such as requiring their participants to meet face-to-face to discuss ideas, risking the 
influence from dominating individuals on the final consensus (5, 15, 16). These methods have a 
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similar challenge in organizing real-time meetings, which require extensive resources to be 
executed properly (8, 12). In contrast, the Delphi technique allows non-synchronous consensus 
building process, which is convenient and require minimal resources (2, 9, 10, 14, 15, 17). 
Participants in a Delphi are anonymous to each other, which also minimizes the risk of influence 
from other members during the consensus building process (1, 18, 19).    
 
3.3 Types of Delphi surveys  
The Delphi technique has been modified to improve its applicability to different 
disciplines and to satisfy different research goals (2, 3). The various types of Delphi techniques 
are Classical, Modified, Decision, Real-time, Policy and Argument Delphi surveys (1, 2, 5, 20). 
Two common Delphi methods in health sciences are the Classical and Modified Delphi 
technique, which differ by the structure of their Round 1 (2, 17, 21). 
 
3.3.1 Classical method 
Round 1 in the traditional Classical Delphi method is unstructured and seeks feedback 
using open-ended questions (6, 21). The purpose and open-ended questions must be clear to help 
participants provide targeted information, and avoid vague, broad responses (1). Participants are 
invited to freely provide their ideas and opinions drawn from their knowledge and personal 
experiences (2, 10, 17). Unfortunately, this approach can be time consuming because it usually 
produces a large amount of unstructured raw data for review and analyses (1, 14).  
 
3.3.2 Modified method 
In a modified Delphi, Round 1 does not follow the same open-format as the Classical 
method (3, 7, 14, 22). Instead, the research team specifically identifies the issues or topics to 
include in the survey prior to asking the experts to review and comment (2, 14, 17). The data 
collected is qualitative, focused, and minimizes large volumes of data (compared to the Classical 
method) (1, 2, 18). The content of the survey may be generated in any of the following ways (1, 
14): 
• From existing literature or documents 
• Focus groups, or 
• One-to-one structured interviews  
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Unlike the Classical method, this approach helps experts orientate to the available data and 
researchers to analyze and interpret reasonable volumes of raw data (1, 21). Although this 
minimizes the volume of data, researchers must be aware that this method may limit response 
options and introduce researchers’ bias (1, 6).  
 
3.4 Preparing for a Delphi Survey 
An official guideline to prepare and run a Delphi survey do not exist, but there are several 
notable factors to consider when preparing for one (2, 17).   
 
3.4.1 Outlining the Purpose of the Delphi technique 
One must evaluate whether the Delphi technique will answer or fulfill the intended 
research objectives (2, 17, 23). A Delphi survey may be considered over other consensus 
methods when there are geographical constraints and resource limitations (10, 24). The Delphi 
technique should be considered when the purpose(s) includes any of the following: 1) to explore 
or generate information about a topic; 2) to seek information and establish consensus; 3) to 
expose and educate diverse views of participants; and/or 4) to generate expert opinions or 
recommendations on a topic with limited empirical data (1, 2, 6, 11, 14, 17, 22, 25). The Delphi 
technique is recommended and commonly used for the development of practice guidelines, 
especially in healthcare, when evidence for standards of practice are limited (16). 
 
3.4.2 Resources for Delphi survey  
The resources required to smoothly run a Delphi study will depend on the sample size, 
the participants’ characteristics, the complexity of the Rounds, and the research team’s skills (2, 
18). Access to appropriate, qualified participants is necessary in a Delphi study. Depending on 
the purpose of the Delphi survey, the participants involved may be individuals who have 
extensive background knowledge or personal experience on a topic, or are from the general 
public (1, 13). Researchers must explicitly outline the desirable characteristics prior to 
recruitment and ensure participants understand the purpose of the study (1, 2, 14, 24). To identify 
and recruit the most suitable participants, see Chapter 3.4.3 Target sampling/ Panelists. 
An individual acquainted with the process usually maximizes the study’s success because 
they provide valuable insight, and can address any complications that may arise (2, 17). 
However, regardless of how experienced a researcher may be, improper management or analysis 
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of the data will threaten the success and integrity of the study (13, 17). Therefore, it is crucial to 
establish a detailed monitoring system to oversee the communication, responses, and data 
analysis of the study (2, 13). 
 The time required to run a Delphi survey, is usually underestimated, but with the popular 
use of electronic platforms, distributing Delphi surveys are easier  (2, 10, 24). Technology and 
online resources facilitate quick communication, and saves time and costs (10, 14). Participants 
need adequate amounts of time for each step of the Delphi study to ensure quality results and 
good response rates (1). Timing required during a Delphi survey is further discussed in Chapter 
3.6.2 Limitations. 
 
3.4.3 Target sampling/ Panelists 
One of the unique features of the Delphi technique is the panel of experts. The term 
expert is liberally used, as it is defined as any individual with the understanding, knowledge, 
experience and skills related to the topic being investigated (1, 24). Because the literature does 
not provide an absolute definition of an expert, researchers should identify their target 
participants by outlining a list of eligibility characteristics prior to the start of the study (2, 6, 10, 
14). The literature suggests recruiting individuals with an assortment of characteristics and 
experience to maximize heterogeneity within the panel to yield high quality results (1, 6, 11, 21). 
Credible experts with variable backgrounds will generate a wide range of information compared 
to homogenous panels, and less credible experts will raise concerns on the validity of the 
consensus (2, 6, 13, 22). In clinical science, there should be considerations of the individual’s 
scientific credibility, work experience, knowledge and influence in the field of study (6, 24). 
Therefore the expert panel must be purposefully sampled, using a variety of techniques such as 
non-random sampling and snowballing technique (2). The size of the expert panel varies greatly 
across studies, ranging from as little as five, up to a few hundred (1, 14). The literature does not 
provide an ideal number of participants to include, but suggest over 30 may be excessive (2, 18, 
24). Larger sample sizes may increase the heterogeneity but are hard to manage and likely to 
experience higher attrition rate (16, 18). In comparison, small sample sizes may be easier to 
manage but may not be representative of the discipline’s collective judgements if recruitment is 
restrictive (14, 22). It is recommended that researchers recruit 15 to 30 participants from the 
same discipline or include 5 to 10 participants from each discipline when considering a 
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multidisciplinary panel (16, 18, 22).  
In summary, the researchers are responsible for defining the characteristics of their expert 
panel and how many should be included to satisfy the purposes of their Delphi study (12, 14). 
Emphasis should be placed on the quality of the experts (to enhance group representativeness) 
instead of focusing on the sample size (6, 11). Additional factors such as the study’s aims and 
resources should be considered when deciding the number of experts to include (7, 10, 16). It is 
best to recruit a manageable size of well-informed individuals to ensure feedback quality, while 
minimizing attrition (6, 10, 13). 
 
3.4.4 Defining Consensus and Stability  
The fundamental objective of using a Delphi study is to determine the level of agreement 
on a topic or problem, amongst experts in a field (4, 14). Currently, a universally accepted 
definition of consensus does not exist and are measured differently across studies (21, 26). Some 
studies do not explicitly state what constitutes consensus, and leave it to the readers’ 
interpretation (6). However, it is recommended that prior to survey initiation, the definition of 
consensus is distinctly defined (2, 17, 20). This is done by statistically analyzing the convergence 
of opinions from the Likert responses in the quantitative Rounds of the Delphi study (22).  
Although the definition of consensus is not always reported in studies, the percentage 
threshold is the most common method (6, 14, 27). The percentage threshold will rely on the 
importance of the research question (21). Many studies use percentages with thresholds ranging 
from 50% to 100%, with 70 to 75% agreement as most common (1, 22, 27). For example, when 
using a 70% cut-off, consensus is achieved when greater than 70% of the participants vote on a 
particular rating on the Likert scale (2, 14). A consensus level of approximately 70% is 
reasonable and is usually within one standard deviation of the mean of all responses (21, 24).  
For other studies, a percentage level may not be sufficient (14, 28). Measures of central 
tendencies and dispersion are the next commonly reported measures of consensus, and showcase 
the distribution of scores collected (2, 3, 14, 22, 26). The mean represents the participants’ 
collective stance on the Likert scale score, and a small standard deviation (minimal dispersion 
around the mean), supports the certainty of consensus (18, 27). The combination of the median 
and interquartile range is just as popular in Delphi studies; they are considered rigorous and 
objective, and are not skewed by outliers (26).  
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Additional statistical analyses may be performed to determine the responses’ confidence 
and stability as measurements for reporting consensus (14). Group stability occurs when there 
are no significant differences between responses across the Delphi Rounds (14, 26), and can be 
measured using parametric or non-parametric statistics (26, 28-30). In surveys with over 30 
participants and normally distributed data, parametric measurements such as the coefficient of 
variation, F-ratios, Pearson’s correlation coefficient or paired t-tests across two consecutive 
rounds may be measured (28, 29). When data is collected from less than 30 participants or is 
skewed, non-parametric tests such as McNemar change test, Spearman’s rank correlation 
coefficient, Wilcoxon paired signed ranks t-test (Mann-Whitney U test), could be considered to 
analzye categorical and ordinal data (23, 28). The use of these categorical analyses may provide 
relevant information about the differences in subgroup opinions (18).  
There is no preferred method to determine consensus, and various measurements are 
reported across different studies (1, 2, 14, 27, 28). Given the flexibility of the Delphi technique, 
it is possible for investigators to consider a combination of statistical analyses when exploring 
their data, in order to thoroughly assess for possible patterns or explanations (1, 18). The Delphi 
technique is utilized for a broad range of topics and disciplines; therefore, a widely accepted 
consensus definition is not possible. Regardless of which statistical analyses are used, it is 
recommended the method used to measure consensus, is decided prior to initiating the study and 
suits the research question (1, 14, 21).  
 
3.4.5 Administration and Informing the Panel  
Delphi surveys may be distributed through the post, or preferably, using an electronic 
platform (10, 22, 24). Once the participants are identified, a formal information sheet detailing 
the research objectives, time commitment, instructions for each Round and the value of their 
opinions, is recommended (2, 10, 17). Informing participants is an important step as it will help 
them understand the goals of the study and build a rapport to enhance response rates (17). The 
key is to maintain constant communication with the participants, as participant retention is 




3.5 Sequential steps of the Delphi survey  
3.5.1 The Pilot Test and Round 1 
The type of Delphi method used will determine the contents of the survey nature of 
Round 1’s format. Whichever type is used, the contents of the survey for Round 1 should be 
piloted in a smaller group of experts (2). A pilot test is optional, and are not consistently reported 
in studies or performed. (2, 24) However this step is essential as it trials the potential survey and 
identify ambiguities in the process. This allows researchers to improve on its feasibility and 
clarify the questions to decrease the risk of study problems, and improve content and face 
validity (2, 6, 11, 24).  
Once the survey contents are finalized for Round 1, it may be distributed to the expert 
panel for review and feedback. It is important to engage with the participants to ensure they 
understand the importance, purpose and timeline of the study (10). Regardless of the type of 
Delphi used, the intention of this Round is to collect open response feedback that will inform the 
contents of the subsequent Rounds (2, 14, 16, 17).  
 
3.5.2 Round 1 and analysis 
The amount of data produced from Round 1 can be large, especially when using the 
Classical Delphi approach (21). Ideas and feedback are reviewed, categorized, condensed and 
cross-referenced based on key terms and recurring ideas (10, 14, 17, 22). Reviewing and 
summarising the information is crucial; avoiding this step will lead to an excessive number of 
statements (21). The content analysis can be performed manually by designated members of the 
research team, or with software such as NVivo, Ethnograph or Nud*ist (10, 17). Round 1 results 
will highlight the important ideas from the panel, and will guide the construction of the 
questionnaire for subsequent Rounds (1, 6).   
 
3.5.3 Round 2 
Rounds following Round 1 are specifically structured to collect quantitative data by using 
a ranked scale, usually a Likert scale (2, 10). The purpose of this Round is to confirm the 
accuracy of the results obtained from Round 1 (1, 10). To ensure participants understand, they 
receive an information sheet for Round 2, detailing the purpose and process (2). Participants are 
asked to rate their level of agreement or disagreement using the rating scale for each item on the 
survey (2, 21).  
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Round 2 Analysis 
The statistical analyses for Round 2 will depend on the research question and methods 
chosen. For example, ratings from Round 2 can be inputted into a statistical software for data 
analysis (2). Each item is evaluated for convergence of responses, and other statistical 
information including frequencies, measures of central tendency and dispersions (22, 24, 26, 28). 
Consensus for an item is reached once it reaches the decided threshold (Section 3.4.4 Defining 
Consensus and Stability) (1, 3, 14).  
For the statements that have reached consensus, the researchers may choose to either 
remove or keep the statements for subsequent Rounds (1, 2, 24). Clear criteria on omitting and 
combining items across Rounds must be outlined before initiation and well-documented 
throughout the study (2). Maintaining all items for future surveys, may help all items gain the 
highest possible level of consensus (2). However, eliminating items when consensus is reached 
shortens the survey for subsequent Rounds, and minimizes participants’ fatigue (2, 24).  
 
3.5.4 Round 3 to n Rounds 
Rounds subsequent to Round 2 follow the same format (2, 14). The purpose of Round 3 
is for participants to review opinions from the previous Round (based on a summary of the 
statistical results) (2, 10, 14, 24), and to keep or reconsider their answers (14). This is an 
opportunity for participants to clarify information and explain why their responses may have 
fallen outside the consensus range (14, 22). The data analysis for Round 3 (and the Rounds 
following) is identical to Round 2 (2, 14). 
 The total number of Rounds for the Delphi survey is based on the main research 
objective, and the degree of consensus desired as early termination may yield meaningless results  
(2, 14, 17). Often it is terminated when all questionnaire items reach consensus; however, this 
may not be feasible due to limited resources, time and increase participants’ fatigue and attrition 
(2, 7, 10, 25). Traditionally, the Delphi technique consisted of 3 to 4 Rounds, but over the years, 
2 to 3 Rounds were deemed sufficient (17). To minimize fatigue, many studies have opted to 





3.5.5 Completing the Delphi study 
There may be items in a Delphi survey that do not gain consensus. Different statistical 
analyses and thoughtful review should be considered to evaluate and understand the reasons why 
(14, 27). If consensus is achieved on all items, it does not mean the results are the final solutions 
to the original research question or issue; a Delphi survey does not replace scientific studies (21). 
The results from Delphi studies are the sum of the available evidence and research data, aimed to 
direct future research and discussions (7, 17, 21, 22).  
 
3.6 Benefits and limitations of using Delphi  
3.6.1 Benefits 
There are several advantages associated with using a Delphi technique. This technique is 
a flexible and cost-effective way to generate information from a group of experts for the unique 
purposes of each study (3, 10, 18, 22). The Delphi can also be time-efficient, since most 
questionnaires are now distributed and managed with electronic tools, which facilitates data 
collection and communication (2, 10, 14).  
The Delphi technique minimizes biases and group think as participants respond 
anonymously, and have considerable amounts of freedom to express their opinions and explore 
new ideas without embarrassment or scrutiny from their colleagues (3, 7, 10, 14). Though 
anonymous to each other, the Delphi technique as a whole is quasi-anonymous because the 
researchers are able to see all responses from all participants (13). This feature ensures 
accountability and scientific merit because it allows researchers the opportunity to follow up 
with participants to clarify responses or gather more data if necessary (6, 22, 31). However, it is 
crucial to remember that the consensus derived from a Delphi survey is specific to that specific 
group of experts during that period of time (13). 
 
3.6.2 Limitations  
 Lack of universal guidelines 
While the Delphi technique can be modified to meet unique purposes, this feature is 
considered a weakness as well (21, 24). The lack of scientific or universally accepted methods 
threatens the technique’s methodological rigor and validity, especially when poorly managed (3, 
10, 20, 24). Variations can occur during participant selection, when consensus definitions are 
established, in the number of Rounds, and during reporting. To address this issue researchers can 
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utilize methods journals or logbooks to monitor and manage the study, and to preserve its 
integrity (4, 6).   
 
Participants  
The definition of expert is often ambiguous; the criteria for experts can be broad or 
specific. As a result, researchers’ bias can influence the panel selection, affecting who and how 
many participants are recruited (2, 7, 12, 17, 21). This limitation has led to several debates on the 
validity of professional opinions (6, 17).  
Another disparity across studies is the size of the panel. Some have suggested a minimum 
of 10 participants is ideal, but some studies have included up to a few hundred (1, 14). Including 
over 30 participants may not improve results, as larger groups are harder to manage and may 
result in higher attrition rates (1, 10). Sample size should be dependent on the characteristics of 
the involved participants, as the goal is to include participants that are not only qualified, but 
representative of the larger population (31).  
 
Lack of complete anonymity 
The Delphi technique is quasi-anonymous, which may increase the risks for participant 
and researcher bias (13, 21). Since the recruitment is selective, participants may refer 
acquaintances to participate in the study, making it difficult to maintain anonymity amongst the 
participants (17). Thus, true anonymity is not guaranteed and may potentially influence 
participant responses to conform with the group majority (21).  
Participants are also identifiable to the researchers, allowing them to follow-up with 
participants to enhance response rate, and clarify any ambiguities (2, 14). However, researchers 
are in an influential and powerful position, which may cause participants to feel pressured into 
completing the surveys (13, 24). And the quasi-anonymous feature may be a concern and risk for 
participant’s privacy and confidentiality. 
 
Achieving Consensus   
Consensus is not universally defined, and it is the researchers’ responsibility to decide 
which method is the most appropriate for their objectives (14, 21, 24). It is recommended that the 
consensus threshold is defined prior to data collection, and clearly reported in publications, 
though this is not exercised in all studies (6, 27). 
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The Delphi survey has been criticized for “forcing consensus” or “molding of opinions” 
(7, 14). The Delphi survey reduces opportunities for participants to discuss their ideas, which 
may lead them to rely on group results to inform their opinions (17). Some experts may actually 
change their responses to conform with consensus instead of conveying different and valid issues 
(22, 24).  
 
Resources  
Organization, time and resources are required to efficiently and properly execute Delphi 
studies, but descriptions on the time and dedication required to run them is underreported and 
underestimated (2, 17, 22). Although electronic platforms minimize many of the traditional costs 
such as paper copies and postage fees, virtual subscriptions and other expenses may be required 
to ensure smooth administration (2, 13). Furthermore, ongoing attention and time commitments 
from both the participants and researchers are required (1, 3). It is recommended that a minimum 
of 45 days is set aside to complete the Delphi survey, with two weeks in between Rounds (14, 
22). If there are large quantities of statements, it will increase the time required to revise and 
analyze. More time may be required to follow up with non-respondents and to adequately 
analyze the data in between Rounds (13). Increasing the time required to complete the Delphi 
survey, may affect participants’ motivation and response rates (14, 24). In addition, the 
continuous repetitiveness and isolation from other participants may induce frustration (1, 24). 
Thus, it is important that the required time commitment, purposes, and study protocol are 
explicitly explained to participants prior to study initiation (2).  
 
Response Rates   
There are several factors that may increase the risk for low response rates (14). This 
includes the complexity and number of Delphi Rounds, prolonged turn-around times between 
Rounds, or large groups of participants (causing attrition) (10, 22). Response rates for Delphi 
surveys have ranged widely between 8% to 100% (1). Low response rates are undesirable and 
will jeopardize the quality of the results; therefore, striving for the highest possible response rate 
will support the survey’s validity (10, 14). It is suggested that at a minimum 70% response rate is 
required to safeguard content validity (20). Section 3.7 Addressing Attrition describes important 
ways to maximize response rates.   
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3.7 Addressing Attrition 
The Delphi technique may have issues with attrition if the process is time consuming, 
causing participants to fatigue and withdraw from the study (3, 24). This will introduce non-
response bias into the data (31). There are several factors that can be incorporated to minimize 
attrition, summarized in Table 7. 
 
3.7.1 Factors to Consider When Designing the Delphi study  
As described in Section 3.4.3 Target sampling/ Panelists, large numbers of participants 
can be difficult to manage and are prone to high levels of attrition (7, 11, 24). Researchers should 
personally engage with a small group of 15 to 30 participants (18).  A manageable panel size will 
also allow researchers to personally convey information and instructions, and to emphasize the 
goals and importance of the study (10, 17).  
Running a Delphi survey can take substantial amounts of time, especially if there are 
many statements in the survey for participants to review (14). Participants should be made aware 
of the expected time requirement, and the importance of their involvement (10). Researchers 
must also be considerate of work and personal schedules by allowing flexibility on how and 
when participants complete Rounds (2). To decrease the length of the questionnaires, and the 
amount of time required to complete them (14), researchers may consider removing items (that 
have received consensus in prior Rounds) in subsequent Rounds (1, 24). Researchers can 
compensate participants for their time with a small token (e.g. gift card) and/or participation 
certificate (2). 
Another consideration when designing the Delphi study is the type of data-collecting and 
analysis tools (10). Electronic tools are recommended, as they efficiently collect data and 
distribute data to minimize delays (1, 10, 14). Online survey platforms can quickly deliver and 
gather data from participants, and statistical software can facilitate quick data analysis (10). 
 
3.7.2 Factors to Consider During the Delphi study  
Throughout the study, researchers should continuously engage with the participants to 
maintain their interest and provide encouragement (2). Time limits should be enforced during 
and between Rounds, to prevent unnecessary delays (20). It is important that participants do not 
feel pressured, to avoid introducing involuntary biases (2, 13). Table 7 lists several strategies to 
support the participants and minimize non-response. 
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Table 7: Methods to minimize attrition. 
Strategies to minimize attrition (2, 10, 14):  
• Limited the number of Rounds, 2 to 3 is sufficient and will minimize fatigue  
• Provide clear explanations of the Delphi process, describing the expectations of 
commitment and feedback process  
• Obtain written consent or intent to commit  
• Develop personal rapport with participants 
• Respond to questions or concerns 
• Ongoing communication, incentives and continual reminders  
• Quick turnaround times for data collection to maintain interest  
• Conduct study around participants’ work and holiday schedules  
• Communicate the importance of individual’s contribution to the research results  
• Clearly indicate the time commitment and the expected deadlines 
• Motivate and acknowledge participation with incentives/ compensation  
 
3.8 Conclusion  
The Delphi technique is a widely used consensus method to establish priorities, and 
define and clarify practices and information when there is limited knowledge on a topic (1, 7, 18, 
19, 22). Distinguishing features of the Delphi technique include the use of a diverse expert panel, 
anonymity between the participants, cost-effectiveness, flexibility, and convenience (14). 
Limitations associated with its use include, lack of universal guidelines for the methods and 
panel sizes, and varied “expert” and consensus definitions (2, 14). It is the researchers’ 
responsibility to ensure all precautions are in place to enhance validity, reliability, credibility, 
dependability, transferability, confirmability and ethics (13, 20). The Delphi survey provides 
valuable knowledge and ideas to inform future practice and research in health sciences and 
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Chapter 4– The Pediatric Mechanical Ventilation in Canada (PeMViC) Study: 
A Delphi Survey of Pediatric Mechanical Ventilation Practices by Canadian 





Currently, there is a gap in knowledge for pediatric mechanical ventilation (MV) 
management due to the ethical liabilities, variability in size, maturity and underlying conditions 
in children. Standardization of pediatric MV management is difficult because practices are often 
adopted from clinical experience and/or data from the neonatal and adult populations. Although 
protocols and guidelines are available, they vary across centers and are not always integrated into 
the practice culture. Inconsistent MV management may be associated with adverse events. 
The European Society for Pediatric and Neonatal Intensive Care (ESPNIC) established 
consensus recommendations on many aspects of pediatric MV management from the 
perspectives of European physicians. In Canada, respiratory therapists (RTs) are considered to be 
one of the experts in MV management, and they do not exist in Europe.  
 
Research objective 
The purpose of this study was to determine Canadian RTs’ recommendations on common 
pediatric MV management, based on the European (ESPNIC) consensus guidelines.   
 
Method 
 A Modified e-Delphi Survey Technique was used. The contents of this Delphi study 
were based on the published ESPNIC recommendations. The 142 recommendations that reached 
strong agreement were individually reviewed by three research team members, including a 
pediatric RT content expert. Recommendations that were relevant to Canadian RT practices, 
specifically to acute MV therapy management, were included for the survey. Statements that did 
not provide practice recommendations were excluded, and the subsections of chronic MV/ 
congenital diseases and lung hypoplasia syndromes were omitted. The included 
recommendations were reviewed, regrouped and revised into 10 different subtopics for the 
Delphi survey.  
The expert panel consisted of RTs with ≥5 years, working at pediatric acute care facilities 
or centers with dedicated pediatric beds across Canada (recruited from national and provincial 
registries and by snowball sampling). Research Electronic Data Capture (REDCap) was used to 
collect demographic information and data from participants.  
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Prior to Round 1, a pilot trial was conducted with three expert RTs to review and finalize 
the contents of the survey. For Round 1, participants provided open-text feedback for each of the 
statements in the survey. The feedback from Round 1 were reviewed and incorporated into the 
statements for Round 2. In Round 2, participants ranked their level of agreement or disagreement 
using a 5-point Likert scale. Statements that received significant feedback on its content or did 
not receive consensus in Round 2 were reviewed and rephrased for Round 3. The remaining 
statements that achieved consensus were not included for Round 3. In Round 3, participants 




  Three study personnel discussed and revised the statements to reflect participants’ 
feedback prior to finalizing the survey for Round 2. The Likert scale responses from Round 2 
and Round 3 were categorized into three groups: disagree, no opinion, and agree. Raw scores 
with 75% of participants in a categorized group were considered as consensus and verified 
using the coefficient of variation (CV). The Wilcoxon Signed Rank test and CV difference were 
performed to measure the differences between Round 2 and 3. Descriptive statistics was 
completed using IBM® SPSS Statistics and Microsoft Excel.  
 
Results 
N=56 (41 females/ 14 males, 1 unreported) participants from 15 different Canadian 
pediatric acute care facilities or hospitals with dedicated pediatric beds were enrolled into the 
study. RT participants had an average of 15 years of PICU experience, and were in various 
positions including: clinical supervisor, practice/ team leaders, clinical educators, core PICU 
staff, rotating clinical staff, transporters and ECMO specialists. After the pre-Round 1 and pilot 
work, Round 1 survey had 53 statements. After Round 1, some statements were modified and 
five were added. The finalized Round 2 survey had 58 statements. After Round 2, three 
statements did not reach consensus and were modified. Significant feedback for seven statements 
were identified and revised, and one additional statement was added. All 11 modified statements 




This guideline consists of 10 sections, 1) Non-invasive ventilation, 2) tidal volumes and 
inspiratory pressures, 3) respiratory rate and inspiratory time, 4) PEEP and FiO2, 5) Advanced 
Mechanical Ventilation, 6) Weaning, 7) Physiologic Targets, 8) Monitoring, 9) General MV 
practice and 10) Equipment adjuncts, for a total of 59 recommendation statements. These 
commonly practiced pediatric MV techniques were based on the perspectives of Canadian 
pediatric RT experts and reached consensus by Round 3. These recommendations can be used as 
a foundation for other pediatric MV health care providers, and to inform standardized protocols 
to help minimize interventional variabilities in future studies. This may reinforce our 
understanding of the clinical impacts of MV in critically ill children.   
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4.1 Introduction  
MV is a life-sustaining therapy used to assist children’s breathing when they are unable 
to (1-5). However, prolonged MV is associated with adverse events (AEs), including ventilator-
induced injury, pneumonia, and sedation complications (1, 3). Research in critically ill children 
is scarce and is complicated by the fact they vary greatly in size, maturity and underlying 
conditions (6, 7). Collectively, these factors make it challenging for pediatric clinical studies to 
thrive, which leads to knowledge gaps, and decreased external validity. The European Society of 
Pediatric and Neonatal Intensive Care (ESPNIC) reported that there is insufficient to no evidence 
available on all aspects of MV weaning and extubation processes for critically ill children, with 
most clinical practice based on personal experience or adult data (8). This group challenged 
“everybody involved in paediatric mechanical ventilation to embark on local or global initiatives 
to fill this huge knowledge gap” (8).  
Clinical practice guidelines or protocolized procedures are generally evidence-based and 
allow for systematic application of various health interventions, thereby reducing variability, and 
delays in care (9-15). A systematic review and meta-analysis of MV weaning (two of 16 trials 
included children), reported a decrease in MV duration and intensive care unit (ICU) length of 
stay (LOS) when there was a protocol in place to minimize practice variation and emphasize 
objective decision-making (9). Similarly, another systematic review reported that protocolized 
weaning may decrease MV duration, PICU LOS, mortality and adverse events (1). Several other 
studies on MV report reduced AEs and improved clinical outcomes when standardized protocols 
or guidelines were implemented (9, 16, 17). Unfortunately, much of the evidence describes only 
one aspect of MV management (e.g. weaning, non-invasive ventilation, or high flow oxygen 
therapy) (1, 9, 16, 18), or include children with one disease or disorder (e.g. acute respiratory 
distress syndrome) (4, 19-25). The variability of MV practices, and limited trials with children, 
make it difficult for researchers and health care providers to determine which methods are best 
practice (6-8). A standardized guide or protocol for overall MV pediatric management across a 
wide range of diseases may help minimize practice variability, improve safety, and have a 
positive impact on clinical outcomes (1, 8).  
To address the knowledge gaps and help inform standard practice, the ESPNIC 
developed consensus recommendations for pediatric MV (8). It detailed all aspects of pediatric 
MV including ventilation modalities, monitoring, targets of oxygenation and ventilation, 
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weaning and extubation readiness in children with various diseases. These recommendations 
were developed and scored by a panel of 15 European physician experts and may have limited 
applicability in the Canadian practice setting. Furthermore, RTs have a large clinical role in MV 
management in Canada, but they do not exist in Europe. RTs (75% working in critical or acute 
care) are rigorously trained in all aspects of respiratory care, especially MV management (26-
29). Studies have shown that RT-driven MV weaning protocols have significantly reduced 
duration of MV and ICU LOS compared to physician directed MV weaning (12, 13, 30, 31).  
This knowledge gap in RT specific pediatric MV management can be explored with the use of a 
Delphi study, using the ESPNIC consensus recommendations as the content foundation. The 
expert panel would consist of RTs (instead of physicians) in institutions where they have a 
significant role in pediatric MV management. Their feedback will further increase the scientific 
merit of the recommendations and may identify differences in Canadian practices.   
This study will be the first step in the development of standardized pediatric MV 
practices in Canada. It will develop pediatric MV consensus recommendations from the 
perspectives of Canadian RTs with expertise in pediatric critical care. These recommendations 
can then be used as a foundation in all Canadian pediatric critical care centres by incorporating 
the perspectives of each centre’s unique culture, including other members of the clinical team, 
and patients and caregivers. 
 
4.2 Methods 
4.2.1 The Delphi Technique 
A Delphi survey is a systematic consensus method that collects experts’ opinions on a 
particular topic when there is limited data or knowledge (32-34). There are several different 
types of Delphi, with the Classical and Modified as the most common in health sciences (32, 35). 
These two differ by how the contents for Round 1 are finalized; the Classical Delphi uses a series 
of broad questions about a topic in Round 1 to collect responses to inform the subsequent 
Rounds, whereas the Modified Delphi uses existing literature, focus groups or interviews to 
develop statements in Round 1 to minimize large volumes of qualitative data (34, 36, 37). This 
study adopted the Modified format, as the ideas explored in the subsequent Rounds were based 
on ESPNIC recommendations. 
Experts are individuals with the understanding, knowledge, experience, credibility, and 
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skills related to the topic being investigated (32, 34, 36-39). Experts are chosen based on specific 
criteria outlined by the research team, and by considering the research objectives and topics of 
interest (36, 38). The quality of the results relies on the traits of the experts, as less credible 
experts will impact the validity of the consensus and collected data (34, 40).  
The Delph Technique is based on the impression and belief that combined intelligence is 
superior and reliable, compared to individual, anecdotal experiences (33, 39, 41). It utilizes a 
series of surveys, referred to a Rounds, to gather controlled feedback from a group of 
participants, identified as experts in the field (42). The process generates ideas and seeks 
consensus from these experts to resolve problems or clarify information (32-34). It is cost-
effective, especially when there are geographical constraints (33, 43), and it is administered 
electronically (electronic Delphi [e-Delphi]) (34). Participants are anonymous to other 
participants, which limits the influence or judgement of their peers (33, 39, 44). 
There are gaps and inconsistencies in pediatric MV management evidence, making the 
Delphi method an appropriate consensus approach for this study (33, 39). As RTs are one of the 
experts in MV management, RTs working at pediatric facilities would provide valuable feedback 
and information for the topic of interest. In addition, the wide geographical distribution of 
centres across Canada makes an e-Delphi survey cost-effective and ideal way to manage the data 
collection (33, 34, 43).  
 
4.2.2 Study Design 
A three-Round Modified e-Delphi survey was performed (33, 34, 39). For all Delphi 
survey Rounds, Research Electronic Data Capture (REDCap, licensed by the Hospital of Sick 
Children [SickKids]) was used to collect the results for each round (45). REDCap provided 
participants the option to return to their survey using a “return code”, if they were not able to 
complete it during one sitting. It also recorded where in the survey a participant stopped, and 
when it was completed. These features made it possible for partially completed surveys to be 
included in the analyses. Other employed methods to maximize response rates in this study 
included open communication, participant engagement, and individualized email reminders (32, 
34, 37, 42, 43). This study was approved by the SickKids and Ontario Tech University research 




 The experts in this study were pediatric RTs, working in Canada. For this Delphi study, 
an expert was defined as an individual who fulfilled the eligibility criteria for inclusion. The 
inclusion criteria was any RT who: 1) was a registered RT with a regulatory body in Canada; 2) 
had at least 5 years of pediatric critical care experience; 3) worked at a facility with either a 
stand-alone pediatric unit or dedicated beds; 4) had experience in leadership, either as staff 
involved in leadership activities (e.g. involved in policy/ procedure reviews, orientating new 
staff) and/ or are in leadership positions, including but not limited to practice leaders, clinical 
educators, supervisors, managers, or senior staff; 5) provided written consent; 6) was fluent in 
English (reading and writing). The exclusion criteria were anyone who were: 1) a student or 
graduate RT; 2) primarily working in adult or neonatal critical care; 3) primarily working in non-
critical care units or facilities, e.g., long term care, diagnostics, sleep, rehabilitation. Pediatric 
critical care was defined as the practice of providing specialized intensive care treatments, 
including MV to manage acutely ill children with life-threatening conditions or diseases (3, 46, 
47).  
 In Canada, there are 15 pediatric hospitals with stand-alone pediatric critical care units 
and seven hospitals with dedicated pediatric care beds (48). The goal was to recruit one RT-
expert from each pediatric hospital for a minimum of 15 participants (34, 49). With the 
assistance of the Canadian Society of Respiratory Therapy (CSRT), a list of RTs in leadership 
positions from across these different facilities, and their contact information, was used as our 
sampling frame. All individuals on the list provided consent to the CSRT for release of this 
information. Additional names were obtained from publicly available hospital registries. We 
were able to get the contacts from 19 out of the 22 facilities (see Supplementary table 2 for full 
list of centers). All RT leadership teams who were contacted, responded to our request, and 
forwarded the recruitment poster and consent form (Chapter 8.3- Recruitment materials) to their 
respective RT department. The recruitment poster and study information were also posted on the 
CSRT members’ professional practice forum. Recruitment began in July 2020 and officially 
closed once Round 2 ended on November 3, 2020 (for the study timeline, please see Figure 3). 
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Figure 3: Study timeline, from the Pilot to Post-Delphi review phase. 
 
 
Participants were compensated for their time and dedication to the study with a gift card 
and CSRT continuing education/ continual professional development credits.  
 
4.2.3 Delphi Survey Content 
The contents of this survey were derived from the ESPNIC consensus guidelines (8). 
These guidelines included 152 recommendations on various topics, with 142 receiving strong 
agreement from their expert panel. We reviewed, re-grouped and condensed (amalgamated 
similar items and topics) these 142 recommendations. Statements of clinical importance and 
relevance within Canada and RT practices were included (as determined by study team). 
Statements that did not provide practice recommendations, and/or address MV management for 
children not acutely ill were excluded e.g. chronic diseases such as lung hypoplasia or 
neuromuscular diseases. A total of 53 recommendations remained for the Delphi survey. 
 
4.2.4 Pilot survey 
The research team finalized a draft for Round 1 in March 2020. This was pilot tested by 
three pediatric RT experts, with over 5 years of critical care experience at SickKids. Feedback 
from this pilot Round was used to amend the content and wording of the recommendation items 




4.2.5 Round 1  
Expert participants reviewed and reflected on all 53 recommendation statements based on 
their personal practice and experiences, using free-text comments and feedback. They did this for 
statements they felt could be improved, or they disagreed with. If the participant agreed with the 
recommendation statement, no feedback was required.  
Participants also completed a demographics questionnaire that included details of their 
personal characteristics (e.g. age, gender, education), individual practice (e.g. years of practice in 
pediatric critical care), and practice location (8.5 - Demographic Information survey). Round 1 
data collection started on August 10, 2020 and remained open for seven weeks (closed 
September 27, 2020). Participants were initially given four weeks to complete the survey; 
however, due to lower than anticipated response rate (<50%), the deadline was extended. 
Reminder emails were sent to non-respondents every week and on the day before the deadline. 
Non-respondents were still eligible for Round 2 if they did not complete Round 1.   
 
4.2.6 Round 1 Analysis 
Completed surveys were tabulated into Microsoft Excel. Partially completed surveys 
were also included for analysis, but only the sections with feedback. Initial assessment of the raw 
text feedback was performed by one researcher (SQ), before review by the whole research team. 
Key words, terms, ideas and phrases in the text feedback were highlighted, tabulated and 
summarized for each recommendation statement. Feedback that did not explicitly address the 
recommendation statements were not considered when revising the contents for the next Round. 
Similarly, any comments that were irrelevant or not applicable to RT practices in Canada were 
omitted. Grammatical and content suggestions were incorporated. The draft for the Round 2 
survey was reviewed and revised by each research team member separately until a final draft was 
collectively agreed upon. 
  
4.2.7 Round 2 and Round 3 
In Round 2 and Round 3, participants were instructed to rank their level of agreement or 
disagreement using a 5-point Likert scale for each of the recommendations (Figure 4). If the 
recommendation statement was not practiced at their work location, participants were instructed 
to choose “0 No comment”.  
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Figure 4: 5 point Likert scale. 
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At the end of each section, participants had the opportunity to provide open-text feedback 
if they strongly disagreed or disagreed (Likert score 1 or 2) with any of the recommendation 
statements or had additional concepts or feedback to provide.  
Invitations for Round 2 were sent to participants on October 15, 2020 and was open until 
November 3, 2020. Participants who failed to complete Round 2 by the deadline were considered 
lost to follow up and were not invited for Round 3. The remainder were invited for Round 3 on 
November 12, 2020 and given 16 days to complete (Round 3 ended November 29, 2020). Email 
reminders were sent to non-respondents weekly and the day before the deadline for both Round 2 
and Round 3. Participants were considered lost to follow up if they did not respond by end date. 
 
4.2.8 Round 2 and Round 3 Analysis  
Descriptive statistics of the quantitative data from Rounds 2 and 3 included measures of 
central tendencies, response frequencies, dispersion, consensus (defined as  75% threshold), 
and additional statistics (see below). All statistical analyses were performed using Microsoft 
Excel and IBM® SPSS Statistics, with a p-value <0.05 considered significant.  
The five Likert ranks were grouped into three categories to determine whether consensus 
for a particular statement was achieved. For each statement, the responses with rank 0 were 
eliminated from the tabulation, and the remainder were categorized into three separate ranking 
groups:  Group 1 (disagree) included 1- strongly disagree and 2- disagree; Group 2 (neutral) 
included 3- neutral; Group 3 (agree) included 4- agree and 5- strongly agree. Consensus was 
achieved when 75% of participants’ responses fell within one particular ranking group. The 
proportion (%) of participants (consensus) in each ranking group was calculated by dividing the 
number of participant responses in a ranking group by the number of total responses.  
The open-text feedback for each section were analyzed similar to Round 1 analysis. 
 Round 2 statements that did not reach consensus and/or reached consensus but received 
significant feedback were revised for Round 3’s re-evaluation. Statements that reached 
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consensus in Round 2 and/or did not have significant feedback, were not included in Round 3 to 
decrease the length of the survey in order to minimize participant fatigue and attrition (32, 37). 
The percentage consensus data for each recommendation statement was summarized and 
distributed to each participant for viewing at the beginning of Round 3 and at the end of the 
study. 
Three additional statistics were performed to strengthen the validity of the Delphi data 
(44). First, the Coefficient of Variation (CV) for each statement was calculated to report the ratio 
of the standard deviation of the responses, to its respective mean. Statements with CV ≤0.5 
suggest minimal variations in the responses, supporting ceasing of further Rounds (44, 50). 
Second, the stability between the statements in Round 2 and 3 were assessed by comparing the 
CV difference in Likert responses. CV differences close to zero (statistically similar results) 
indicate consensus stability in responses across the two Rounds, supporting ceasing of further 
Rounds (44, 50, 51). Since the response data was skewed, the Wilcoxon Signed-Rank test 
(WSRT) was used to compare the CV differences between Round 2 and 3 (44, 50). Finally, for 
exploratory purposes we performed the Kruskal Wallis test (KWT) for subgroup analyses of 
Likert responses between participants with different years of PICU experience (>15 years versus 
≤15 years).  
 
4.2.9 Post Delphi Review  
 All the finalized consensus recommendation statements, some with clinical remarks, were 
provided as a written report (8.10- Post-Delphi summary for participants). The clinical remarks 
were derived from the open text responses received throughout each Round. They were created 
because it was not possible to incorporate all the suggested concepts into each recommendation 
statement. The clinical remarks elaborated on unique and special circumstances not captured in 
the general statement recommendation e.g. those that require further discussions with the 
interprofessional team.  
In addition to the recommendation statements (plus clinical remarks), summaries of the 
original written feedback and statistical results from all Rounds were provided. A total of three 
documents and a video presentation of the study results were available for participants to review 
between February 8 to March 5, 2021. Participants were invited to review and provide, if any, 
additional comments or feedback.  
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4.3 Results  
4.3.1 Participants 
A total of 56 participants (41 females, 14 males, 1 non-respondent) from 15 facilities, 
across nine provinces were included in the study (see Figure 6). Two regional hospitals with 
dedicated pediatric beds reported they were rarely used; therefore, participants were not recruited 
from these centers. One participant consented into the study but did not complete any Rounds or 
the demographic survey. Three participants completed the demographic information survey but 
did not complete any Rounds. Figure 5 provides a detailed overview of the number of 
participants involved in each Round of the Delphi study.  
 
Figure 5: Number of participants across the Delphi Rounds. 
 
The majority of the participants in this study were from Alberta (n=11, 1 male), Ontario 
(n=12, 2 males) and Quebec (n=11, 3 males). The Atlantic Provinces were represented by six 
participants (2 males) across three facilities. All participants graduated from a Canadian 
respiratory therapy program. The average  standard deviation (SD) years of pediatric RT 
experience in the expert panel was 15.04  8.33 years, and 72 27.78% of their practice time 
were in the PICU (Table 8). The expert panels consisted of RTs in multiple roles including 
charge supervisors, practice leaders, team leaders, clinical educators, ECMO specialists, 
transport RTs, pediatric core and rotating staff. All RT participants had work experience in the 
PICU, with 80% also experienced in the neonatal ICU and 20% in the adult ICU (Table 8). RT 
participants partook in different professional development activities for various reasons, as 

































n=2 loss to follow up
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Table 8: Characteristics of Expert Participants, N=55* 
Variable N (%) or Mean ±SD  
Female 41 (74.5) 
Age, years 40.64 ± 8.81 
Education 
Bachelor’s degree 26 (47.3) 
Additional credentials 2 (3.6) 
Practice experience 
# of years as RT 16.37 ± 8.82 
# of years in PICU 15.04 ± 8.33 
Hours of clinical work / week 38.06 ± 12.14 
% of clinical work in PICU 72 ± 27.78 
Clinical role ** 
Charge supervisor 14 (25) 
Practice Lead 9 (16) 
Team Lead  14 (25) 
Clinical Educator 14 (25) 
Core Staff 27 (49) 
Rotating Staff 11 (20) 
Transport 5 (9) 
ECMO specialist 2 (4) 
Other*** 12 (22) 
Additional practice areas 
Neonatal 44 (80) 
Adults 13 (24) 
Professional activities  
Reading research and medical literature  50 (91) 
Presentations 51 (93) 
Conferences  19 (35) 
Courses, Workshops 38 (69) 
Simulation Labs 53 (96) 
Other† 5 (9) 
Reasons for attending professional activities 
Challenging clinical case(s) 27 (49) 
Supervisor/ colleagues highlighting opportunities 36 (65) 
Mandatory Staff Education 33 (60) 
Identified area of improvement through self-reflections and/ or 
performance reviews 
37 (67) 
Personal interest 6 (11) 
Continuing Education 3 (5) 
ECMO: Extracorporeal membrane oxygenation; N: total sample size; PICU: pediatric intensive care unit; RT: 
respiratory therapist; SD: standard deviation; *Includes n=3 who did not complete any Rounds; ** Respondents 
may have chosen more than one role; ***Other: clinical practice coordinator, clinical educator for interprofessional 




Figure 6: Graphical representation of the Canadian expert panel. 
 
N=55; Center, n (%); Includes n=3 who did not respond to any Rounds. Information is also 
presented in text summary (Supplementary table 3).  
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4.3.2 Pilot Round results 
The initial draft of the Delphi survey from the ESPNIC recommendations included 53 
statements. This draft was reviewed by three individual SickKids’ RTs for its relevance, clarity 
and applicability. Based on their feedback, several statements were reworded and modified to be 
more applicable to Canadian practices.   
 
4.3.3 Round 1 results 
After review of the original ESPNIC recommendations and pilot testing, 53 statements 
were included for Round 1. The statements were separated into 10 different sections: 1) Non-
invasive ventilation, 2) Tidal volume and inspiratory pressures, 3) Respiratory rate and 
inspiratory time, 4) PEEP and FiO2, 5) Advanced modes of ventilation, 6) Weaning, 7) 
Physiologic targets, 8) Monitoring, 9) Other General MV practice and 10) Equipment Adjuncts.  
A total of 43 out of 54 participants responded (80% response rate), one withdrew, and 11 
did not respond. Of the 43 who responded, two participants partially completed Round 1. Given 
the nature of Round 1, we received a large volume of written open-text feedback which was 
tabulated in Microsoft Excel. Review of this feedback played a significant role in its revision for 
Round 2 (4.2.6 Round 1 Analysis). Participants reported several statements were too wordy 
and/or consisted of too many concepts. Therefore, several statements were broken into two 
statements. Additionally, participants suggested the addition of new concepts, because of their 
relevance and importance in pediatric MV practices. Feedback led to the introduction of several 
MV recommendation statements that were not originally included: use of high-flow nasal 
cannula oxygen therapy, high-frequency jet ventilation, guidelines from various health 
associations (e.g. Heart and Stroke Foundation’s Pediatric advanced Life support, Extracorporeal 
Life Support Organization, etc.) and ventilator acquired pneumonia prevention practices. See 
Supplementary Table 4 for the open text feedback from Round 1. 
The Round 2 draft was reviewed and revised by each research team separately, and 
collaboratively, until a final draft was agreed upon. The 53 recommendations statements from 
the Round 1 survey were modified to 58 recommendations statements for Round 2. A 
comparison between Round 1 and 2 are available in Supplementary Table 5. The finalized 
Round 2 survey is in Chapter 8- Appendix. 
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4.3.3 Round 2 Results 
A total of 51 out of 55 participants (91% response rate) completed Round 2. Three 
participants did not respond, and 1 withdrew. Fifty-five out of the 58 statements (95% of the 
survey) reached consensus: one statement between 75% to 80% (1.7% of survey), 16 statements 
between 81% to 90% (28% of survey) and 38 between 91% to 100% (66% of survey). Three 
statements did not reach consensus (5% of survey). Six reached consensuses but had 
considerable open-text feedback (10% of survey). One recommendation was added, resulting in a 
total of 11 recommendation statements for Round 3. The CV indicated stability in the 
participants’ responses, as values for each of the 58 statements were less than 0.5, ranging from 
0.09 to 0.31.  
The three statements that did not reach 75% consensus came from each of the following 
sections: 2) Tidal volumes and inspiratory pressures, 5) Advanced modes of ventilation and 10) 
Equipment adjuncts. In section 2, the statement: “For specific congenital cardiac patients 
requiring optimal venous return, higher tidal volumes of >8ml/kg may be used to if peak 
pressures are <25cmH2O” had 60% consensus (CV 0.21). Participants noted these children 
could be ventilated with target tidal volumes less than 8ml/kg, and at times, with higher peak 
inspiratory pressures up to 28 to 30cmH2O (depending on the underlying lung condition). In 
section 5, one recommendation explicitly described high frequency jet ventilation (HFJV), and 
had 57% consensus (highest CV 0.31). Many participants commented that children were not 
commonly placed onto HFJV, as this practice is seen more in the NICU, and in specific 
pathologies. Lastly, a recommendation in section 10 described proximal flow sensor use in the 
PICU and gained a consensus of 71% (CV 0.26). Some participants noted it had limited use in 
the PICU, and was more common in the NICU, where smaller tidal volume measurements are 
required. Generally, children under a specific weight may have tidal volumes monitored with a 
proximal flow sensor, but the reported thresholds varied across centers. Table 9 describes the 
changes of the statements that did not achieve consensus from Round 2 to Round 3. 
Seven statements received consensus but were still included for Round 3 (Table 9). The 
research team believed the open text-feedback would strengthen the practice recommendation. 
One statement in section 1 “Consider the use of high flow nasal cannula oxygen therapy (form of 
oxygen therapy) prior to NIV, to alleviate work of breathing” gained 76% consensus (CV 0.25). 
Many participants believed NIV and HFNC may be considered in parallel instead of one before 
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another, and NIV should not be delayed if indicated. The remaining six statements did achieve at 
least 80% consensus, but were revised to include: a broader range of numerical thresholds, 
practice exceptions and/ or grammatical and content reorganization. One additional statement 
was added into Section 9- General MV practice recommendations, which emphasized the 
necessity of interprofessional collaboration. Though it was not explicitly about MV management, 
it was a reoccurring theme amongst the open response feedback.  
The consensus and revised statements from Round 2 to Round 3 are summarized in Table 
9. Supplementary table 6 presents consensus and descriptive statistics for each recommendation 
statement. A summary of the Round 2 results was made available to the participants to view 
prior to starting Round 3. 
 
Table 9: Round 2 statements that were revised for Round 3. 
Section R2 statement (consensus %, CV) Revised for R3 
1 Consider the use of high flow nasal 
cannula oxygen therapy (form of oxygen 
therapy) prior to NIV, to alleviate work 
of breathing. (76%, 0.26) 
Consider the use of HFNC prior to NIV, 
to alleviate any work of breathing. 
However, the use of HFNC is not a 
substitute for NIV and should not delay 
or replace the use of NIV, if NIV is more 
appropriate. 
2 Target tidal volumes in the physiologic 
range (5-8ml/kg ideal body weight) for 
pediatric patients >10kg with healthy 
lungs. Target tidal volumes 
5-8ml/kg measured weight for pediatric 
patients ≤10kg with healthy lungs. (92%, 
0.15) 
In pediatric patients >10kg, target tidal 
volumes in the physiologic range (5-
8ml/kg ideal body weight). In pediatric 
patients ≤10kg, target tidal volumes 5-
8ml/kg measured weight.  
2 For all pediatric patients on pressure-
limited modes, aim to achieve optimal 
tidal volume in the physiological range 
(5-8ml/kg ideal body weight) with 
minimal delta pressure (PIP-PEEP). 
(94%, 0.18) 
For pediatric patients on pressure-limited 
modes, aim to achieve optimal tidal 
volume in the physiological range (5-
8ml/kg ideal body weight) with minimal 
driving pressure (PIP-PEEP).  
2 In absence of transpulmonary pressure 
measurements, limit the inspiratory 
plateau pressure to 30cmH2O in all 
pediatric patients. (82%, 0.21) 
In absence of transpulmonary pressure 
measurements, the inspiratory plateau 
pressure should be limited to 30cmH2O 
in pediatric patients. Site specific limits 
should be within 28 to 32 cmH2O. 
2 For specific congenital cardiac patients 
requiring optimal venous return, higher 
tidal volumes (>8ml/kg ideal body 
weight) may be used if peak pressures 
If unable to achieve physiologic tidal 
volumes (5-8ml/kg) within pressure 
limits (30cmH2O), targeting ranges 
outside these limits should be discussed 
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are within safe range (< 25cmH2O). This 
would allow a lower set respiratory rate 
to minimize mean airway pressure. 
(60%, 0.21) 
with the interprofessional team. For 
example, congenital lesions, congenital 
hypoplastic lung, severe PARDS. 
Similarly, there may be circumstances 
where tidal volumes >8ml/kg may be 
cautiously used, but should not be 
routinely used. 
5 When conventional mechanical 
ventilation has failed, consider high 
frequency jet ventilation (HFJV) in 
pediatric patients with restrictive or 
mixed diseases and severe oxygenation 
and/or ventilation failure. (57%, 0.31) 
 
 
When conventional mechanical 
ventilation and/or HFOV has failed for 
pediatric patients, consider the use of 
other advanced modes, acknowledging 
that each has unique benefits and / or 
limitations. These modes include high 
frequency jet ventilation (HFJV) and 
Airway Pressure Release Ventilation 
(APRV). These advanced modes should 
not substitute or delay inevitable ECLS, 
if appropriate. 
5 Consider the use of other advanced 
ventilation techniques to optimize 
patient-ventilator interactions, 
acknowledging that each has unique 
benefits and/or limitations. These modes 
include Airway Pressure Release 
Ventilation (APRV), Neurally Adjusted 
Ventilatory Assist (NAVA), Proportional 
Assist Ventilation (PAV), high 
frequency jet ventilation (HFJV), 
automated weaning etc. (83%, 0.21) 
Other advanced ventilation techniques 
may optimize patient-ventilator 
interactions. Consider their use while 
acknowledging that each has unique 
benefits and/or limitations. These modes 
include Neurally Adjusted Ventilatory 
Assist (NAVA), Proportional Assist 
Ventilation (PAV), automated weaning 
etc. 
5 Strongly consider Extracorporeal life 
support (ECLS) such as NovaLung, or 
extracorporeal membrane oxygenation. 
Use ECLS in pediatric patients with 
reversible diseases, if available within 
the facility, not contraindicated, and/or 
when conventional and/or high 
frequency oscillatory ventilation has 
failed. Follow guidelines (e.g. 
extracorporeal life support 
organizations) for specific criteria. Early 
consultation with an ECLS center should 
be considered if this therapy is not 
available within the facility (81%, 0.2) 
When conventional mechanical 
ventilation and/ or HFOV has failed, 
consider the use of Extracorporeal life 
support (ECLS) in pediatric patients with 
reversible diseases, if available within 
the facility and not contraindicated. 
Follow guidelines (e.g. ECLS 
organizations) for more specific criteria. 
Consider early consultation with an 
ECLS center when ECLS is not available 
within the facility. 
10 Use a proximal flow sensor for accurate 
tidal volume measurements in small 
patients (<10kg) or patients with small 
Proximal flow sensors are not routinely 
used for pediatric patients. Follow the 
specific ventilator’s recommendations on 
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tidal volumes (<10mL). Follow the 
specific ventilator’s recommendations on 
its use. (71%, 0.26) 
proximal flow sensor use. In the absence 
of specific ventilator recommendations, 
use a proximal flow sensor for small 
tidal volumes (<10mL) 
10 Avoid routine use of manual hand-
ventilation to minimize frequent circuit 
disconnects. If manual hand-ventilation 
is required, pressure manometers, 
pressure relief valves and PEEP valves 
should be used on self-inflating and 
flow-inflating bag. (84%, 0.22) 
Minimize routine use of manual 
ventilation to avoid circuit disconnects. 
Manual ventilation may be used to 
augment pulmonary hygiene as part of 
chest physiotherapy. Manual 
resuscitation devices should be capable 
of maintaining PEEP, limiting and 
monitoring pressures 
9 Additional statement Mechanical ventilation management and 
anticipated plans should be discussed as 
an interprofessional (IP) team at 
minimum on a daily basis. Any changes 
in the patients’ trajectory or mechanical 
ventilation needs should be 
communicated between all members of 




4.3.4 Round 3 Results  
Of the total 51 participants who completed Round 2, 49 completed Round 3 (97% 
response rate). Two participants were lost to follow up. All 11 statements received consensus; 
three statements achieved consensus within 81-89% and eight statements over 90%. The CV 
indicated stability in the participants’ responses, as values for each of the 11 statements were less 
than 0.5, ranging from 0.12 to 0.24 (Table 10).  
Nine of the 10 statements revised from Round 2, obtained greater consensus in Round 3, 
increasing between 1% to 38%. The respective CV values also decreased, between 0.005 to 0.14. 
One statement (finalized statement #2.1) decreased consensus from 92% to 81%, with an 
increase of CV from 0.15 to 0.24. The newly added statement for Round 3 (Statement 9.7) 
achieved 100% consensus (CV 0.10). When the rank responses were compared across Rounds 2 
and 3 (WSRT), there were four statements with significant differences (p<0.05). These were the 
four statements that had the greatest increased change in consensus percentage. Further details 
can be viewed in Supplementary Table 7. Open text feedback for Round 2 and 3 are collectively 
summarized in Supplementary table 9. 
 
Table 10: comparison between the consensus for the statements included in Round 3, compared to 



















1.6 76% 92% +16% 0.25 0.19 -0.07 <0.01 
2.1 92% 81% -9% 0.15 0.24 +0.09 0.23 
2.2 60% 98% +38% 0.21 0.12 -0.09 <0.01 
2.3 94% 96% +2% 0.18 0.18 -0.005 0.79 
2.4 82% 93% +11% 0.21 0.15 -0.07 0.13 
5.3 57% 90% +33% 0.31 0.17 -0.14 <0.01 
5.4 83% 84% +1% 0.21 0.19 -0.02 0.44 
5.5 81% 96% +15% 0.20 0.15 -0.05 0.03 
10.4 71% 84% +13% 0.26 0.21 -0.05 0.89 
10.5 84% 94% +10% 0.22 0.15 -0.07 0.44 
*refer to the Finalized Consensus Statements with clinical remarks (Chapter 6- Finalized 
Canadian Pediatric MV management Consensus Guideline). CV=coefficient of variation. 
 
 The evolution (revisions and comparisons) of the statements, consensus percentage, 
Likert score, and CVs from Round 1 to 3 are summarized in Table 11. 
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Table 11: Evolution of the statements from Round 1 to 3. 
Section 2: Tidal volumes and inspiratory pressures 




Recommendation statement  
Statement #1.6 
1 - - - 
2 76% 
0.26 
3.820.97 Consider the use of high flow nasal cannula (HFNC) oxygen therapy 
prior to NIV, to alleviate work of breathing. 
3 92% 
0.19 
4.370.81 High flow nasal cannula oxygen therapy (a form of oxygen therapy) 
is not a substitute for NIV. Consider the use of high flow nasal 
cannula oxygen therapy prior to NIV to alleviate work of breathing. 
However, the use of high flow oxygen therapy should not delay or 
replace the use of NIV, if NIV is more appropriate. 
Section 2: Tidal volumes and inspiratory pressures 




Recommendation statement  
Statement #2.1 
1 - - Use tidal volumes in the physiologic range (5-8ml/kg ideal body 
weight) for pediatric patients with healthy lungs. 
2 92% 
0.15 
4.160.62 Target tidal volumes in the physiologic range (5-8ml/kg 
ideal body weight) for pediatric patients >10kg with healthy lungs. 
Target tidal volumes 5-8ml/kg measured weight for pediatric patients 
≤10kg with healthy lungs. 
3 81% 
0.24 
4.00.95 In pediatric patients >10kg, target tidal volumes in the physiologic 
range (5-8ml/kg ideal body weight). In pediatric patients ≤10kg, 
target tidal volumes 5-8ml/kg measured weight. 
Statement #2.2 
1 - - Avoid using tidal volumes >8ml/kg ideal body weight in pediatric 
patients with restrictive lung, obstructive lung and/or congenital 
diseases. 
For cardiac patients, higher tidal volumes (>8ml/kg ideal body 
weight) can be used to allow a lower set respiratory 
rate to promote venous return. 
2 60% 
0.21 
3.70.78 For specific congenital cardiac patients requiring optimal venous 
return, higher tidal volumes (>8ml/kg ideal body weight) may be 
used if peak pressures are within safe range (< 25cmH2O). This 




4.30.51 If unable to achieve physiologic tidal volumes (5-8ml/kg) within 
pressure limits (30cmH2O), targeting ranges outside these limits 
should be discussed with the interprofessional team. For 
example, congenital lesions, congenital hypoplastic lung, severe 
PARDS. Similarly, there may be circumstances where tidal volumes 
>8ml/kg may be cautiously used but should not be routinely used. 
Statement #2.4 
1 - - In absence of transpulmonary pressure measurements, limit the 
inspiratory plateau pressure to 28cmH2O in pediatric patients with 
healthy lungs. 
 - - In absence of transpulmonary pressure measurements, limit the 
inspiratory plateau pressure 32cmH2O in patients with decreased 




4.020.85 In absence of transpulmonary pressure measurements, limit the 
inspiratory plateau pressure to 30cmH2O in all pediatric patients. 
3 93% 
0.15 
4.170.61 In absence of transpulmonary pressure measurements, the inspiratory 
plateau pressure should be limited to 30cmH2O in pediatric patients. 
Site specific limits should be within 28 to 32 cmH2O. 
Section 5: Advanced modes of ventilation (#5.3) 




Recommendation statement  
1 - - -not included 
2 57% 
0.31 
3.41.06 When conventional mechanical ventilation has failed, consider high 
frequency jet ventilation (HFJV) in pediatric patients with restrictive 
or mixed diseases and severe oxygenation and/or ventilation failure. 
3 90% 
0.17 
4.140.72 When conventional mechanical ventilation and/or HFOV has failed 
for pediatric patients, consider the use of other advanced modes, 
acknowledging that each has unique benefits and / or limitations. 
These modes include high frequency jet ventilation (HFJV) and 
Airway Pressure Release Ventilation (APRV) and severe 
oxygenation and/or ventilation failure. These advanced modes should 
not substitute or delay inevitable ECLS, if appropriate. 
Section 10: Equipment adjuncts (#10.4) 




Recommendation statement  
1 - - Measure tidal volumes proximally in pediatric patients < 10kg. 
2 71% 
0.26 
3.881.02 Use a proximal flow sensor for accurate tidal volume 
measurements in small patients (< 10kg) or patients with small 
tidal volumes (< 10mL). Follow the specific ventilator's 
recommendations on its use. 
3 84% 
0.21 
3.910.82 Proximal flow sensors are not routinely used for pediatric 
patients. Follow the specific ventilator's recommendations on 
proximal flow sensor use. In the absence of specific ventilator 
recommendations, use a proximal flow sensor for small tidal volumes 
(< 10mL). 
 
 Since all the recommendation statements reached consensus at the end of Round 3, 
further Rounds were not required. Supplementary table 6, Supplementary Table 7 and 
Supplementary table 9 presents consensus and descriptive statistics for each recommendation 
statement, and the original open-text feedback in Round 2 and 3. The guideline was finalized and 
included a total of 10 sections for a total of 59 recommendations with clinical remarks (Table 







Table 12: The 10 sections and the number of recommendations in each. 
 
 
4.3.5 Subgroup analyses: Years of PICU experience  
 The years of PICU experience in this expert panel ranged from 1 to 36 years. This 
variable was categorized into 2 subgroups: 1) ≤15 years (meanSD age = 34.55.4 years) and 2) 
>15 years (age 47.86.4 years). For Round 2, the subsamples were 28 participants with ≤15 years 
and 23 participants with >15 years of PICU experience. In Round 3, each subgroup lost 1 
participant (27 and 22 participants, subgroup 1 and 2 respectively). Of all the statements in both 
Rounds, only six statements from Round 2 showed significant differences between subgroups 
(p<0.05) (Supplementary Table 8). For each of these six statements, the Likert scores were 
higher for the less experienced group, compared to the group with > 15 years experience. The 
statistical data for these six statements are summarized in Supplementary Table 8.   
 
4.3.6 Post Delphi review 
 There was no additional feedback returned from the participants. We assumed the 
participants agreed with the finalized guideline and clinical remarks. 
 
4.4 Discussion  
This is the first study to use the Delphi technique to develop pediatric MV consensus 
recommendations based on the expertise of Canadian RTs. Of the 152 European (ESPNIC) 
guideline statements, we derived 53 recommendation statements that were applicable to 
Canadian RT practices. These recommendation statements reached consensus by Round 3, 
ranging from 80% to 100% consensus. We almost achieved our original hypothesis that 
Section # of recommendation statements 
1 Noninvasive ventilation  8 
2 Tidal Volumes and Inspiratory Pressures 4 
3 Respiratory Rates and Inspiratory Times 3 
4 PEEP and Fio2 6 
5 Advanced Mechanical Ventilation modes 5 
6 Weaning  5 
7 Physiologic targets 7 
8 Monitoring 9 
9 General MV practices 7 
10 Equipment adjuncts  5 
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consensus would be achieved by Round 2, as only three statements did not reach 75% consensus. 
However, we made the conservative decision to revise one statement that achieved 76% 
consensus (CV 0.25), and statements that did reach consensus and had a lot of feedback. The 
finalized consensus document on essential MV management in pediatrics, consisted of 59 
recommendation statements, describing 10 different subtopics. 
 After Round 2, a high proportion of the survey achieved consensus: 55 out of 58 
statements (95%). There could be a few reasons why this level was reached early. First, the 
Modified Delphi technique was used, allowing the research team to generate the topics to focus 
on. We decided to create our survey based on the existing ESPNIC consensus MV guideline (8), 
and taking in consideration practices that were applicable to Canadian RTs. Our Round 1 results 
were ample, but likely much more focused, especially in comparison to the Classical technique 
(where Round 1 is unstructured and seeks feedback using open-ended questions) (32, 34, 36, 39). 
Secondly, the main themes and concepts of our guideline, had already gone through a vigorous 
consensus process by another group of experts, international pediatric physicians, and the 
existing literature. Only the statements in the ESPNIC guideline that had strong agreement 
amongst their panelists were considered for our Delphi survey.  
When looking at individual sections of our survey, we observed a few interesting points. 
The first section about NIV had eight practice statements which all reached at least 75% 
consensus at the end of Round 2, and only two of these statements had consensus <90%. These 
two statements were practice recommendations on NIV Neurally Adjusted Ventilatory Assist 
(NIV-NAVA) (85% consensus, CV 0.18) and HFNC (76% consensus, CV 0.25). In the ESPNIC 
recommendation guideline, the panel concluded there was insufficient evidence to recommend 
the use of NAVA or HFNC in children with mixed diseases (8).  
Introduced within the last decade, NIV-NAVA has been trialed in adults. Although it 
may provide benefits, there are minimal studies to confirm its use in children (52, 53). In our 
study, 39 (76%) participants used NIV-NAVA in their institutes; the other 25% indicated it was 
unavailable at their center. Therefore, the minimal use and availability of NIV-NAVA in the 
pediatric population may be due to the lack of large clinical trials, high cost, and lack of 
guidance in its use and management (52). This suggests the use of NIV-NAVA in children is still 
relatively new (52, 53). 
Another relatively new therapy is HFNC, which has become increasingly available, and 
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frequently used to treat adult and neonatal populations as a respiratory support. It has become 
more common for children to help reduce their work of breathing, and/ or as a treatment for 
respiratory failure (avoiding use of CPAP or intubation) (54, 55). There is also evidence 
supporting its efficacious and safe use for children, particularly in bronchiolitis (18, 54, 56). 
There is still a lack of large interventional trials to support its use, and clear national or 
international guidelines do not exist (55, 57). These may be the reasons why the HFNC 
recommendation statement required several revisions in this Delphi study. Originally, we did not 
include any recommendation statements for HFNC use in Round 1; however, a majority of 
participants emphasized that it is used regularly and should be included for Round 2. The new 
HFNC statement in Round 2 resulted in a consensus of 76% (CV 0.25, Likert mean±SD 
3.820.97). Participants also stated that HFNC should be described as an option to alleviate work 
of breathing and should not delay NIV or intubation in children of specific diseases. The 
statement was revised to incorporate these factors, which led to an increase of consensus to 92% 
(CV 0.19; 4.370.81) in Round 3 (see Table 11 for the evolution of the statement #1.6 from 
Round 1 to 3 and Supplementary Table 7 for more details). 
In the ESPNIC consensus guideline, the panelists could not agree on which ventilation 
mode, such as PC or VC, was ideal for children with healthy lungs, mixed diseases or cardiac 
diseases. In our survey, section 2 and 3 focused on ventilating children with specific goals and 
management considerations, including target tidal volumes, inspiratory pressures, minute 
ventilation, and ventilatory synchrony. These topics are discussed below. 
 With respect to tidal volume, one particular statement had poor consensus after Round 2 
at 60% (CV 0.21; 3.720.78), in addition to large amounts of open text feedback. The evolution 
of this statement #2.2 is described in Table 11. The initial low consensus and substantive 
feedback of this statement in our survey, may have been due to participants balancing the 
benefits and harms of various tidal volume thresholds. Generally, the literature does not 
recommend tidal volumes greater than the physiologic range of 5 to 8ml/kg ideal body weight 
(IBW) (3-6ml/kg for children with poor lung compliance, 5-8ml/kg for children with better lung 
compliance) (4, 5, 22, 58, 59). Ventilating adult patients with acute respiratory distress syndrome 
(ARDS) over this physiologic range has resulted in increased mortality and lung injury risks (4, 
19, 58, 60). Some studies support maintaining tidal volumes below and within these limits, 
however patients may need to be in “permissive” hypercapnia and hypoxemia (4, 19, 22). In 
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addition, for children post-cardiac surgery, higher tidal volumes with lower set respiratory rate 
may be indicated to minimize mean airway pressure (4). The decisions made to balance these 
factors must be discussed with the interprofessional team (61) (see Chapter 6- Finalized 
Canadian Pediatric MV management Consensus Guideline). 
 Another recommendation related to tidal volume also had several iterations. The 
evolution of this statement #2.1 is described in Table 11. This statement had a decrease from 
92% to 81% consensus with an increase of CV of +0.09 from Round 2 to 3 (Likert mean 4.16 
0.62, CV 0.15 vs. 4.00.95, CV0.24). We believed this was related to omitting “healthy lungs” 
from, and using IBW (versus actual measured weight) in the statement for Round 3. The 
ESPNIC consensus and Pediatric Acute Lung Injury Consensus Conference Group (PALICC) 
guidelines recommended that optimal tidal volumes be based on IBW (8, 59). The purpose of 
using the IBW is to normalize tidal volumes for MV, and may minimize the risk of under- or 
over-ventilating children, compared to using their actual weights (4, 62). In our survey there was 
significant feedback on whether to use IBW or actual measured weight for tidal volume settings. 
In Round 1, some participants noted that smaller children should be ventilated using their actual 
measured weight. Others suggested IBW should be used if the child is a specific weight (the 
range varied widely between 10kg to 50kg), or is a certain age group (“school aged”). Currently, 
there is no universal method to calculate IBW; it can be calculated using various techniques, all 
which yield different results (4, 62, 63). In addition, differences between IBW calculations and 
actual body weight, increase in children over 25kg (62). For our survey, we chose the lowest 
suggested threshold, using IBW for children > 10kg, and actual measured weight for children ≤ 
10kg. This threshold captured a large proportion of the pediatric population, while minimizing 
overlapping with neonates. We also suggested that obesity or fluid overload should factor into 
the tidal volume setting (see Chapter 6- Finalized Canadian Pediatric MV management 
Consensus Guideline).  
Another ventilatory mode/setting addressed in our survey was inspiratory pressures. The 
evolution of this statement #2.4 is described in Table 11. The ESPNIC consensus and PALICC 
guidelines do not provide specific plateau pressure recommendations, but suggest various limits 
in different pediatric diseases, ranging from 28 to 32 cmH2O (8, 22). This may have explained 
the improvement in consensus from Round 2 to 3 (11% increase, CV difference -0.07), because 
throughout these Rounds, the plateau pressure limit changed from 28 to 32cmH2O.  
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 The result of Section 5- Advanced Modes of Ventilation included five statements. In 
Round 2, one statement describing the use of HFJV did not reach consensus (at 57%, CV 0.31). 
The evolution of this statement #5.3 is described in Table 11. Neither PALICC or ESPNIC 
guidelines provided definitive recommendations on the routine use of HFJV in any children, and 
we originally excluded it from our survey (8, 59). However, in Round 1, open-text feedback 
from participants highlighted that HFJV should be mentioned and has potential use in children, 
so we introduced the concept in Round 2. In Round 2, only certain centers used HFJV 
(participant response n=35, 69% in Round 2; n=42, 86% in Round 3), and open responses 
mentioned that HFJV could be used in children, though not regularly. Thus, we recommended 
HFJV and other modes like airway pressure release ventilation (APRV), NAVA and 
proportionally assist ventilation (PAV) as “other advanced modalities to consider”. With respect 
to APRV, NAVA and PAV, research is still limited, and these modes are not extensively used in 
children (5, 8, 64). For our survey, we wanted to bring awareness of these modalities, but stress 
they should only be considered after evaluating the benefits and limitations. Though the 
Extracorporeal Life Support (ECLS) statement already had 81% consensus in Round 2 (CV 0.20; 
4.15±0.83), we received feedback that the statement had many elements and could be reworded 
for clarity. Thus, we made adjustments to clearly state the indications, and had it reviewed by an 
ECLS specialist prior to including it in Round 3. This may have explained the improvement of 
consensus from 81% to 96% (CV 0.15; 4.45±0.65).  
 Another recommendation statement that required several revisions in our survey 
addressed the use of proximal flow sensors. The evolution of this statement #10.4 is described in 
Table 11. Our participants suggested that proximal flow sensors were not routinely used in the 
pediatric population and may not be available for certain ventilators. ESPNIC (8) recommended 
that proximal sensors be used in children under 10kg as delivered tidal volumes can be 
underestimated in small children. We modified our statement to acknowledge this, and 
recommended its use be based on ventilator manufacturer recommendations (8).   
 Sections 4- PEEP and Fio2, 6-Weaning, 7-Physiologic targets, 8- Monitoring, 9- 
General MV practice and 10-Equipment adjuncts achieved consensus for each statement by the 
end of Round 2. All the statements in Round 2 and 3 have CVs less than 0.5, indicating the 
dispersions of the responses relative to their means were minimal and consensus was achieved. 
Ideally, the CV values should decrease from Round 2 to 3, indicating even smaller variation in 
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the subsequent responses. This occurred for all our statements except one that decreased in 
consensus from Round 2 to 3, which unsurprisingly led to an increase in CV. The WSRT was 
also performed to analyze the change in Likert responses across Round 2 and 3. Of the 10 
statements, the four statements with the greatest change in consensus percentage and CV, were 
significantly different between Rounds (p<0.05) (Table 10). These four statements described 
HFNC (p=0.002), tidal volume thresholds (p<0.01), HFJV (p<0.01) and ECLS (p=0.03).  
 Subgroup analyses by years of PICU experience (4.3.5 Subgroup analyses) demonstrated 
significant differences in several statements. The less experienced subgroup had higher Likert 
scores (closer to strongly agree), compared to the more experienced subgroup. We were unable 
to find Delphi studies that reported differences in Likert scoring across years of expert 
experience. However, it is possible that experienced RTs encountered more varieties of clinical 
scenarios and cases that could not be generalized, requiring unique decisions outside set 
recommendations. In a systematic review by Jordan et al (10), they reported that clinicians’ 
values, preferences, knowledge and skills were factors that influenced the successful 
implementation of weaning protocols in the PICU. Additionally, weaning processes in the PICU 
depended on the workflow, context and clinicians’ characteristics, which included years of 
experience (10). Though this review does not explicitly state whether clinical years of experience 
would result in decreased agreement with practice recommendations, it does suggest that clinical 
experience may influence successful implementations of weaning protocols. This demonstrates 
the necessity of designing recommendations with clinical remarks, to address unique and special 
circumstances seen in the clinical setting.  
In summary, these consensus recommendation guidelines describe and emphasize 
mechanical ventilation goals and management considerations broadly for all critically ill 
children, based on RT perspectives. These statements were similar to the ESPNIC guideline 
recommendations, which are already supported by other evidence such as the PALICC 
guidelines and the ARDSnet protocol (5, 19). These statements also referred to other 
organizational and workgroup guidelines such as the Extracorporeal Life Support organization, 
American Heart and Stroke Foundation (Pediatric Advanced Life support program), Safer 
Healthcare now!, Canadian Institute for Health Information, Solutions to Patient Safety, for 
specific recommendations. This is the first Canadian RT consensus recommendations to provide 
an overview of pediatric MV practices, and respiratory care in critically ill children. It will serve 
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as a living document as more evidence, and innovative MV practices emerge.  
 
4.5 Strengths and Limitations 
There are several strengths in this study. There was a significant and diverse panel size; 
51 participants from 12 pediatric facilities and 2 hospitals with dedicated pediatric beds, across 
nine provinces, with 27% males. This is a good representation of RT pediatric practices in 
Canada (12 of the 15 [80%] pediatric facilities; 64% of all Canadian facilities with stand-alone 
PICU or dedicated pediatric beds). Our sample size included RTs in various clinical roles. 
Participants were anonymous to each other, allowing them to independently provide honest 
feedback, and minimizing the risk of judgement from peers and influence of strongly opinionated 
members (32, 34, 36, 37). Another strength was the increasing response rate across the Rounds; 
Round 1 had a response rate of 78%, Round 2 of 91% and Round 3 of 97%. Round 1 likely had a 
lower response rate because participants were required to provide their own original text 
comments, compared to Round 2 and 3 which required selection of one numeric rating. 
Typically, the response rate decreases in subsequent Rounds (33, 34, 36). We had high response 
rates because our research team sent frequent reminders and were highly engaged with 
participants to address technical difficulties and clarify questions. Furthermore, the length and 
time required to complete each Round decreased (32, 34). In addition to our high response rate, 
we also had good participant retention. We had two participants withdraw from the study, and 
five lost to follow up by the end of Round 3; therefore, our retention rate for this Delphi study 
was 88% (49 participants/ 56 recruited and enrolled).  
Prior to initiating this Delphi study, a pilot Round was conducted to confirm whether the 
survey contents were relevant and appropriate. In addition, a post-Delphi review was included, 
where participants were asked to review and provide feedback for the finalized version of the 
guideline. Both pilot and post-Delphi measures are not commonly performed or reported (34, 35, 
38, 65), but we believe they helped enhance the content validity and trustworthiness of the 
results (34, 35, 38, 42).   
There were a few limitations to the study. Our pilot phase only included three expert RTs, 
and they were all SickKids employees, thus the feedback incorporated may be limited to this 
center’s practice. In addition, some practice perspectives might have been missed because there 
were several centers that were not involved in this study. These centers included B.C. Children’s 
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Hospital, McMaster Children’s hospital and Children’s hospital at London Health Sciences. We 
contacted these centers but were unsuccessful with recruiting any participants. Although we did 
recruit RTs from Janeway Children’s Hospital, CHUL et centre mere-enfant Soleil, Saint John 
Regional Hospital, Victoria General Hospital, and University of Northern B.C, we were unable 
to recruit at least three participants from each. We managed to recruit three participants from 
IWK Health center, but one participant did not have at least 5 years of PICU experience; we 
believed this person had the relevant expertise, and included them to increase representativeness. 
There was one more participant with approximately 4.5 years of PICU experience in Ontario, 
and they were included for the same reason.   
It may have been possible that participants provided feedback from information they 
read, heard or witnessed, and not personally experienced. For example, 80% of our participants 
also practiced in the NICU, and some of the feedback mentioned neonatal practices (which were 
omitted for analyses). There was also an observed difference in the number of participants who 
selected “0 – No comment” for the same statements across Round 2 and 3. It is possible that as 
the statements evolved from Round 2 to 3, participants were clearer on whether the practices 
were applicable to their current approach in pediatric MV management. These factors could 
possibly explain why several statements in the guideline did not reach at least 90% consensus. 
Lastly, this Delphi study only included Canadian RTs working in PICU and may not be 
generalizable for other interdisciplinary team members with experience in pediatric MV and/or 
outside Canada.  
Though this guideline is based on a strong consensus recommendation by ESPNIC, the 
concepts have little empirical scientific evidence supporting them. Therefore, the finalized 
Canadian consensus guideline for pediatric MV management should be practiced with caution 
and only by trained and experienced clinicians.  
 
4.6 Future Research 
 This Delphi study provided insight into Canadian RTs’ perspectives on the best pediatric 
MV management practices, however these recommendations are not definitive. Since many of 
the recommendation statements in this guideline were adopted from limited pediatric data and/ or 
adult and neonatal evidence (8, 22, 59), many of them will require updates as new evidence 
emerge. This guideline can serve as a foundational document at different Canadian pediatric 
critical care units to help standardize pediatric MV practices. This guideline may be utilized by 
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other clinicians involved in MV management and/or outside of Canada e.g respiratory 
physiotherapists, nurses, physicians. This guideline should be amended to consider practices 
variations across institutions, geographical regions, and countries.  
The lack of scientific literature should encourage both researchers and clinicians to 
embark on clinical trials to understand the effects of pediatric MV therapies in critically ill 
children. The efficacy of the pediatric MV recommendations in this study on patient outcomes is 
unknown. It is essential to investigate this in order to boost consensus and optimize 
standardization of care for acutely ill children (8). Until the evidence emerges, applying the 
practices in this guideline may assist in standardizing pediatric MV care that RTs provide. To 
date, there is still limited information on the effects of standardized MV management in critically 
ill children (4, 8), and some studies report poor compliance to implemented protocols (8, 10, 66-
71). Therefore, large interventional studies are required to address the efficacy of pediatric MV 
management guidelines and methods to maximize protocol adherence (3, 8, 10, 14, 68, 72, 73). 
 
4.7 Conclusions 
 To date, this is the only Canadian pediatric MV management consensus guideline for 
critically ill children. It is based on the collective agreement and clinical experiences of RTs 
across Canada. Our modified e-Delphi study achieved consensus in 95% of the recommendation 
statements at the end of Round 2, and 100% by the end of Round 3. There was a total of 59 
recommendations in the finalized guideline, organized into 10 sections: 1) non-invasive 
ventilation, 2) Tidal volumes and inspiratory pressures, 3) respiratory rates and inspiratory 
times, 4) PEEP and Fio2, 5) Advanced Modes of Ventilation, 6) Weaning, 7) Physiologic targets, 
8) Monitoring, 9) General MV and 10) Equipment Adjuncts. This guideline may be incorporated 
into protocols and RT practice policies in Canadian pediatric critical care units as an initial step 
to standardize pediatric MV management. However, this guideline is not definitive and will 
require consistent updates as new evidence emerge. Future research will need to address the 
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Mechanical ventilation (MV) is a form of life support therapy, specifically used to assist 
patients’ breathing to sustain life when they are unable to (1-5). MV management is dynamic and 
complex, as MV can be delivered in various forms, settings and modes by different devices for 
various diseases, either invasively or non-invasively  (2, 6-8). Despite overall therapy 
improvement and decrease in pediatric mortality over the last few decades (3, 4, 9), practices in 
pediatric MV management still lack standardization as clinical studies on the best techniques are 
scarce. Protocols and guidelines are available but vary across centers and are not always 
integrated into the practice culture (10-13). Potential barriers to successful implementation may 
include, not considering the social and cultural work environment, the intensivists’ level of 
acceptability to the protocol, and lack of large multicenter data to support the practice (10, 14-
16). This inconsistency of MV practices make it difficult to determine which method is best 
practice, and are associated with adverse events. Therefore, minimizing practice variability may 
improve patients’ safety, treatment efficiency and clinical outcomes (15, 17-19).  
The European Society for Pediatric and Neonatal Intensive Care (ESPNIC) was the first 
group to establish a consensus guideline for pediatric MV recommendations, detailing use of 
many different modes, interventions and adjuncts across various diseases. In Canada, respiratory 
therapists (RTs) are specially trained health care professionals, responsible for providing 
respiratory support and care for patients, and are considered to be one of the experts in MV 
management. RTs are a unique group of professionals with a specific role in respiratory care (20, 
21). This role does not exist in several geographical locations, including Europe. Since the 
ESPNIC recommendations were based on the perspectives of European physicians only, it would 
be of interest to compare and contrast the differences with Canadian RTs’ perspectives. 
Therefore, this study aimed to answer: What are Canadian RTs consensus recommendations on 
pediatric MV practice and management in critical care?   
 A Modified e-Delphi Survey Technique was used to collect Canadian RT’s consensus on 
pediatric MV management in this study. Raw scores with 75% of participants in a categorized 
group were considered as consensus and verified using the coefficient of variation (CV). The 
contents of this Delphi study were derived from the published ESPNIC recommendations into 53 
statements, and were verified in a pilot Round. The expert panel (n=56) consisted of pediatric 
intensive care unit (PICU) RTs in various clinical roles with ≥5 years working at pediatric acute 
care facilities or centers with dedicated pediatric beds across Canada. In Round 1, expert 
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participants suggested a few new topics to include, for a total of 58 statements. For Round 2 and 
3, participants ranked their level of agreement or disagreement using a 5-point Likert scale. Fifty 
five of the 58 statements in Round 2 achieved consensus, and only statements that received 
significant feedback on its content or did not receive consensus were revised for another 
reiteration in Round 3. In Round 3, all 11 statements achieved consensus. The final 
recommendation guideline consisted of 59 statements, divided into 10 subtopics.  
 This is the first Canadian pediatric MV management guideline for critically ill children, 
from the perspectives of RTs. The purpose of this guideline is to emphasize the goals and MV 
management recommendations for any critically ill child, not specific to a particular disease or 
type of MV therapy. The majority of the recommendation statements in our Delphi study 
achieved consensus by the end of Round 2 (95% of statements). By the end of Round 3, all 
statements received consensus with at least 80% consensus for each. Using a Modified e-Delphi 
technique to specifically tailor the survey to focus on the relevant Canadian RT practices from 
the ESPNIC guideline (7), may have contributed to this high consensus. The Modified form most 
likely orientated our participants to the available information, and encouraged RT-focused 
feedback and ideas. In addition, the content and topics of our survey had already gone through a 
vigorous consensus process by international physicians, and other existing literature (7).  
There were a few statements that went through extensive revisions throughout the 
Rounds before its finalized version in the consensus guideline. This included the statement about 
the indications and use for high flow nasal cannula [HFNC] oxygen therapy, an increasingly 
popular respiratory support to alleviate work of breathing in children in respiratory failure and 
bronchiolitis (22, 23). Because the ESPNIC guideline could not provide a practice 
recommendation for the use of HFNC (7), we originally opted to exclude it. However, 
participants emphasized its common use and importance in clinical practice and the topic was 
introduced in Round 2 with 76% consensus (CV 0.25, Likert mean±SD 3.820.97). Participants 
suggested that the recommendation could be strengthened by clearly stating that HFNC should 
not delay non-invasive ventilation (NIV) initiation in children with specific diseases, which 
greatly improved the consensus to 93% (CV 0.19, 4.370.81), with a significant change in Likert 
score means from Round 2 to 3 (Wilcoxon Signed Rank test [WSRT] p=0.002).  
Another topic that was not originally included was high frequency jet ventilation (HFJV). 
As ESPNIC was unable to comment on the use of HFJV in children (7), we decided to exclude 
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this modality in our survey as well. However, feedback led to its inclusion for the following 
Rounds. This statement gained poor consensus in Round 2 (60%, CV 0.31, 3.4± 1.06) but 
improved after the statement was modified to consider its limited use in children (98%, CV 0.17, 
4.14 ±0.72).   
One statement about target tidal volumes, gained poor consensus at 60% (CV 0.21, 
3.720.78), and received substantial open-text feedback on the tidal volume thresholds. The 
literature suggests physiologic tidal volumes range of 5 to 8ml/kg ideal body weight (IBW) but 
there may be circumstances that make it difficult to achieve target tidal volumes (4, 5, 24-26). 
These factors were included into the next reiteration in Round 3, which demonstrated an 
improvement in consensus to 97% (CV 0.12, 4.31±0.51) with significant change in Likert 
response means from Round 2 to 3 (WRST p<0.01).  
One other statement that required several revisions was the recommendation on the use of 
proximal flow sensors. The use of proximal flow sensors was inconsistent across centers and 
resulted in poor consensus (71%, CV 0.26, 3.88± 1.02). Thus, we incorporated ESPNIC’s 
recommendation on proximal sensor use, and participants’ feedback, to finalize a statement 
about its limited use (84%, CV 0.21, 3.91± 0.82).  
A subgroup analysis were done for years of PICU experience. The less experienced group 
had higher Likert mean scores compared to the more experienced. The group with more clinical 
PICU experience, likely witnessed a wider variety of clinical scenarios and circumstances where 
generalized recommendations are not applicable. Different clinical scenarios and circumstances 
warrant special considerations that may not be within the limits of the recommendations. This 
makes the clinical remarks a crucial part of this consensus guideline. 
 There were several strengths in this study, including the diverse expert panel. Across nine 
provinces, a total of 14 facilities participated: 13 pediatric facilities and 2 hospitals with 
dedicated pediatric beds. The participants were in various clinical roles with a range of PICU 
experience. Our response rate was high across all three Rounds, Round 1 with 78%, Round 2 
with 91% and Round 3 with 97%. Another strength of this study is the inclusion of a pilot trial 
and post-Delphi review to enhance the content validity and trustworthiness of the results (27-30). 
These are usually not performed or reported in previous Delphi studies.  
There were a few limitations in this study. The pilot phase only included RTs from 
SickKids, limiting the feedback to this one center. Another limiting factor was that several 
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centers were not involved in this study. Although we managed to successfully recruit and engage 
participants from 14 facilities, our subgroup sizes for several centers were less than the goal of 
three per center. In addition, there were two identified participants with less than five years of 
PICU experience, but they were included to improve the representativeness in our study. Though 
we achieved consensus, these Canadian RT consensus guidelines must be practiced with caution 
as they are based on limited empirical evidence, and have limited applicability to other 
interprofessional team members with MV experience.  
 This is the first consensus guideline document to describe pediatric MV management for 
critically ill children in Canada, based on the perspectives of RTs across Canada. Our Delphi 
study received at least 80% consensus on all the statements by Round 3, with a total of 59 
statements, organized into 10 sections: 1) non-invasive ventilation, 2) Tidal volumes and 
inspiratory pressures, 3) respiratory rates and inspiratory times, 4) PEEP and Fio2, 5) 
Advanced Modes of Ventilation, 6) Weaning, 7) Physiologic targets, 8) Monitoring, 9) General 
MV and 10) Equipment Adjuncts. The guideline can be integrated into Canadian RT practices 
and is the initial step to standardizing pediatric MV care.  
Because many of the recommendations in this guideline are based on the existing 
literature, they will require constant updates and revisions as evidence emerges. The purpose of 
this guideline is to serve as a fundamental support document to encourage the use of 
standardized management techniques across different Canadian pediatric critical care units. 
Furthermore, this guideline could also be utilized by pediatric MV health care practitioners 
across different regions. The guideline must be used by trained professionals, and relevant 
practices discussed with the interprofessional team; special circumstances may warrant 
adjustments of these recommendations. The efficacy of the MV recommendations in this 
guideline and their effect on clinical outcomes are unknown at this time. Future research should 
focus on taking the steps to implement this guideline in clinical practice, and research its impact 
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All the “patients” in this document are Pediatric patients. 
A list of all the abbreviations is provided at the end of the document 
 
Section 1: Non-invasive ventilation (NIV) Recommendations 
 
Non-invasive ventilation (NIV) refers to any positive pressure ventilation that is provided via a 
headgear, face mask or nasal interface. This includes CPAP or BiLevel non-invasive support e.g. 
NIV, spontaneous timed (ST), pressure control (PC), pressure support (PS), proportional assist 
ventilation (PAV), non-invasive neurally adjusted ventilatory assist (NIV-NAVA). 
 
1.1 Consider the use of NIV in patients with mild to moderate cardiorespiratory failure, if not 
responsive to or in combination with other medical management (e.g. inotropes, diuretics). 
 
1.2 Consider the use of NIV to reduce work of breathing and decrease afterload for patients with 
left ventricular failure, if not responsive to or in combination with other medical management 
(e.g. inotropes, diuretics).  
 
1.3 Aim to use NIV interfaces with minimal leak and appropriate for their size, age and skin 
integrity. Monitor leaks within an acceptable range to optimize patient comfort, compliance, 
patient ventilator synchrony, and to preserve patient trigger sensitivity.  
The factors that impact interface selection are varied, and each clinical situation will 
require the clinician to balance these factors. Other factors not listed in the statement 
that may impact the interface selection includes the intentional leak built into the device, 
head gear size, and the compressible volume of the mask. In addition to these, the 
development of any interface-related pressure injury may prompt an alternate mask 
selection.  
 
1.4 Optimize patient ventilator synchrony by adjusting trigger sensitivity and optimizing mask 
seal in any triggered non-invasive ventilation mode (e.g. bilevel, S/T). 
 
1.4a If available, specialty modes of NIV such as NIV-NAVA can be used to optimize patient-
ventilator synchrony. 
The use of specialty modes varies across centres, based on both the availability of 
specialty modes and the institutional clinical guidelines for use. Factors that may 
influence success of specialty modes may be user’s clinical experience as well as 




1.5 Consider the use of NIV prior to intubation, in patients with mixed diseases (decreased 
compliance and/or increased resistance), unless contraindicated. Common contraindications 
are decreased level of consciousness, impending respiratory failure/arrest, airway 
compromise, decreased respiratory drive, and poor skin integrity (e.g. burns, contusions). 
The decision to use NIV prior to intubation should be carefully evaluated with the 
interprofessional team. There are additional situations whereby invasive ventilation may 
offer additional stability beyond the list of common contraindications. 
 
1.6 Consider the use of HFNC prior to NIV, to alleviate any work of breathing. However, the use 
of HFNC is not a substitute for NIV and should not delay or replace the use of NIV, if NIV is 
more appropriate. 
After careful evaluation, the use of HFNC may be considered in a variety of clinical 
situations prior to NIV. If a clinical situation warrants a stable or defined positive 
pressure level, NIV should be used. There are certain clinical situations where NIV is the 
preferred therapy (e.g. obstructive sleep apnea).    
 
1.7 The use of HFNC and/or NIV should not delay inevitable intubation. 
Using NIV and/or HFNC prior to intubation is a complex clinical decision which should 
consider the patient’s clinical status, and discussed with the interprofessional team.  
 
 
Section 2: Tidal Volume & Inspiratory Pressure Recommendations 
 
2.1 Aim to achieve a tidal volume in the physiologic range (5-8ml/kg ideal body weight) in 
patients <10kg. Alternatively, aim to achieve tidal volumes of 5-8ml/kg measured weight in 
patients ≤10kg. 
The recommendation for 5-8mL/kg tidal volume assumes the delivery of mechanical 
ventilation to two lungs of anatomically appropriate size. If patients have anatomical 
differences (e.g., single lung, known lung hypoplasia), the target tidal volume should be 
discussed with the interprofessional team.  
 
There are a variety of opinions on the appropriate age or size threshold to estimate tidal 
volume based on ideal body weight (as opposed to measured weight). Some suggestions 
include school-age, or 20kg. Clinicians should avoid over estimating lung volume if 
patients are obese or have excess weight due to excessive fluid overload. 
 
On occasion, higher tidal volume ranges may be warranted for post-operative cardiac 
surgeries to keep the set respiratory rate lower to optimize venous return to the heart (by 
keeping the mean airway pressure lower through the respiratory cycle).  
 
 
2.2 Aim to achieve tidal volume in the physiological range (5-8ml/kg ideal body weight) with 
minimal driving pressure (PIP-PEEP) in patients on pressure limited modes.  
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2.3 Aim to limit inspiratory plateau pressure (Pplat) to approximately 30cmH2O, in the absence 
of transpulmonary pressure measurements. Limits should be between 28 to 32 cmH2O. 
There are many centres that pressure ventilate and do not routinely measure Pplat. In the 
absence of a Pplat measurement, aim to limit peak pressure (PIP) to 30cmH2O.  
 
2.4 If unable to achieve physiologic tidal volumes (5-8ml/kg) within plateau pressure limits 
(30cmH2O), targeting ranges outside these limits should be discussed with the 
interprofessional team. There may be circumstances where tidal volumes < 5mL/kg and 
>8ml/kg may be cautiously, but not routinely used.  
Examples where smaller tidal volumes may be acceptable include congenital hypoplastic 
lung or severe PARDS.  
 
On occasion, higher tidal volume ranges may be warranted for post-operative cardiac 
surgeries to keep the set respiratory rate lower to optimize venous return to the heart (by 
keeping the mean airway pressure lower through the respiratory cycle).  
 
 
Section 3: Respiratory Rate and Inspiratory Time Recommendations 
 
3.1 Set inspiratory time and respiratory rate based on the patient’s age, respiratory mechanics 
(including waveforms), and clinical data (e.g. blood gases, vital signs) in controlled 
ventilation modes. This will allow for full exhalation (acceptable I:E ratio), optimized patient 
synchrony and ventilation.  
 
3.2 Set the trigger setting and cycling setting on the ventilator to achieve the above goals 
(Recommendation 3.1) in all spontaneous ventilation modes.  
 
3.3 Increase the set respiratory rate when tidal volumes and/or PIP are reaching limits to 
maintain minute ventilation. Ensure there is sufficient expiratory time to avoid air-trapping. 
Increase the RR to a reasonable threshold based on age, maintaining adequate 
inspiratory time to deliver tidal volume, and maintaining I:E ratio (a specific threshold 
has not been defined, though should not be inverse). 
 
 
Section 4: PEEP and FiO2 Recommendations  
 
4.1 Set a minimum PEEP level of 5-6cmH2O, to maintain adequate lung inflation, in all patients. 
PEEP is used to maintain adequate functional residual capacity (FRC). There may be 
rare circumstances in which PEEP may be set below 5-6 cmH2O (Recommendation 4.2). 
4.2 Set PEEP to maintain end expiratory lung volume, and an optimal balance between 
hemodynamic stability and oxygenation, in all patients.  
 
4.3 Titrate PEEP incrementally while assessing lung compliance, oxygen saturation, 
hemodynamic stability and chest x-ray findings for patients with challenging oxygenation 
needs (e.g. PARDS). 
 133 
The titration of PEEP should be based on multiple factors and aim to avoid over or 
under-distension.  
New technology such as Electrical Impedance Tomography (EIT) can be considered 
when deciding the appropriate PEEP level. 
 
4.4 Titrate PEEP to allow for the lowest possible FiO2 (to maintain target oxygenation goals), 
while maintaining adequate hemodynamic status. 
In the absence of other clinical status changes, FiO2 requirements can be helpful to 
assess and support the titration of PEEP (in addition to factors listed in 4.3). Increased 
FiO2s  during PEEP weaning may indicate that lung inflation is worsening.  
 
4.5 Set higher levels of PEEP (≥10cmH2O) to maintain adequate lung inflation in patients with 
moderate to severe PARDS, if necessary. 
 
4.6 Set higher levels of PEEP (≥10cmH2O) to stabilize airways in patients with tracheomalacia 
and/or bronchomalacia, if necessary. 
The level of PEEP for patients with tracheomalacia and/or bronchomalacia should 
consider patient WOB, and tidal volumes/waveforms. Flexible laryngoscopy may also be 
used in collaboration with otolaryngology services (or the designated care team that 
manage these patients). 
 
 
Section 5: Advanced Mechanical Ventilation Recommendations 
 
General remark: All forms of advanced mechanical ventilation recommendations assume that 
practitioners have experience with their use. Availability of devices may vary across different 
institutions/units, reflecting when they are used.   
 
5.1 Consider the use of high frequency oscillatory ventilation (HFOV) in patients with restrictive 
or mixed diseases and severe oxygenation and/ or ventilation failure. 
The decision to transition from conventional to HFOV should be individualized. Broadly 
it should occur when the limits of conventional ventilation have been reached (see tidal 
volume and inspiratory pressure, Section 2; respiratory rate and inspiratory time, 
Section 3; and PEEP and FiO2, Section 4).  
 
5.2 Consider the use of HFOV in patients with cardiac issues and severe respiratory failure. 
Cautious use of increased mean airway pressure is advised in patients with passive 
pulmonary blood flow or right ventricular dysfunction. 
See clinical remarks from 5.1.  
 
5.3 Consider the use of other advanced modes (such as HFJV or APRV) when conventional 
mechanical ventilation and/or HFOV has failed. Consider the unique benefits and/or 
limitations for each of these advanced modes. These advanced modes should not substitute or 
delay inevitable ECLS, if appropriate. 
Decisions on the use of advanced modes should consider the quality of pediatric research 
evidence, frequency and consistency of use, and/or availability. 
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5.4 Consider the use of other advanced ventilation modes/techniques (such as NAVA, PAV, or 
automated weaning) to optimize patient-ventilator interactions. The unique benefits and/or 
limitations for each of these advanced modes must be acknowledged.  
The use of specialty modes to optimize patient-ventilator interactions should be based on 
both the availability of specialty modes and institution-specific clinical guidelines. 
Factors that may the influence success of specialty modes may be user’s clinical 
experience as well as alternative strategies available at centres. 
 
Decisions on the use of advanced modes should also consider the quality of pediatric 
research evidence.  
 
5.5 Consider the use of ECLS in patients with reversible diseases when conventional mechanical 
ventilation and/ or HFOV has failed, if available within the facility, and not contraindicated. 
Follow guidelines (e.g. ECLS organizations) for more specific criteria. Consider early 
consultation with an ECLS center when ECLS is not available within the facility.  
 
 
Section 6: Weaning Recommendations  
 
6.1 Routinely assess all patients, with the aim to wean ventilator settings as early and often as 
possible.  
 
6.2 Use weaning principles guided by respiratory mechanics, pathologies and disease trajectory 
in patients with complex presentations (e.g. restrictive, obstructive, mixed or cardiac 
diseases). 
 
6.3 Consider the use of pressure support ventilation when adequate respiratory drive is present 
and disease trajectory is improving. This allows the patient to breathe spontaneously to 
maximize comfort and avoid asynchrony/muscle atrophy.  
Pressure support ventilation can be used for prolonged periods of time. Parameter 
changes should be based on ongoing assessments of tolerance and patient’s overall 
clinical status. 
 
6.4 Routinely assess the pressure support level, rise time and sensitivity of flow cycling to 
maintain patient comfort/synchrony and physiologic tidal volumes (5-8ml/kg) in patients on 
pressure support ventilation.  
Please also see all recommendations related to tidal volume (Section 2).  
 









Section 7: Physiologic Target Recommendations 
 
7.1 Physiological targets should be guided by patient respiratory mechanics, both respiratory and 
non-respiratory pathologies, and disease trajectories.  
 
7.2 Target normal arterial CO2 levels for patients with healthy lungs (i.e. no respiratory disease). 
If arterial CO2 is not available, target normal venous and capillary CO2 levels. 
 
7.3 Permissive hypercapnia (pH ≥ 7.25) may be acceptable for acutely ill patients, unless specific 
disease conditions dictate otherwise (e.g. pulmonary hypertension, traumatic brain injury). 
 
7.4 Target a SpO2 92-99% in patients with healthy lungs, in the absence of respiratory disease. If 
the patient is post-resuscitation, follow the Heart and Stroke PALS recommendations of 
SpO2 94-99%. 
Excessive use of oxygen should be avoided. Supplemental oxygen should be continuously 
titrated down if the patient maintains an SpO2 within the target range. SpO2 >97% is 
acceptable if a patient is on FiO2 0.21 (or as minimal as possible) to avoid frequent 
desaturations. 
 
7.5 Target SpO2 92-97% when PEEP is <10cmH2O in patients who meet the PARDS criteria (as 
described in the PALICC guidelines).  
These recommendations are made in the context of PARDS alone. If patients have other 
clinical factors that warrant PEEP titration or higher levels of PEEP, these should be 
incorporated into PEEP and SpO2 clinical decisions. 
 
7.6 Target SpO2 88-92% when PEEP is ≥ 10cmH2O in patients who meet the PARDS criteria (as 
described in the PALICC guidelines). 
These recommendations are made in the context of PARDS alone. If patients have other 
clinical factors that warrant PEEP titration or higher levels of PEEP, these should be 
incorporated into PEEP and SpO2 clinical decisions. 
 
7.7 Target SpO2 75-85% (or as recommended by the interprofessional team), for patients with 
cyanotic cardiac lesions (e.g. fixed Right to Left shunts). 
 
 
Section 8: Monitoring Recommendations 
 
8.1 Use continuous SpO2 monitoring to assess oxygen saturation in all patients on invasive and 
non-invasive mechanical ventilation. 
 




8.3 Consider the use of transcutaneous CO2 in patients on advanced forms of mechanical 
ventilation (e.g. HFOV, HFJV). These monitoring options should be frequently correlated 
with arterial blood gas values.  
 
8.4 Use arterial lines for accurate pH, PaO2, and lactate measurements, in moderate to severely 
ill patients on mechanical ventilation. 
 
8.5 Use central SvO2 and lactate measurements to assess oxygen extraction and/or cardiac 
output, in cardiac and/or severely ill patients on mechanical ventilation.  
 
8.6 Consider the use of capillary gases to assess gas exchange in mechanically ventilated patients 
with good perfusion and mild diseases. They may be used to provide estimates or trends 
when arterial/central lines are not available.  
Before taking a peripheral venous sample, consider an arterial blood gas puncture or 
capillary gas. Balance this by considering patient perspectives including procedural 
pain, willingness, and frequency of measurements.  
 
8.7 Cautiously use peripheral venous PCO2 measurements to provide estimates and trends of 
ventilatory gas exchange, when arterial/ central lines are not available.  
 
8.8 Use pH as a tool to modify the pulmonary vascular resistance for specific disease conditions, 
(e.g. pulmonary hypertension, single ventricle heart disease).  
 
8.9 Aim to maintain normal pH, PaCO2 and PaO2 in pulmonary hypertension and traumatic brain 
injury. Consider targeting normal-high pH and normal-low CO2 values. 
The management of pulmonary vascular resistance may also include the use of oxygen, 
inhaled nitric oxygen, or other medications, and is beyond the scope of these 
recommendations. 
 
Section 9: Other General Recommendations 
 
9.1 Routinely assess patients to allow for spontaneous breathing, except for severely ill patients 
receiving muscle relaxants and sedation. 
 
9.2 Routinely monitor and assess the impacts of muscle relaxants and sedation on mechanical 
ventilation (respiratory rate, tidal volumes, minute ventilation) when they are in use for the 
patient’s clinical management. 
Continuously assess the benefits and harms of muscle relaxants and sedation, with the 
goal to minimizing use. Wean the muscle relaxant or sedation using a safe approach and 
with careful monitoring.  
 
9.3 Routinely assess ventilator waveforms (e.g. flow-volume loops, pressure-volume loops) as 
they provide real-time data about patient-ventilator interactions such as breath-by-breath 
ventilation status, response to therapies, and lung mechanics.   
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9.4 Use the Pediatric Acute Lung Injury Consensus Conference (2015) recommendations on 
nitric oxide, neuromuscular blockade, prone position and surfactant use, if safe to do so. 
 
9.5 Reduce the risk of Ventilator acquired pneumonia (VAP) by following the VAP bundles 
published by safety groups (e.g. Safer Healthcare Now!, Canadian Institute for Health 
Information, Solutions to Patient Safety). Elements include: 1) elevate the head of the bed 
30-45 degrees (15-30 degrees in infants), unless specific disease or conditions dictate 
otherwise, 2) perform consistent oral hygiene, 3) minimize unnecessary circuit disconnects, 
and 4) perform daily assessment for extubation readiness.  
 
9.6 Different Organization and Working Group guidelines and recommendations may be 
incorporated into practice and may include, but are not limited to: Pediatric Acute Lung 
Injury Care Conference (PALICC), National Heart, Lung, and Blood Institute (NHLBI) 
ARDS Network Protocol, Pediatric Advanced Life Support (PALS), Neonatal Resuscitation 
Program (NRP), Extracorporeal Life Support Organization (ELSO). 
 
9.7 Mechanical ventilation management and anticipated plans should be discussed as an 
interprofessional team, at minimum, on a daily basis. Any changes in the patients’ trajectory 
or mechanical ventilation needs should be communicated with all members of the 
interprofessional team.  
 
 
Section 10: Equipment adjuncts recommendations 
 
10.1 Use dual-limb, heated, filtered circuits with active airway humidity for invasive mechanical 
ventilation.  
 
10.2 Use active airway humidification at 100% relative humidity at 37°C in patients on invasive 
mechanical ventilation. Use active airway humidification in the range of 31- 37°C, and 
titrate to avoid excessive rain out in the interface in patients on NIV. 
 
10.3 Minimize the use of apparatuses or connectors that add dead space to ventilator circuits, 
whenever possible. 
Many devices have neonatal and pediatric-sized adaptors, use the appropriate size for 
the patient based on the devices’ recommendations.  
 
10.4 Do not routinely use proximal flow sensors, or follow the specific ventilator’s 
recommendations on proximal flow sensor use. In the absence of specific ventilator 
recommendations, use a proximal flow sensor for small tidal volumes (<10mL).  
The use of a proximal flow sensor should be guided by the accuracy of the ventilator tidal 
volume measurement, and its acceptability as a measurement. Use proximal flow sensors 
for accurate measurement of tidal volume in smaller patients when internal 
measurements are inaccurate. Variability in practice may exist based on ventilator 
measurement accuracy, with some centres never using proximal flow sensors, and others 
using it for all patients.  
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10.5 Minimize routine use of manual ventilation to avoid circuit disconnects. Manual ventilation 
may be used to augment pulmonary hygiene as part of chest physiotherapy. Manual 
resuscitation devices should be capable of maintaining PEEP, monitoring and limiting 
pressures. 
Use manual ventilation judiciously. Circumstances include managing acute desaturation, 
facilitating emergent patient transports, patient repositions to new beds, and/or ventilator 
circuit changes. Patients with certain pathologies may require manual ventilation for 
chest physiotherapy or secretion clearance techniques such as In-exsufflation. When 
manual ventilation is used, assess the patient for any transient or prolonged clinical 
changes such as lung de-recruitment. 
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List of abbreviations 
 
APRV  Airway Pressure Release Ventilation 
CO2  carbon dioxide  
ECLS  Extracorporeal Life Support 
ECMO  Extracorporeal membrane oxygenation  
FiO2  Fraction of inspired oxygen 
HFJV  High frequency jet ventilation 
HFNC  High flow nasal cannula 
HFJV  High frequency jet ventilation  
HFOV  High frequency oscillation ventilation 
IBW  Ideal body weight  
NAVA  Neurally adjusted ventilatory assist 
NIV-NAVA Non-invasive neurally ventilatory assist 
PaO2  Arterial partial pressure of oxygenation  
PALICC Pediatric Acute Lung injury Consensus conference 
PALS  Pediatric Advanced Life Support 
PARDS Pediatric acute respiratory distress syndrome 
PAV  Proportional Assist ventilation 
PCO2  Partial pressure of carbon dioxide 
PEEP  Positive end expiratory pressure  
PICU  Pediatric intensive care unit 
PIP  Peak inspiratory pressure 
Pplat  Plateau pressure 
PSV  Pressure support ventilation  
SpO2  oxygen saturation   
SvO2  Venous saturation  
VAP  Ventilator acquired pneumonia  
WOB  Work of breathing 
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Chapter 7 – Supplementary materials  
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Supplementary Table 1A 
 
Outlined inclusion and exclusion criteria for literature review.  
 
Item Inclusion Exclusion 
Participants/ 
Population 
• Children (pediatrics) 
• Critical Care setting/ pediatric intensive 
care unit (PICU)  
• Adults  
• Neonates  
• Animals   
Intervention • Protocolized MV therapy 
• Any form of protocolized MV 
mode/settings were included e.g. Non-
invasive MV, high flow oxygen therapy, 
high frequency oscillation/ jet ventilation, 
conventional MV  
• Long term (chronic) / home 
MV 
• Transport ventilation 
• Medical treatments not outlined 
in the inclusion criteria  
Comparison • Non-protocolized MV therapy i.e. 
management not guided by protocols or 
guidelines  
• MV therapy management directed by 
physician or team  
• Long term (chronic) / home 
MV 
• Transport ventilation 
• Medical treatments not outlined 
in the inclusion criteria 
Outcomes • Clinical outcomes of MV, including (but 
not limited to): length of stay, length of 
MV therapy, adverse events, mortality, 
quality of care indicators etc.  
• Studies without reported 
outcomes  
Publication • Published in English 
• Within last 20 years (2000 to 2021) 
• Full text articles  
• Duplicate publications 




• Primary research studies 
• Retrospective or prospective 
• Quantitative: randomized controlled trials 
(RCT), pseudo-RCTS, cohort studies, 
case-control studies, case series, cross-
sectional studies 
• Peer-reviewed secondary research 
publications 
• Systematic reviews, meta-analysis 
• Theses 
• Reviews and summaries of 
recommendations, protocols, guidelines, 
consensus (Clinical practice guidelines/ 
protocols)  
• Mixed methods including surveys, 
questionnaires, conference reports on 
recommendations or guidelines 








Supplementary table 1B 
Search results for each of the databases. 
Database Number of articles found Number of relevant articles  
Pubmed 251 25 
Embase 213 9 
MEDLINE 375 18 
CINAHL 25 2 
Cochrane Reviews 40 3 




Supplementary table 2 
List of pediatric facilities and facilities with dedicated pediatric critical care bed(s). A total of 19 
centers were contacted and 15 centers enrolled into the study. 
Facilities with stand-alone 
pediatric unit/ or dedicated 
bed(s) 
Facilities that were contacted Facilities involved in the 
study  
• British Columbia 
Children’s hospital  
• Stollery Children’s 
• Alberta Children’s  
• Janeway Children’s 
• Jim Pattison Children’s 
• Children Hospital of 
Manitoba  
• McMaster Children’s 
Hospital 
• Sick Kids Hospital 
• Children’s Hospital of 
Eastern Ontario  
• Montreal children’s 
hospital 
• IWK Healthcenter 
• Centre hospitalier 
universitaire Sainte-Justine 
• CHUL et centre mère-
enfant Soliel 
• London Health 
• Saint John’s Regional 
hospital 
• Victoria General Hospital 
• University Hospital of 
Northern British Columbia  
• Regina General hospital 
• Moncton hospital 
• CSSS Rimouski-Neigette 
• University of Cardiology 
and Respiratory Quebec  
• Hôpital Fleurimont 
(CHUS) 
• British Columbia 
Children’s 
• Stollery Children’s 
• Alberta Children’s  
• Janeway Children’s 
• Jim Pattison Children’s 
• Children Hospital of 
Manitoba  
• McMaster Children’s 
Hospital 
• Sick Kids Hospital 
• Children’s Hospital of 
Eastern Ontario   
• Montreal children’s 
hospital 
• IWK Healthcenter  
• Centre hospitalier 
universitaire Sainte-Justine 
• CHUL et centre mère-
enfant Soliel 
• London Health 
• Saint John’s Regional 
Hospital 
• Victoria General Hospital 
• University Hospital of 
Northern British Columbia  
• Regina General hospital 
• Moncton hospital 
 
• Stollery Children’s 
• Alberta Children’s 
• Janeway Children’s 
• Jim Pattison Children’s 
• Children Hospital of 
Manitoba 
• Sick Kids Hospital 
• Children’s Hospital of 
Eastern Ontario  
• McMaster Children’s 
hospital 
• Montreal Children’s 
hospital  
• IWK Healthcenter 
• Centre hospitalier 
universitaire Sainte-Justine 
• CHUL et centre mère-
enfant Soliel 
• Saint John’s Regional 
hospital 
• Victoria General Hospital 
• University Hospital of 






Supplementary table 3  
Practice locations and centers of the RT expert panel (N=55*) 
Province  
# of RTs 
(%) 
Practice location # of RTs 
Alberta 11 (20.0) Stollery Children’s hospital 6 
  Alberta Children’s hospital 5 
British Columbia 3 (5.5) Victoria General hospital 2 
  University hospital of Northern BC 1 
Manitoba 5 (9.1) Children’s hospital of Manitoba 5 
Saskatchewan 7 (12.7) Jim Pattison Children’s hospital 7 
Ontario 12 (21.8) Hospital for Sick Children 7 
  Children Hospital of Eastern Ontario 4 
  McMaster Children’s hospital 1 
Quebec 11 (20.0) Montreal Children’s hospital 5 
  CHU Sainte Justine 5 
  CHUL et centre mere-enfant Soleil 1 
New Brunswick 1 (1.8) Saint John Regional hospital 1 
Newfoundland 2 (3.6) Janeway Children’s hospital 2 
Nova Scotia 3 (5.5) IWK Health center 3 
*Includes n=3 who did not complete any Rounds 
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Supplementary Table 4 
Open responses from participants for Round 1. The open-text feedback in this chart are as 
written by participants. Minimal revisions. 
 Recommendation statement from 
Round 1 
Original comments  
Non invasive ventilation (NIV) 
1.1 Consider the use of non-invasive 
ventilation in pediatric patients with 
moderate cardiorespiratory failure.  If 
not responsive to other medical 
management e.g. inotropes, diuretics 
 
• We use HFNC (Airvo or Optiflow) in pediatric 
patient, sometime prior to NIV. If not 
responsive, initiate NIV 
• We consider the use of NIV for all patients with 
mild to moderate cardio-respiratory failure, with 
or without response to other medical 
management. 
• We would use NIV either in conjunction with or 
before inotropes/diuretics, not after. Inotropes or 
diuretics imply cardiac failure, not necessarily 
cardiorespiratory failure due to other disease 
processes.   
• I would have serious concerns if a paediatric 
patient was on inotropes with a refractory 
response, and the next step chosen is to add 
NIV. As well, children often require sedation to 
tolerate NIV, which adds yet another layer of 
complexity to managing these patients 
(vasoplegia, decrease responsiveness therefore 
difficult to clinically assess the effectiveness of 
therapy)  
• Full list of contraindications to NIV therapy 
should be given in these guidelines as well (ex: 
too many oral secretions, facial 
contusions/burns, decreased level of 
consciousness etc). Duration of "trial" on NIV as 
well as signs it is/isn't working and where to go 
next can also be explained. 
• Assess patient's ability to protect his/her airway 
and level of consciousness. NIV should not be 
used in cases of respiratory failure where cardio-
respiratory arrest is impending  
• We do not want to be recommending NIV in the 
presence of airway compromise. These 
guidelines will be read by rural sites that may or 
may not have ventilation experts like RRTs on 
site and may take the abridged original statement 
at face value. NIV is lethal on the wrong patient. 
1.2 Use non-invasive ventilation to reduce 
work of breathing and decrease 
afterload for pediatric patients with left 
ventricular failure, if not responsive to 
other medical management e.g. 
inotropes, diuretics.  
• "in conjunction with other medical 
management". Sometimes, you do not want to 
wait for other things to fail before trying some 
NIV! 
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 • The use of NIV may help to reduce the work of 
breathing and decrease afterload for pediatric 
patients with left ventricular failure (e.g. dilated 
cardiomyopathy), while awaiting other treatment 
or if the patients is not responding to other 
medical management. 
• Only in pediatric critical care settings where 
patients can be monitored by expert clinicians 
and if not responsive to other left ventricular 
failure management. 
• Or HFNC if patient is not comfortable with the 
mask 
1.3 Before intubation, consider non-
invasive ventilation as a first approach 
in pediatric patients with mixed 
respiratory diseases (decreased 
compliance, or increased resistance), if 
the clinical condition does not dictate 
otherwise. 
• NIV may provide a bridge until other medical 
management becomes effective (eg ventolin, 
steroids)" 
• great caution should be taken when initiating 
NIV for diseases of increased resistance.  e.g. 
using it in an asthmatic patient may increase 
work of breathing, as well as hasten respiratory 
failure. On the other hand, there are times when 
NIV will work by decreasing the WOB with 
application of PEEP to reduce large changes in 
intrathoracic pressure.  One statement CANNOT 
be applied to all pathology and clinical 
conditions. 
• NIV is always a first approach for us at [site 
removed] and has deterred many intubations. 
Almost 100% of our pediatric patients are placed 
on NIV with a total face mask. and that includes 
our patients in resp distress transferred by the 
peds transport team. 
• Must have very specific guidelines for the 
"otherwise" situations. Example: pH<7.20, 
decreased LOC, decreased drive to breath etc. 
• NIV should be considered in pediatric patients 
with diverse respiratory disease processes (ie, 
restrictive or obstructive) unless otherwise 
contraindicated, or if the patient has progressed 
to respiratory failure. 
• Pressures MUST be titrated to clinical 
assessment, unlike in adults - there is no 
standard prescription  
• This is to be considered if it will not delay 
inevitable intubation 
• We would also include high flow therapy before 
intubation as well as NIV 
1.4 During non-invasive ventilation, aim to 
use interfaces without excessive leak. 
Monitor leaks within an acceptable 
range to preserve patient trigger 
• Always favor a nasal mask for security reasons 
as pediatric patients may not be able to remove a 
full-face mask in the event of vomiting and may 
aspirate gastric contents. Full face masks should 
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sensitivity be used with caution when nasal masks are not 
achieving good synchrony and under direct 
supervision 
• leak is very dependent upon the patient's 
age/size.   
• Excessive leak can also impact synchrony 
• Circuit leak, asynchrony, mask fit, mask 
selection, NIV devices vs critical care devices 
all need to be considered otherwise the 
application of NIV can make the situation 
worse.    
• Consider patient comfort for best leak and 
patient compliance.  Monitor leaks within and 
acceptable range to preserve patient trigger 
sensitivity. 
• If optimal mask seal cannot be obtained, also 
consider changing the trigger sensitivity to 
optimize the patient. 
• Monitor leaks within an acceptable range to 
preserve patient trigger sensitivity as well as 
ensure patient compliance with therapy along 
with optimal ventilation and oxygenation... 
• excessive leak and/or excessive dead space 
minimize dead space and monitor leaks within 
an acceptable range... 
• aim to use age-appropriate interfaces that 
minimize excessive leak. Monitor leaks within 
an acceptable range and ensure patient is 
triggering effectively 
• Add "Regular assessment of skin integrity 
should be performed to limit potential injury" 
• There is also the aspect that skin can break down 
for those at higher risk with poor cardiac 
function, poor nutrition and prolonged use of 
NIV (on for 24 /7), and for those requiring 
higher pressures.   
• Would mention to assess interface frequently or 
as part of assessment to check for pressure 
sores/skin integrity.   
• Patient interfaces should be assessed often, using 
a collaborative approach with nursing and RT. 
• Consider interfaces that provide some level of 
comfort, to improve patient compliance 
• the good choice of interface is the most 
important thing as the wrong interface may be 
the failure of NIV. 
• Interface choice is crucial for NIV success.  The 
goal of minimizing leak remains a key aim for 
successful NIV ventilation both to maximize 
ventilation but also improve patient ventilator 
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synchrony.  To reduce patient ventilator 
asynchrony, we use oronasal mask and 
performax mask for smaller patients. 
• devices with large dead spaces 
(helmet/performax etc.) have a large amount of 
compressible volume within them, and this can 
make triggering more difficult - choosing an 
interface with minimal dead space will preserve 
patient trigger sensitivity -- CO2 clearance is 
usually pretty good because overall flows in 
these circuits are high, but trigger sensitivity can 
be difficult especially in a case with leak + large 
mask deadspace volume\ 
1.5 Target optimal patient ventilator 
synchrony in any triggered non-invasive 
ventilation mode e.g. bilevel, 
spontaneous/timed (S/T). 
• Avoid ST mode. Instead, stick to using a 
SPONT mode and check for optimal mask fit, 
adjust sensitivity etc before placing patient on a 
backup rate. 
• adjust the trigger to achieve optimal patient 
synchrony in any triggered mode. 
• adjust the patients device to more sensitive 
triggering or use other device settings (such as 
mask type/recognition of mask leak) to enhance 
triggering if needed. 
• Be watchful for non-triggered breaths and breath 
stacking 
• choose synchronizing modes whenever possible 
and not limited by equipment and/or patient size 
• We use NIV with NAVA to optimise the patient 
ventilator synchrony if we have problem of 
synchrony with standard triggered NIV 
1.6 Additional comments for section • There should be strong encouragement that NIV 
should not delay endotracheal intubation  
• For patients hypercapnea, consider BiLevel 
forms of respiratory support, unless hypercapnea 
is anticipated to be solely associated with lung 
collapse that can be solved by CPAP alone. 
Consider CPAP for patients with respiratory 
distress but reasonably preserved ventilation, or 
as an escalation of support if HFNC is failing.    
Tidal volumes and Inspiratory Pressure  
2.1  Use tidal volumes in the physiologic 
range (5-8ml/kg ideal body weight) for 
pediatric patients with healthy lungs. 
 
• We actually use 5-7 ml/kg in most cases  
• Depends on the size of the patient. We use IBW 
when patients are greater than 10 KG.  If they 
are less than 10 kg we just use their weight in 
KG. Our doctors at [site removed] use 4 to 6.5 
mls/kg.  It is rare that they use anything higher. 
• We tend to use actual body weight, especially 
for our younger patient ie ideal body weight for 
older patients. 
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• Consider adaptive ventilation modes to optimize 
patients with highly fluctuating Vts or patients 
with quickly changing compliance/resistance. 
(e.g. following surfactant administration) 
• daily chest x-rays to monitor for hyperinflation 
and daily blood gases for optimal settings. 
2.2 Avoid using tidal volumes greater than 
8ml/kg ideal body weight in pediatric 
patients with restrictive lung, 
obstructive lung and/or congenital 
diseases 
• Avoid 8mL/kg for ALL patients, due to 
increased risks of high pressures, overdistension, 
volutrauma etc. Focus on smaller physiologic 
volumes and instead increase the respiratory rate 
if needed 
• For patients with a need for strict PCO2 targets, 
consider volume-targeted ventilation or adaptive 
modes of ventilation to maintain a stable MV  
• VTs of 8mL/kg or higher should only be 
considered in special circumstances, such as 
DKA to blow off CO2 or for pt comfort with 
healthy lungs,  and should ESPECIALLY be 
avoided in restrictive lung, obstructive lung and 
congential diseases. 
• In certain pathologies, >8ml/kg may be 
acceptable. Greater than 8ml/kg can be 
acceptable if driving pressure is low. Driving 
pressure is tidal volume normalized for 
compliance and should be used to guide if tidal 
volume setting outside of a physiologic range (5-
8ml/kg) is acceptable. 
• But for patients with bronchodysplasia, 10 ml/kg 
is recommended. 
2.3 For cardiac patients, higher tidal 
volumes (>8ml/kg ideal body weight) 
can be used to allow a lower set 
respiratory rate to promote venous 
return 
• We always use 5-8 ml/kg even for cardiac 
patient  
• For cardiac patients, higher tidal volumes 
(>8ml/kg ideal body weight) can be used to 
allow a lower set respiratory rate promoting 
venous return.   
• For cardiac patients, higher tidal volumes 
(>8ml/kg ideal body weight) may be used to 
allow a lower set respiratory rate to promote 
venous return. Include a line about acceptable 
driving pressure when doing this 
• We use 7-9 ml/kg in such cases with a lower 
respiratory rate and longer inspiratory time 
• This is only acceptable if other parameters such 
as driving pressure and plateau pressure are 
maintained at appropriate levels. 
• Also need to consider the pressure required to 
achieve the tidal volumes. If you increase the 
delta pressure and increasing your mean airway 
pressure then you may not be aiding venous 
return. 
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• It is worthwhile to include a statement about the 
rationale - "to lower mean airway pressure and 
promote venous return" 
• perhaps mentioning decreased mean airway 
pressure, decreasing thoracic pressure to 
promote venous return. 
• Mean airway pressure is often higher in this 
strategy as higher delta-P and longer insp. time 
are typically used to achieve similar minute 
ventilation when lower rate and high Vt strategy 
is used (however exp. time will be longer). 
• This is used when there is concern about venous 
return or right heart function however the 
respiratory rate should be set to the 
physiological normal for the age (especially 
when patients are not sedated and relaxed) 
• Closely monitor flow waveforms to ensure that 
inspiratory time is optimized, to allow for 
effective delivery of tidal volume but avoiding 
inspiratory holds --> a short It can limit your 
tidal volume delivery!     
• This should only be used once other 
management strategies are optimized. 
2.4 Set a delta pressure (PIP-PEEP) to less 
than or equal to 10cmH2O to achieve 
optimal tidal volume in the 
physiological range (5-8ml/kg ideal 
body weight) for all pediatric patients. 
• When it comes to managing more acute patients 
with restrictive or obstructive lung diseases we 
need to set a delta P much greater than 
10cmH2O. 
• Try to minimize pressures in pediatric patients, 
but stating less than or equal to 10 for ALL 
patients is simply not achievable. Maybe 
something along the lines of "use the minimum 
set delta pressures possible to maintain tidal 
volumes in the physiological range and achieve 
normal blood gases".  
• I would aim at a delta pressure to less than or 
equal to 10 cmH2O but I would not say that all 
patients have as low pressures 
• Pplat-PEEP 10cmH2O appropriate for patients 
with normal respiratory system compliance. For 
patients that do not have a normal respiratory 
system compliance, it is unknown what is a safe 
pressure. Adult ARDS data suggests a driving 
pressure <15 
• Delta P of 10 may be a good starting point if the 
patient doesn't have any lung issues (restrictive 
or obstructive), but we frequently use higher 
delta pressures with invasive ventilation, we will 
even start with a delta pressure of 15 cmH2O. 
• Consider: Set a delta pressure (PIP-PEEP) to 
less than or equal to 15 cmH2O to achieve 
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optimal tidal volume in the physiological range 
(5-8ml/kg ideal body weight) for all pediatric 
patients. 
• We use delta pressure's set at whatever level will 
achieve optimal VTs (5-8ml/kg) while also 
maintaining our PIP's less than 25-30 cmH2O in 
all pediatric patients. 
• Suggest using a PRVC/APVCMV mode, where 
you are targeting a set volume using the minimal 
amount of pressure possible. Often in extremely 
sick kids, this delta P will be much higher than 
10 cmH2O, although 10 is a fair starting point 
• If having trouble maintaining gases with 
Pplat>30, increase rate and accept smaller tidal 
volumes (4mL/kg) to obtain the same minute 
ventilation. 
• In patients with severe restriction (in upper or 
lower airways), use inspiratory plateau 
measurements to determine alveolar pressures.   
• Delta pressure should be Pplat-PEEP as this 
delta pressure (driving pressure) is tidal volume 
normalized for compliance (VT/CRS). This 
assists in setting the appropriate tidal volume for 
the amount of lung available for ventilation. It 
has been shown that compliance correlates with 
the amount of lung available for ventilation.  
2.5 In absence of transpulmonary pressure 
measurements, limit the inspiratory 
plateau pressure to 28cmH2O in 
pediatric patients with healthy lungs 
• our site considers <32cmH2O for poor 
compliance or lung pathologies 
• Use less than 25 cmH20, if the child is under 1 
year and after that go with 30 cmH20. 
• We usually use <30 cmH2O. However, 
sometimes we have to go above 30cmH2O.  I 
would add something like "all attempts should 
be made to limit the inspiratory plateau..." 
• In the absence of transpulmonary pressure 
measurements, limit the inspiratory plateau 
pressure to 28cmH2O in pediatric patients with 
decreased chest wall compliance.   
• I would say to try to limit inspiratory plateau 
pressures to less than or equal to 25 cmH2O in 
all pediatric patients, except in extreme 
circumstances eg. severe ARDS. 
2.6 In absence of transpulmonary pressure 
measurements, limit the inspiratory 
plateau pressure 32cmH2O in patients 
with decreased chest wall compliance 
2.7 Measure tidal volumes proximally in 
pediatric patients <10kg 
• we use proximal flow monitoring for all 
pediatric patients 4kg, as this provides a 
reasonable compromise for us within our patient 
population. 
• Ideally measure flow, pressure and tidal volumes 
as proximally as you can in patients less than 10 
kg. 
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• Measure use proximal tidal volumes 
measurement based on ventilator machine's 
recommendations; this will typically be for Vts 
less than 10mL. Consider the value of precision 
Vt measurement versus the additional dead 
space and weight on the ETT.   
• The other big reason to do proximal flow 
monitoring / volume measurement is because of 
leaks & we're using more uncuffed tubes. 
• it increases complexity to ventilator circuit and 
additional weight at patient wye, increasing risk 
of unplanned extubation.  I understand principle 
of having accurate tidal volume measurements 
however not sure the clinical impact is as 
significant as the risk.  A small difference in 
flow sensor vs. ventilator measured tidal 
volumes, whereas clinical assessment of chest 
rise, gas exchange (ventilation and oxygenation) 
may be more impactful. 
Respiratory rate and Inspiratory time 
3.1 Set inspiratory time and RR based on 
the patient's age, ventilatory waveforms 
and clinical evolution, to allow for full 
exhalation (good I:E ratio) and 
optimized pediatric-patient synchrony. 
• “In controlled ventilation modes, [set insp 
time....]. On spontaneous modes, set end-
inspiratory/cycling setting to achieve the same 
goals as above. 
• "recommend setting the inspiratory time and 
respiratory rate related to respiratory system 
mechanics and disease trajectory. Both are 
closely correlated and cannot be judged as 
independent from each other"   
• "use Vt and RR settings to achieve minute 
ventilation target desired to achieve acceptable 
CO2 clearance and appropriate blood gas 
values." 
• Recommend settings which avoid flow end 
inspiratory or expiratory flow interruption    
• We always assure our patients are fully exhaling 
by making sure the flow/time waveform returns 
to zero before the next breath is given 
• I might add something that too short of 
inspiratory times can be equally as detrimental 
to ventilation as an inspiratory hold. 
• Recommend taking into consideration the time 
constant of the respiratory system when deciding 
on rate and inspiratory time/I:E ratio in order to 
optimize patient synchrony and avoid air-
trapping. 
3.2 Increase the set RR when tidal volumes 
and/or PIP are reaching limits to 
maintain minute ventilation in 
restrictive diseases. 
• Optimize Ti in pressure supported ventilation ie. 
rise time/expiratory flow cycling 
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• Increase the set RR when tidal volumes, PIP or 
both reach limits to maintain minute ventilation 
in restrictive diseases. 
• "Increase the set RR when the tidal volumes 
>6ml/kg or Pplat >30 cmH2O to maintain minute 
ventilation in restrictive diseases." 
• Consider: “set PIP/Vt appropriate for the 
patients compliance/resistance and use RR 
adjustments to achieve desired minute 
ventilation” 
• Consider inadequate inspiratory time, I:E ratio 
and observe inspiratory/expiratory flow 
waveforms. 
• Ensuring sufficient exp. time (good I;E ratio) to 
allow for complete emptying of lung units, avoid 
gas trapping 
• As long as our pH goals are being met, we 
would allow lower tidal volumes in restrictive 
disease patients 
• Other than alveolar ventilation, the other targets 
could be ordered goals for ABGs/ EtCO2/SpO2 
• Include: "Set shorter inspiratory times and 
Allow for longer expiratory times in Obstructive 
diseases eg. asthma. Ensure flow waveform is 
returning to baseline to avoid air trapping." 
PEEP and Fio2 
4.1 Set a minimum PEEP of 5cmH2O, to 
prevent alveolar collapse in pediatric 
patients with healthy lungs 
• Perhaps add "except where limiting mean airway 
pressure for venous return is a consideration (ie. 
some cardiac cases)."  We will occasionally go 
down to PEEP of 3 or 4 in the more extreme 
cases. 
• Substitute: "to achieve optimal lung recruitment 
and adhere to protective lung ventilation 
strategies." And add "certain disease conditions 
may preclude this. eg Status Asthmaticus" 
• We typically use more than 5 cmH20 for most 
patients but it is fine as a minimum (minimum of 
6cmH2O for PEEP) 
4.2 Set PEEP to maintain end expiratory 
lung volume, and an optimal balance 
between hemodynamics and 
oxygenation in all pediatric patients. 
Carefully titrate PEEP to avoid 
cardiovascular compromise 
• Increase in increments of 2 cmH2O every 15 
minutes if unable to oxygenate patient. Carefully 
watch the monitor for all cardiac compromise 
signs, especially bradycardia/hypotension in 
children. Continue to monitor Pplat as PEEP is 
increased to maintain <30 cmH2O. 
• Set PEEP to maintain appropriate end expiratory 
lung volume, and an optimal balance between 
hemodynamics and oxygenation/ventilation in 
all pediatric patients. Carefully titrate PEEP to 
avoid cardiovascular compromise. 
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• I would also add: "Consider doing Optimal (or 
Best) PEEP studies in patient's requiring high 
PEEP and high FiO2" 
• We encourage our staff to do an optimal PEEP 
exercise by looking at the dynamic compliance 
as well as the end inspiratory pressure vs PEEP 
as long as the patient is in constant flow and is 
not breathing above the set rate 
4.3 High levels of PEEP (>10cmH2O) may 
be required for pediatric patients with 
severe ARDS. 
• PEEP level should be adjusted based on oxygen 
requirements and determination of optimal 
PEEP Maybe that could be rephrased as higher 
levels of PEEP, rather than calling 10 cmH2O 
high. 
• If FiO2 is greater than 0.4, always consider 
optimizing PEEP by increasing in increments of 
2 cmH2O every 15 minutes. If patient is on 
100% oxygen and has low oxygen saturations, 
may increase PEEP faster or use a recruitment 
maneuver to open up collapsed areas. 
• Potentially add "Consider using transpulmonary 
pressure monitoring (ie. esophageal balloon) in 
these cases." 
• Also for patients with pulmonary 
edema/hemorrhage/ bronchopulmonary 
Dysplasia. 
4.4 High levels of PEEP (>10H2O) may be 
required to stabilize airways in pediatric 
patients with tracheomalacia and/or 
bronchomalacia. 
• Maybe that could be rephrased as higher levels 
of PEEP, rather than calling 10 high. 
• PEEP >10cmH2O may be required to stabilize 
airways in pediatric patients with tracheomalacia 
and/or bronchomalacia. 
4.5 Set the lowest possible FiO2 to maintain 
target oxygenation goals 
• for patients with cardiac disease and right-to-left 
shunting, consider the value of increasing FiO2 
but avoid high levels of oxygen when only 
minimal improvement in saturations is observed.   
• I would emphasize recruiting collapsed lung 
areas and protective lung strategies vs 
oxygenation. 
• Once optimal PEEP is achieved, set the lowest 
possible FiO2 to maintain target oxygenation 
goals 
• we use a peep fio2 table for optimization 
• 'target oxygenation goals' should be defined in 
the recommendations to include:  95 in most 
healthy kids breathing room air, >95% with 
pulmonary hypertension, 92-97% in ventilated 
kids with PEEP <10, 88-92% in ventilated kids 
with PEEP 10 or as otherwise defined by the 
institution  
Advanced Mechanical ventilation  
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5.1 Consider high frequency oscillatory 
ventilation (HFOV) in pediatric patients 
with restrictive or mixed diseases with 
severe oxygenation and/or ventilation 
failure 
• should include "if conventional mechanical 
ventilation has failed" since there's no actual 
evidence to recommend it over conventional 
ventilation 
• Try conventional methods first with high 
respiratory rates, low tidal volumes, and high 
PEEPs before switching to HFOV. HFOV often 
causes cardiac compromise in pediatric patients, 
and should be used with caution. 
• Consider high frequency oscillatory ventilation 
(HFOV) in pediatric patients with restrictive or 
mixed diseases with severe oxygenation and/or 
ventilation failure who have failed conventional 
mechanical ventilation 
• Include High Frequency Jet Ventilation 
• We also look at the CXR; for HFOV, we 
recommend an homogeneous picture; for non-
homogeneous and severe CO2 retention, we may 
go for high frequency jet ventilation 
5.2 Careful use of high frequency 
oscillatory ventilation (HFOV) can be 
considered in pediatric patients with 
cardiac issues suffering from severe 
respiratory failure. Caution is advised in 
patients with passive pulmonary blood 
flow or right ventricular dysfunction 
• Include High Frequency Jet Ventilation 
• I've rarely (if ever) seen HFOV used for cardiac 
patients; we would likely proceed directly to 
ECLS for a patient with this degree of failure.  
Time should not be spent on HFOV if it would 
be better spent elsewhere.     
• Cautious use of Mean Airway Pressure is 
advised in patients with passive pulmonary 
blood flow or right ventricular dysfunction. 
• If the patients cardiac system is compromised or 
the BP is unstable, that needs to be addressed 
first 
• Cardiac function should be assessed prior to 
initiation. 
• If the cardiac issues are being caused by severe 
respiratory failure despite conventional 
mechanical ventilation techniques, HFOV could 
be trialled, however, it will often worsen cardiac 
symptoms in children, so use extreme caution, 
and minimal settings. You may have to add 
cardiac medications to the child while the 
respiratory component of the illness is being 
managed/fixed. 
5.3 Careful use of high frequency 
oscillatory ventilation (HFOV) can be 
considered in cardiac pediatric patients 
suffering from severe respiratory 
failure. 
5.4 Methods of ventilation such as Airway 
Pressure Release Ventilation (APRV), 
Neurally Adjusted Ventilatory Assist 
(NAVA), Proportional Assist 
Ventilation (PAV), automated weaning 
etc, may be considered to optimize 
patient-ventilator interactions 
• and with adequate support and training to 
optimize ventilation. 
• These modes should be recommended with 
caution due to a lack of strong evidence 
regarding outcome or utility.   
• APRV isn't exactly in the same category as PAV 
or NAVA in that it's not a patient-physiology or 
effort-targeted mode. APRV is something else 
 156 
entirely (usually a non-conventional high mean 
airway pressure mode) and doesn't belong in this 
category. 
• APRV is not designed to improve patient 
ventilator interactions. The NAVA and PAV are 
Weaning 
6.1 Start weaning ventilator settings as early 
as possible. 
• Routine/daily assessments for weaning 
ventilator settings as early as possible is 
recommended. 
• As soon as patient begins triggering above set 
rate (when patients have sufficient respiratory 
drive), switch to a PSV/SPONT/CPAP mode of 
ventilation. Look for signs of increased work of 
breathing/deterioration of gases in order to 
determine whether child is tolerating the change. 
Titrate pressure support to obtain physiological 
volumes with minimal WOB present. 
• Attempt weaning ventilator settings once O2 
saturation goals and CO2 goals have been met. 
As patient condition improves continue to wean 
down to extubatable settings. 
• Monitoring oxygenation & pH, work of 
breathing, patient comfort, etc. 
• Most current recommendations indicate that we 
should be frequently assessing the patient for 
weaning READINESS and then weaning as 
soon as readiness is identified. Seems like that 
should be defined. 
6.2 In any complex cases (e.g. restrictive, 
obstructive, mixed or cardiac pediatric 
patients), use weaning principles 
specific to the pathology and titrate 
ventilator settings more carefully. 
• In very difficult patients, a systematic "weaning 
schedule" may be used. Ex: on a patient who has 
been on a ventillator for an extended amount of 
time where muscle weakness is an issue, they 
may have to do "trials" of decreased pressure 
support each day until they can tolerate it for 24 
hrs. Gradually increase the time the patient 
spends on the lower support in 30-60 min 
intervals each day. 
• it would probably be more correct to state that in 
disease states, the weaning principle should be 
guided by respiratory system mechanics, 
pathology, and disease trajectory. 
• Principles related to pathology should be used to 
titrate ventilator settings at all times, not just 
during the weaning phase.  Pathologies do not 
just include lung and cardiac pathologies (e.g. 
restrictive, obstructive, mixed or cardiac) but 
other pathologies suggest as traumatic brain 
injury and sepsis need to be considered in 
ventilator titration. 
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• whenever possible, adapt a multidisciplinary 
approach to difficult to wean patients. Use a 
regimented, gradually increasing workload/time 
trial approach to build respiratory muscles with 
regimented FULL rest periods. the only proven 
successful slow wean methods all involve 
careful regimented weaning that is consistent. 
6.3 If adequate respiratory drive is present, 
pressure support ventilation may be 
considered allowing the pediatric patient 
to breathe spontaneously 
• This is with the assumption that their time 
constants are appropriate and do not lead to 
shorter than needed inspiratory times. 
• And should be considered early to aid patient 
comfort /prevent dysynchrony 
• Patient should be changed to a spontaneous 
mode as soon as possible to avoid muscle 
fatigue/ventilator asynchrony. 
• If adequate respiratory drive is present, pressure 
support ventilation should be considered 
allowing the pediatric patient to breathe 
spontaneously, except in early ARDS 
• We use modes that allow supported spontaneous 
ventilation on all our patients to ensure their 
respiratory muscles are being used 
• This recommendation holds true for all but the 
most severely ill child with obstructive airway, 
restrictive airway or mixed disease.  In these 
children sedation or neuromuscular blockade 
and controlled mandatory ventilation may be 
necessary to facilitate improved oxygenation.   
6.4 If pressure support ventilation is used, 
the pressure support, sensitivity, flow 
cycling, and rise time should be 
adjusted to maintain patient 
comfort/synchrony and physiologic tidal 
volumes 
• In spontaneous breathing modes, the support, 
sensitivity, flow cycling, and rise time should be 
adjusted to maintain patient comfort/synchrony 
and physiologic tidal volumes. 
• There are more than pressure support for 
spontaneous ventilator modes. Volume Support 
and ASV would be examples of other 
spontaneous modes that don't have a pressure 
support setting.  These parameters (e.g. cycling, 
rise time, sensitivity, etc) should be adjusted for 
patient comfort/synchrony in control modes. 
• We never use a pressure support less then +6 in 
order to overcome the resistance of the ETT 
6.5 Routine daily assessment for weaning 
and extubation should be performed. 
• I think this also depends on the patient and the 
pathology/ why they are admitted. 
Physiologic targets 
7.1 Target normal arterial CO2 levels for 
pediatric patients with healthy lungs and 
electively ventilated e.g. 
post-operative. 
 
7.2 Permissive hypercapnia (pH ≥ 7.2) may 
be acceptable for acute pediatric 
• Must be mindful of CO2 levels in brain injury 
pediatric patients. 
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patients, unless specific disease 
conditions dictate otherwise e.g. 
pulmonary hypertension 
• maybe add in acceptable CO2 levels.  pH may 
be indicative of a metabolic issue, not only a 
respiratory one. 
• avoid focusing on PaCO2. focus on pH. 
• ARDSnet makes no mention of PaCO2 goals at 
all. make sure clinicians are targeting pH and not 
getting wrapped around the axle of PaCO2.  
• 7.20 seems low; we'd typically say 7.25 at a 
minimum and more likely 7.30. It may be 
worthwhile to specifically mention head 
trauma/ICP as a specific condition where 
hypercapnia is inappropriate. 
7.3 Target a SpO2 > 95% on room air in 
pediatric ventilated patients with healthy 
lungs. 
• Patients with SpO2 of 99-100% should have 
their oxygen weaned, if not on FiO2 =0.21. 
• We use SpO2>92%. Be mindful of SpO2 sitting 
at 100% and wean oxygen whenever possible to 
avoid oxygen free radical accumulation. Best to 
maintain 92-99% 
• I would remove "on room air", because if their 
saturations are not 95% oxygen will be added. 
• though healthy lungs can probably achieve 
>95%. But we wouldn't target on room air - we 
would simply give patients whatever FiO2 they 
need to achieve SpO2. In healthy lungs, minimal 
FiO2 should be required to achieve SpO2 goals 
though  
• Target an SpO2 > 95% on room air in pediatric 
ventilated patients with healthy lungs. 
• In the absence of severe disease or known shunt, 
provide FiO2 to achieve a SpO2 >92% . 
• pre-oxygenate for routine cares that may impede 
effective ventilation/oxygenation (e.g. 
suctioning), unless detrimental to patient (e.g. 
unrepaired cardiacs). 
7.4 Target SpO2 92-97% when PEEP is less 
than 10cmH2O in pediatric patients who 
meet the pediatric ARDS criteria as 
described in the PALICC guidelines 
(access article here). 
• the PEEP and SpO2 relationship should not limit 
our target range. PEEP can be targeted using 
various methods that do not automatically mean 
we would lower their SpO2 targets if we end up 
on a higher level. 
• SpO2 Targets should not be linked to PEEP. 
PEEP should be titrated to based upon 
optimization of end-expiatory lung volume and 
pulmonary mechanics not FiO2 or SpO2. 
7.5 Target SpO2 88-92% when PEEP is 
10cmH2O or higher in pediatric patients 
who meet the pediatric ARDS criteria as 
described in the PALICC guidelines 
(PALICC Guidelines 2015). 
• PEEP may be set higher than 10 for various 
reasons, and if targeted to optimize end 
expiratory lung volume, may not always have to 
lower goals. 
• SpO2 Targets should not be linked to PEEP. 
PEEP should be titrated to based upon 
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optimization of end-expiatory lung volume and 
pulmonary mechanics not FiO2 or SpO2. 
• Lower SpO2 can be tolerated if end organ/tissue 
oxygen demand is being met indicated by 
normal lactate and acceptable end organ 
function (ex. urine output, level of 
consciousness appropriate, etc.) 
7.6 Target SpO2 75-85% for pediatric 
patients with cyanotic cardiac lesions 
e.g. fixed Right to Left shunts. 
• keeping in mind there are some patients that we 
allow for lower SpO2 when sick. 
• depend on the shunt usually we target around 
80% 
• Consider adding; "Target Spo2 75-85% or the 
defined range as determined by medical team"/ 
cardiologist  
• Can change depending on specific heart 
defects/surgeries performed, therefore we 
always have patient specific SpO2 ranges 
defined by a cardiologist. 
• Not all patients with cyanotic heart lesions will 
have saturations in this range.  For example, a 
patient with hypoplastic left heart syndrome 
with forward flow can actually have saturations 
over 90% despite having a duct dependent 
physiology.  As well, all patients with duct 
dependent lesions will have some degree of 
variablity in their saturations. 
Monitoring 
8.1 CO2 monitoring should be used in 
every pediatric patient on invasive 
mechanical ventilation, preferably end-
tidal CO2. 
• CO2 monitoring should be used in every 
pediatric patient on invasive mechanical 
ventilation, preferably end-tidal CO2. 
• maybe mention transcutaneous monitoring for 
patients on HFOV.  Since end tidal will not be 
accurate when ventilated in that mode. 
• Should be correlated to blood gas 
• We find that in some patients it doesn't give 
good feedback (not correlating with blood gases) 
therefore we may remove it as we are doing 
more blood gases chasing a poor monitor.   
8.2 SpO2 monitoring should be used to 
assess oxygenation in every pediatric 
patient on invasive or non-invasive 
mechanical ventilation 
- 
8.3 Use indwelling arterial lines for 
accurate pH, PaO2, PaCO2, and lactate 
measurements, in severely ill pediatric 
patients on mechanical ventilation 
• Moderately-severely ill patients should all have 
arterial lines for real time blood pressure 
measurements 
8.4 Use central venous saturation (SvO2) 
and lactate measurements to assess 
presence or absence of oxygen debt 
and/or cardiac output, in severely ill 
• Use central venous saturation (SvO2) and lactate 
measurements to assess the presence or absence 
of oxygen debt and cardiac output, in severely ill 
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pediatric patients on mechanical 
ventilation 
pediatric patients/ cardiac patients on 
mechanical ventilation. 
• It should be done when warranted.  Lactate 
should be followed, and that can indicate when 
central sats should be followed. 
8.5 Use central venous saturation (SvO2) 
and lactate measurements to assess 
presence or absence of oxygen debt 
and/or cardiac output, in cardiac 
pediatric patients on mechanical 
ventilation. 
8.6 Peripheral venous PCO2 measurements 
are of limited use in providing 
information about ventilatory gas 
exchange. However, they may be used 
for providing estimates or trending. 
• Use caution when interpreting these results. In 
line with clinical presentation, they may be used 
for providing estimates or trending. 
• We actually use them quite a bit when we do not 
have an arterial or central line. Maybe 
"Peripheral venous PCO2 measurements may be 
used for providing estimates or trending values 
when arterial/central lines are not available". 
8.7 Capillary gases are adequate to assess 
gas exchange in pediatric patients with 
mild diseases on mechanical 
Ventilation 
• or in the absence of any indwelling lines.  Use 
caution when interpreting these results. 
• if obtained using the correct procedure in 
patients with good peripheral perfusion eg. 
warming site, not milking etc.  
• would classify use of capillary gases as similar 
to peripheral PaCO2 monitoring and useful as 
trend or estimation.   
• Capillary blood gases can be used to assess 
ventilation (PaCO2) for patients with mild 
diseases however would not use to guide 
oxygenation.  Also, lactate should not be 
interpreted from capillary blood gases as an 
assessment of end oxygen delivery. 
8.8 Use pH as a tool to modify the 
pulmonary vascular resistance for 
specific disease conditions 
• It would be helpful to have a list of or examples 
of specific disease conditions where this can be 
useful (pulmonary hypertension, PPHN, single 
ventricle heart disease after specific stages of 
surgical intervention) 
8.9 Maintain normal pH and PCO2 in 
pulmonary hypertension 
• as well as high normal PaO2 in these patients 
• I think it needs a qualifier of "attempt to 
maintain..." as by placing patients on harmful 
mechanical ventilation settings this may be 
doing more harm than accepting mild acidosis 
and some degree of hypercapnia in a patient 
with pulmonary hypertension especially if they 
have secondary lung disease (ex. viral or 
bacterial infection or pneumonia or PARDS on 
top of having pulmonary hypertension) 
• or the medically ordered pH/PCO2 range by 
medical team. Consider achievable pH/PCO2 
goals and balance lung protection with severe 
cases. 
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• We usually try to hyperventilate our patient with 
pulmonary hypertension (PH:7.40-7.45). Even 
with normal SPo2 we give O2 to help lower the 
capillary resistance in the lung   
• As a general rule, we would seek to avoid 
acidosis - either normal or alkalotic could be 
acceptable depending on the patient. 
• There should be a section about aiming for 
lower normal CO2 in Traumatic Brain Injury 
scenarios. "Target low-normal CO2 ranges (35-
40) for Traumatic Brain Injury patients." 
General   
9.1 All pediatric patients on mechanical 
ventilation should be allowed to breathe 
spontaneously, with the exception of the 
most severely ill and/or those requiring 
intermittent neuromuscular blockade or 
those with surgical contraindications 
(e.g. airway surgery). 
• airway surgery should not be a contraindication 
for breathing ability...or drive to breath 
• Unless unstable, if a patient who underwent 
airway surgery is not agitated, we allow them to 
breathe spontaneously while intubated. Each 
case is different; we must consider the long term 
effects of sedation/paralytic agents vs patient's 
status 
• If patient is at risk of self extubating, optimize 
the medications so that the patient is still able to 
breathe, but is not waking up pulling at things. 
The goal is to always have the patient breathing, 
so this may mean using 3/4 sedatives instead of 
placing patient on a paralytic. Only times a 
paralytic should be used are in the patients that 
you cannot ventilate/oxygenate, uncontrollable 
seizures, or head injury patients who are 
shivering. 
• Routine assessments for assessing the need for 
sedation, neuro-muscular blockades and perhaps 
weaning these based upon these assessments, 
could enhance early weaning of respiratory and 
hemodynamic supports. 
9.2 Ventilator waveforms e.g. flow volume 
loops, pressure volume loops, provide 
real-time data about 
patient-ventilator interactions such as 
breath-by-breath ventilation status, 
response to therapies, and lung 
mechanics. 
• this is more of a statement than a 
recommendation. I think you're recommending 
that these waveforms be analyzed on a regular 
basis in order to glean data about 
status/response/mechanics 
9.3 The Pediatric Acute Lung Injury 
Consensus Conference (2015) 
recommendations on nitric oxide, 
neuromuscular blockade, prone position 
and surfactant use should be followed. 
*Inhaled nitric oxide is not 
recommended for routine use in 
PARDS. However, its use may be 
• We always start our nitric at 20 ppm and assess 
response. If no effect, it is turned off. If it has 
effect, we leave it on until ready to wean. 
Weaning process:20ppm --> 15 ppm-->10 ppm--
>5 ppm, and then decrease in increments of 1 
ppm until off. We usually decrease every 2-4 
hours 
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considered in patients with documented 
pulmonary hypertension or severe right 
ventricular dysfunction. In addition, it 
may be considered in severe cases of 
PARDS as a rescue from or bridge 
to extracorporeal life support. When 
used, assessment of benefit must be 
undertaken promptly and serially to 
minimize toxicity and to eliminate 
continued use without established 
effect. Finally, future study is needed to 
better define its role, if any, in the 
treatment of PARDS. (PALICC 
guidelines 2015) 
• I think we should be cautious about prone 
positioning in PALICC guidelines as I feel that 
most adult centres now apply prone positioning 
to severe ARDS patients when lung protective 
ventilation is failing.   
 
9.4 Caution is advised when using sedation 
and muscle relaxants in pediatric 
patients with altered cardiac function 
• If patient is on ventilator; adjustments must be 
made to appropriately ventilate and oxygenate 
patient. 
• Sedation is an important factor in trying to 
ventilate sick patients. Optimizing sedation 
levels when trying to ventilate sick patients can 
be crucial. Also review optimizing peep. 
9.5 Extracorporeal life support (ECLS) e.g. 
NovaLung, extracorporeal membrane 
oxygenation, should be considered 
when conventional and/or high 
frequency oscillatory ventilation fail in 
pediatric patients with reversible 
diseases. 
Follow guidelines for specific criteria 
eg. Extracorpeal Life Support 
Organization 
• add HFJV in there too. Jet is now replacing 
HFOV as the go-to mode of choice for severe 
patients that are small enough for Jet to work on. 
• [name removed] doesn't have ECMO and must 
then transfer severely unstable patients by air 
transport to [name removed] Children’s hospital. 
We trial Nitric on all severely ill pediatric 
ventilated patients in an effort to be able to keep 
the patient in our ICU rather than risk an 
unstable transfer. 
• In patients with a reversible condition, where 
their conventional ventilator settings are above 
recommendations and likely to cause further 
harm or a trial of HFOV fails, early 
consideration for extracorporeal life support or 
referral to a centre that offers extracorporeal life 
support should be made. 
• ECLS should be used only in established ECLS 
centres where appropriately trained personnel 
and expertise are available; early referral to an 
ECLS centre should occur when ECLS is not 
available at the current centre 
• Maybe add in the bit about consulting an ECMO 
center early before deterioration is such that 
transport is no longer safely feasible. 
Equipment adjuncts 
10.1 Use double limb circuits for acute, 
invasive mechanical ventilation 
•  
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10.2 Minimize the use of apparatuses that 
add dead space to ventilator circuits 
• Consider the impact of additional airway devices 
to dead space, in particular for smaller patients 
(e.g. the addition of EtCo2 monitors or HME for 
transport).  
• Minimize the use of apparatuses that add dead 
space to ventilator circuits, whenever possible. 
10.3 Elevate the head of the bed at 30-45 
degrees in all pediatric patients, unless 
specific disease conditions dictate 
otherwise. 
• Consider eliminating the word "disease" as the 
sentence would convey the message without this 
word.  Often there is no specific disease process 
involved, however a specific head of bed may be 
indicated ie) post-operative procedure, 
neurological care, VAP protocols etc...... 
10.4 Provide airway humidification, 100% 
relative humidity at 37°C, for all 
pediatric patients on mechanical 
ventilation. 
• Provide "active" humidification 
• This is in reference to invasive mechanical 
ventilation; separate recommendations should be 
made for NIV 
• Because of the rainout seen when using NIV, we 
sometimes will turn our humidifiers to non-
invasive (31 degrees) 
10.5 Hand-ventilation should be avoided. If 
hand-ventilation is required, pressure 
measurements, pressure pop up and 
PEEP valves or flow-inflating bags 
should be used to match ventilation 
pressures. 
• ROUTINE use of hand ventilation (using 
manual resuscitator) should be avoided. 
• Manual-ventilation should be avoided. If 
manual-ventilation is required, flow-inflating 
bags with pressure measurements should be used 
to match ventilation pressures. If a self-inflating 
bag is used, pressure measurements, a pressure 
pop off, and PEEP valves will be required. 
• To clarify, in an emergency arrest, it is suitable 
to bag 
• Caution with use of flow-inflating bags and 
matching pressures - still need to ensure patient 
is adequately supported by looking for chest rise 
and clinical indicators of adequate 
oxygenation/ventilation (SpO2, EtCO2).  In my 
experience, typically requires higher pressures 
measured on flow inflating bag manometer as 
compared to ventilator settings to achieve 
similar oxygenation and ventilation targets.  If 
clinician only relying and fixated on manometer, 
than may not adequately ventilate patient and 
cause harm. 
10.6 Additional feedback • Use EVAC tubes (suction set at -30 cmH2O) 
when available to decrease rates of VAP. Use 
inline suction for all patients to avoid circuit 
disconnections. Use minimal occlusive volume 
for endotracheal cuffs. In our center we always 
use cuffed tubes in our pediatric patients. If there 
is no leak, the cuff is simply left down in order 
to avoid any unnecessary trauma. 
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• Consider VAP protocols as equipment adjuncts.  
ie) EVAC endotracheal tubes, elevated HOB, 
oral care, OG tubes and respiratory circuits 
draining away from patient in a gravity 
dependant manner. 
• Routine instillation of saline is not 




Supplementary Table 5 
Comparison table of recommendation statements from Round 1 and the revised statements in 
Round 2. 
 Recommendation statement 
(Round 1) 
Revised Recommendation statement (Round 2) 
Non invasive ventilation  
1.1 Consider the use of non-invasive 
ventilation in pediatric patients 
with moderate cardiorespiratory 
failure. If not responsive to other 
medical management e.g. 
inotropes, diuretics  
Consider the use of non-invasive ventilation in pediatric 
patients with mild to moderate cardiorespiratory failure, if 
not responsive to or in combination with other medical 
management, e.g. inotropes, diuretics. 
1.2 Use non-invasive ventilation to 
reduce work of breathing and 
decrease afterload for pediatric 
patients with left ventricular 
failure, if not responsive to other 
medical management e.g. 
inotropes, diuretics.  
Consider the use of non-invasive ventilation to reduce 
work of breathing and decrease afterload for pediatric 
patients with left ventricular failure, if not responsive to or 
in combination with other medical management, e.g. 
inotropes, diuretics. 
1.3 Before intubation, consider non-
invasive ventilation as a first 
approach in pediatric patients with 
mixed respiratory diseases 
(decreased compliance, or 
increased resistance), if the 
clinical condition does not dictate 
otherwise. 
Consider non-invasive ventilation as a first approach in 
pediatric patients with mixed diseases (decreased 
compliance or increased resistance), unless 
contraindicated, before intubation.  
Examples of contraindications: decreased level of 
consciousness, impending respiratory failure/arrest, airway 
compromise, decreased respiratory drive, poor skin 
integrity (e.g. burns, contusions) 
1.4 During non-invasive ventilation, 
aim to use interfaces without 
excessive leak. Monitor leaks 
within an acceptable range to 
preserve patient trigger sensitivity 
Aim to use interfaces with minimal leak and appropriate 
for the patient’s size, age and skin integrity for patients on 
non-invasive ventilation. Monitor leaks within an 
acceptable range to optimize patient comfort, compliance, 
synchrony, and to preserve patient trigger sensitivity. 
1.5 Target optimal patient ventilator 
synchrony in any triggered non-
invasive ventilation mode e.g. 
bilevel, spontaneous/timed (S/T). 
Optimize patient ventilator synchrony. This includes 
adjusting trigger sensitivity and optimizing mask seal in 
any triggered non-invasive ventilation mode e.g. bilevel, 
S/T. 
 
5. a. If available, specialty modes of NIV such as non-
invasive NAVA can be used to optimize patient ventilator 
synchrony. 
1.6 Additional statements Consider the use of high flow nasal cannula oxygen 
therapy (form of oxygen therapy) prior to NIV, to alleviate 
work of breathing. 
1.7 The use of HFNC and/or NIV should not delay inevitable 
intubation. 
Tidal volumes and inspiratory pressures 
2.1 Use tidal volumes in the 
physiologic range (5-8ml/kg ideal 
body weight) for pediatric patients 
with healthy lungs. 
Target tidal volumes in the physiologic range (5-8ml/kg 
ideal body weight) for pediatric patients with healthy 
lungs, when >10kg. Target tidal volumes 5-8ml/kg 
measured weight for pediatric patients with healthy lungs, 
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when ≤10kg. 
2.2 Avoid using tidal volumes greater 
than 8ml/kg ideal body weight in 
pediatric patients with restrictive 
lung, obstructive lung and/or 
congenital diseases 
**Removed, see original comments 
2.3 For cardiac patients, higher tidal 
volumes (>8ml/kg ideal body 
weight) can be used to allow a 
lower set respiratory rate to 
promote venous return. 
For specific congenital cardiac patients requiring optimal 
venous return, higher tidal volumes (>8ml/kg ideal body 
weight) may be used if peak pressures are within safe 
range (<25cmH2O). This would allow a lower set 
respiratory rate to minimize mean airway pressure. 
2.4 Start at a delta pressure (PIP-
PEEP) less than or equal to 
10cmH2O to achieve optimal tidal 
volume in the physiological range 
(5-8ml/kg ideal body weight) for 
all pediatric patients with 
presumed healthy lungs. Titrate 
pressures to achieve optimal tidal 
volumes. 
In pressure-limited modes, aim to achieve optimal tidal 
volume in the physiological range (5- 8ml/kg ideal body 
weight) with minimal delta pressure (PIP-PEEP) for all 
pediatric patients. 
2.5 In absence of transpulmonary 
pressure measurements, limit the 
inspiratory plateau pressure to 
28cmH2O in pediatric patients 
with decreased chest wall 
compliance 
In absence of transpulmonary pressure measurements, 
limit the inspiratory plateau pressure to 30cmH2O in all 
patients. 
2.6 In absence of transpulmonary 
pressure measurements, limit the 
inspiratory plateau pressure 
32cmH2O in pediatric patients 
with decreased chest wall 
compliance. 
2.7 Measure tidal volumes proximally 
in pediatric patients <3kg 
MOVED TO SECTION 10 
 
Follow the specific ventilator’s recommendation for when 
a proximal flow sensor should be used, to allow for 
accurate tidal volume measurements in small patients 
<10kg or patients with small tidal volumes, <10mL. 
Respiratory rate and inspiratory times 
3.1 Set inspiratory time and RR based 
on the patient's age, ventilatory 
waveforms and clinical evolution, 
to allow for full exhalation (good 
I:E ratio) and optimized pediatric-
patient synchrony. 
In controlled ventilation modes, set inspiratory time and 
respiratory rate based on the patient’s age, respiratory 
mechanics (including waveforms), and clinical data such 
as blood gases and vitals. This will allow for full 
exhalation (good I:E ratio), optimized pediatric-patient 
synchrony and ventilation. 
In spontaneous ventilation modes, set the trigger, and 
cycling to achieve the above goals (Section 3, Statement 
#1). 
3.2 Increase the set RR when tidal 
volumes and/or PIP are reaching 
Increase the set respiratory rate when tidal volumes and/or 
PIP are reaching limits, to maintain minute ventilation. 
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limits to maintain minute 
ventilation in restrictive diseases. 
Ensure there is sufficient expiratory time to avoid air-
trapping. 
PEEP and Fio2 
4.1 Set a minimum PEEP of 5cmH2O, 
to prevent alveolar collapse in 
pediatric patients with healthy 
lungs. 
Set a minimum PEEP of at least 5-6cmH2O, to prevent 
alveolar collapse in all pediatric patients. 
4.2 Set PEEP to maintain end 
expiratory lung volume, and an 
optimal balance between 
hemodynamics and oxygenation in 
all pediatric patients. Carefully 
titrate PEEP to avoid 
cardiovascular compromise. 
Set PEEP to maintain end expiratory lung volume, and an 
optimal balance between hemodynamic stability and 
oxygenation. 
Titrate PEEP incrementally while assessing tidal volumes, 
oxygen saturation, hemodynamic stability and chest x-ray 
findings, for patients with challenging oxygenation. i.e. 
PALICC recommendations, ARDSnet protocol  
4.3 High levels of PEEP (>10cmH2O) 
may be required for pediatric 
patients with severe ARDS. 
Higher levels of PEEP (>10cmH2O) may be required for 
adequate lung recruitment in pediatric patients with 
moderate to severe ARDS. 
4.4 High levels of PEEP (>10H2O) 
may be required to stabilize 
airways in pediatric patients with 
tracheomalacia and/or 
bronchomalacia. 
Higher levels of PEEP (>10cmH2O) may be required to 
stabilize airways in pediatric patients with tracheomalacia 
and/or bronchomalacia. 
4.5 Set the lowest possible FiO2 to 
maintain target oxygenation goals. 
Optimize PEEP to allow for the lowest possible FiO2 to 
maintain target oxygenation goals, while maintaining 
adequate hemodynamic status. 
 
 
Advanced mechanical ventilation  
5.1 Consider high frequency 
oscillatory ventilation (HFOV) in 
pediatric patients with restrictive 
or mixed diseases with 
severe oxygenation and/or 
ventilation failure. 
Consider high frequency oscillatory ventilation (HFOV) in 
pediatric patients with restrictive or mixed diseases and 
severe oxygenation and/or ventilation failure when they 
have failed conventional mechanical ventilation. 
5.2 Careful use of high frequency 
oscillatory ventilation (HFOV) 
can be considered in pediatric 
patients with cardiac issues 
suffering from severe respiratory 
failure. Caution is advised in 
patients with  passive pulmonary 
blood flow or 
right ventricular dysfunction. 
Careful use of high frequency oscillatory ventilation 
(HFOV) can be considered in pediatric patients with 
cardiac issues suffering from severe respiratory failure. 
Cautious use of increased mean airway pressure is advised 
in patients with passive pulmonary blood flow or right 
ventricular dysfunction. 
5.3 Careful use of high frequency 
oscillatory ventilation (HFOV) 
can be considered in cardiac 
pediatric patients suffering from 
severe respiratory failure. 
Consider high frequency jet ventilation (HFJV) in 
pediatric patients with restrictive or mixed diseases and 
severe oxygenation and/or ventilation failure when they 
have failed conventional mechanical ventilation. 
5.4 Methods of ventilation such as 
Airway Pressure Release 
Consider the use of other modes of advanced ventilation 
techniques to optimize patient-ventilator interactions. 
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Ventilation (APRV), Neurally 
Adjusted Ventilatory Assist 
(NAVA), Proportional Assist 
Ventilation (PAV), automated 
weaning etc, may be considered to 
optimize patient-ventilator 
interactions 
These forms of advanced ventilation have unique benefits 
and/ or limitations. These modes include Airway Pressure 
Release Ventilation (APRV), Neurally Adjusted 
Ventilatory Assist 
(NAVA), Proportional Assist Ventilation (PAV), high 
frequency jet ventilation (HFJV), automated weaning etc. 
Weaning  
6.1 Start weaning ventilator settings as 
early as possible. 
Routinely assess (work of breathing, blood gases, 
synchrony etc) and wean ventilator settings as early and 
often, as possible. 
6.2 In any complex cases (e.g. 
restrictive, obstructive, mixed or 
cardiac pediatric patients), use 
weaning principles specific to the 
pathology and titrate ventilator 
settings more carefully. 
Use weaning principles guided by the respiratory 
mechanics, pathologies and disease trajectory of the 
diseases present in complex cases (e.g. restrictive, 
obstructive, mixed or cardiac pediatric patients). 
6.3 If adequate respiratory drive is 
present, pressure support 
ventilation may be considered 
allowing the pediatric patient to 
breathe spontaneously. 
Consider pressure support ventilation if adequate 
respiratory drive is present and disease trajectory is 
improving. This allows the pediatric patient to breathe 
spontaneously to maximize comfort and avoid asynchrony/ 
muscle atrophy. 
6.4 If pressure support ventilation is 
used, the pressure support, 
sensitivity, flow cycling, and rise 
time should be adjusted to 
maintain patient 
comfort/synchrony and 
physiologic tidal volumes. 
Routinely assess the pressure support, sensitivity of flow 
cycling, and rise time in pressure support ventilation to 
maintain patient comfort/synchrony and physiologic tidal 
volumes. 
6.5 Routine daily assessment for 
weaning and extubation should be 
performed 
Routine daily assessment for weaning and extubation 
readiness should be performed. 
Physiologic Targets 
7.1 Target normal arterial CO2 levels 
for pediatric patients with healthy 
lungs and electively ventilated e.g. 
post-operative 
Target normal arterial CO2 levels for pediatric patients 
with healthy lungs and electively ventilated e.g. post-
operative. if arterial CO2 is not available, target normal 
venous and capillary CO2 levels. 
7.2 Permissive hypercapnia (pH ≥ 7.2) 
may be acceptable for acute 
pediatric patients, unless specific 
disease conditions dictate 
otherwise e.g. pulmonary 
hypertension 
Permissive hypercapnia (with pH ≥ 7.25) may be 
acceptable for acute pediatric patients, unless specific 
disease conditions dictate otherwise e.g. pulmonary 
hypertension, traumatic brain injury. 
7.3 Target a SpO2 > 95% on room air 
in pediatric ventilated patients 
with healthy lungs. 
Target a SpO2 > 92% (92-99%) in pediatric patients with 
healthy lungs, in the absence of disease. 
7.4 Target SpO2 92-97% when PEEP 
is less than 10cmH2O in pediatric 
patients who meet the pediatric 
ARDS criteria 
Target SpO2 92-97% when PEEP is less than 10cmH2O in 
pediatric patients who meet the pediatric ARDS criteria as 
described in the PALICC guidelines. 
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as described in the PALICC 
guidelines 
7.5 Target SpO2 88-92% when PEEP 
is 10cmH2O or higher in pediatric 
patients who meet the pediatric 
ARDS criteria as described in the 
PALICC guidelines (PALICC 
Guidelines 2015). 
Target SpO2 88-92% when PEEP is 10cmH2O or higher in 
pediatric patients who meet the pediatric ARDS criteria as 
described in the PALICC guidelines 
7.6 Target SpO2 75-85% for pediatric 
patients with cyanotic cardiac 
lesions e.g. fixed Right to Left 
shunts. 
Target SpO2 75-85% or as recommended by the 
interprofessional collaborative teams, for pediatric patients 
with cyanotic cardiac lesions e.g. fixed Right to Left 
shunts. 
7.7 Additional statements Physiological targets may be guided by patient respiratory 
mechanics, and respiratory and non-respiratory 
pathologies and disease trajectory. 
Monitoring 
8.1 CO2 monitoring should be used in 
every pediatric patient on invasive 
mechanical ventilation, preferably 
end-tidal 
CO2. 
Use CO2 monitoring in every pediatric patient on invasive 
mechanical ventilation, preferably endtidal 
CO2. 
 Consider the use of transcutaneous CO2 in pediatric 
patients on non-conventional mechanical ventilation, e.g. 
HFOV, HFJV. These monitoring options should be 
frequently assessed for its correlation to the blood gases. 
8.2 SpO2 monitoring should be used to 
assess oxygenation in every 
pediatric patient on invasive or 
non-invasive 
mechanical ventilation. 
Use continuous SpO2 monitoring to assess oxygen 
saturation in all pediatric patients on invasive and non-
invasive mechanical ventilation. 
8.3 Use indwelling arterial lines for 
accurate pH, PaO2, PaCO2, and 
lactate measurements, in severely 
ill pediatric 
patients on mechanical ventilation. 
Use arterial lines for accurate pH, PaO2, and lactate 
measurements, in moderate to severely ill pediatric 
patients on mechanical ventilation. 
8.4 Use central venous saturation 
(SvO2) and lactate measurements 
to assess presence or absence of 
oxygen debt and/or cardiac output, 
in severely ill pediatric patients on 
mechanical ventilation. 
Use central venous saturation (SvO2) and lactate 
measurements to assess oxygen extraction and/or cardiac 
output, in cardiac and/or severely ill pediatric patients on 
mechanical ventilation 
8.5 Use central venous saturation 
(SvO2) and lactate measurements 
to assess presence or absence of 
oxygen debt and/or cardiac output, 
in cardiac pediatric patients on 
mechanical ventilation. 
8.6 Peripheral venous PCO2 
measurements are of limited use in 
providing information about 
ventilatory gas exchange. 
However, they may be used for 
Cautiously use peripheral venous PCO2 measurements to 
provide estimates and trends of ventilatory gas exchange, 
when arterial/ central lines are not available. 
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providing estimates or trending. 
8.7 Capillary gases are adequate to 
assess gas exchange in pediatric 
patients with mild diseases on 
mechanical 
ventilation. 
Consider the use of capillary gases to assess gas exchange 
in pediatric patients with good perfusion and with mild 
diseases on mechanical ventilation. They may be used to 
provide estimates or trends when arterial/ central lines are 
not available. 
8.8 Use pH as a tool to modify the 
pulmonary vascular resistance for 
specific disease conditions. 
Use pH as a tool to modify the pulmonary vascular 
resistance for specific disease conditions, e.g. pulmonary 
hypertension, single ventricle heart disease. 
8.9 Maintain normal pH and PCO2 in 
pulmonary hypertension. 
Aim to maintain normal pH, PCO2 and PaO2 in pulmonary 
hypertension and traumatic brain injury. Consider 
targeting normal-high pH and normal-low CO2 values. 
General  
9.1 All pediatric patients on 
mechanical ventilation should be 
allowed to breathe spontaneously, 
with the exception of the most 
severely ill and/or those requiring 
intermittent neuromuscular 
blockade or those with surgical 
contraindications (e.g. airway 
surgery). 
Routinely assess patients to allow for spontaneous 
breathing, except for severely ill pediatric patients 
requiring intermittent neuromuscular blockade and 
sedation. 
9.2 Ventilator waveforms e.g. flow 
volume loops, pressure volume 
loops, provide real-time data about 
patient-ventilator interactions such 
as breath-by-breath ventilation 
status, response to therapies, and 
lung mechanics. 
Routinely assess ventilator waveforms (e.g. flow volume 
loops, pressure volume loops) as they provide real-time 
data about patient-ventilator interactions such as breath-
by-breath ventilation status, response to therapies, and 
lung mechanics. 
9.3 The Pediatric Acute Lung Injury 
Consensus Conference (2015) 
recommendations on nitric oxide, 
neuromuscular 
blockade, prone position and 
surfactant use should be followed. 
*Inhaled nitric oxide is not 
recommended for routine 
use in PARDS. However, its use 
may be considered in patients with 
documented pulmonary 
hypertension or severe 
right ventricular dysfunction. In 
addition, it may be considered in 
severe cases of PARDS as a 
rescue from or bridge 
to extracorporeal life support. 
When used, assessment of benefit 
must be undertaken promptly and 
serially to 
minimize toxicity and to eliminate 
Use The Pediatric Acute Lung Injury Consensus 
Conference (2015) recommendations on nitric oxide, 
neuromuscular blockade, prone position and surfactant 
use, if safe to do so. Inhaled nitric oxide is not 
recommended for routine use in PARDS. However, its use 
may be considered in patients with documented pulmonary 
hypertension or severe right ventricular 
dysfunction. In addition, it may be considered in severe 
cases of PARDS as a rescue from or bridge to ECLS. 
When used, assessment of benefit must be undertaken 
promptly and serially to minimize toxicity and to eliminate 
continued use without established effect. Finally, future 
study is needed to 
better define its role, if any, in the treatment of PARDS. 
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continued use without established 
effect. Finally, future study is 
needed to better 
define its role, if any, in the 
treatment of PARDS. (PALICC 
guidelines 2015) 
9.4 Caution is advised when using 
sedation and muscle relaxants in 
pediatric patients with altered 
cardiac function. 
Routinely monitor and assess the impacts of muscle 
relaxants and sedation on mechanical ventilation 
(respiratory rate, tidal volumes, minute ventilation). 
9.5 Extracorporeal life support 
(ECLS) e.g. NovaLung, 
extracorporeal membrane 
oxygenation, should be considered 
when conventional and/or high 
frequency oscillatory ventilation 
fail in pediatric patients with 
reversible diseases. 
Follow guidelines for specific 
criteria eg. Extracorpeal Life 
Support Organization 
MOVED TO SECTION 5 
 
Strongly consider Extracorporeal life support (ECLS) e.g. 
NovaLung, extracorporeal membrane oxygenation, if 
available and not contraindicated, when conventional 
and/or high frequency oscillatory ventilation fail in 
pediatric patients with reversible diseases. Follow 
guidelines for specific criteria e.g. extracorporeal life 
support organization. Early consultation from an ECLS 
center should be considered if this therapy is not available 
within the facility. 
9.6 Additional statements Different organizational and workgroup guidelines and 
recommendations may be incorporated into practice and 
may include, but are not limited to: Pediatric Acute Lung 
Injury Care Conference (PALICC), National Heart, Lung, 
and Blood Institute (NHLBI) ARDS Network Protocol, 
Pediatric Advanced Life Support (PALS), Neonatal 
Resuscitation Program (NRP), Extracorporeal Life 
Support Organization (ELSO) 
Equipment adjuncts  
10.1 Use double limb circuits for acute, 
invasive mechanical ventilation 
Use double limbed, heated humidified, filtered circuits for 
invasive mechanical ventilation. 
10.2 Minimize the use of apparatuses 
that add dead space to ventilator 
circuits 
Minimize the use of apparatuses that add dead space to 
ventilator circuits, whenever possible. 
10.3 Elevate the head of the bed at 30-
45 degrees in all pediatric patients, 
unless specific disease conditions 
dictate 
otherwise. 
MOVED TO SECTION 9 
 
Reduce the risk of ventilator associated pneumonia (VAP) 
by following the VAP bundles published by safety groups 
e.g. Safer Healthcare Now!, Canadian Institute for Health 
Information, Solutions to Patient Safety. Elements include: 
1) elevate the head of the bed 30-45 degrees (15 degrees in 
infant cribs), unless specific (disease) conditions dictate 
otherwise, e.g. post-operative, indwelling 
catheters, 2) perform consistent oral hygiene, 3) minimize 
unnecessary circuit disconnects, 4) perform daily 
assessment for extubation readiness 
10.4 Provide airway humidification, 
100% relative humidity at 37°C, 
for all pediatric patients on 
Provide active airway humidification, 100% relative 
humidity at 37°C, for all pediatric patients on invasive 
mechanical ventilation. In the case of non-invasive 
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mechanical ventilation. ventilation, humidification at 31°C should be provided to 
avoid excessive rain out in the circuit. 
10.5 Hand-ventilation should be 
avoided. If hand-ventilation is 
required, pressure measurements, 
pressure pop up and 
PEEP valves or flow-inflating 
bags should be used to match 
ventilation pressures. 
Avoid routine use of manual hand-ventilation to minimize 
frequent circuit disconnects. If manual hand-ventilation is 
required, pressure manometers, pressure relief valves and 





Supplementary table 6 
Statistical results of each recommendation statement in Round 2. 
Statement Consensus 
% 
Mean Median Mode Standard 
deviation 





Section 1- Noninvasive ventilation 
1.1 96 4.37 4 4 0.56 3 5 1 0.13 
1.2 98 4.53 5 5 0.54 3 5 1 0.12 
1.3 94 4.49 5 5 0.73 2 5 1 0.16 
1.4 98 4.71 5 5 0.50 3 5 1 0.11 
1.5 100 4.75 5 5 0.44 4 5 1 0.09 
1.5a 85 4.23 4 4 0.76 2 5 1 0.18 
1.6 76 3.82 4 4 0.97 1 5 0 0.25 
1.7 100 4.76 5 5 0.43 4 5 0 0.09 
Section 2- Tidal volumes and inspiratory pressures  
2.1 92 4.16 4 4 0.62 2 5 1 0.15 
2.2 60 3.72 4 4 0.78 2 5 1 0.21 
2.3 92 4.32 4 4 0.79 1 5 1 0.18 
2.4 82 4.02 4 4 0.85 2 5 1 0.21 
Section 3- Respiratory rate and inspiratory time 
3.1 98 4.65 5 5 0.52 3 5 1 0.11 
3.2 98 4.63 5 5 0.53 3 5 1 0.11 
3.3 92 4.31 4 5 0.86 1 5 1 0.20 
Section 4- PEEP and FiO2 
4.1 86 4.29 5 5 1.10 1 5 1 0.26 
4.2 100 4.63 5 5 0.49 4 5 1 0.11 
4.3 96 4.45 5 5 0.73 1 5 1 0.16 
4.4 98 4.61 5 5 0.53 3 5 1 0.12 
4.5 94 4.39 4 4 0.67 2 5 1 0.15 
4.6 94 4.37 5 5 0.87 1 5 1 0.20 
Section 5- Advanced modes of ventilation  
5.1 90 4.25 4 4 0.63 3 5 1 0.15 
5.2 86 4.22 4 4 0.67 3 5 1 0.16 
5.3 57 3.4 4 4 1.06 1 5 1 0.31 
5.4 83 3.94 4 4 0.82 1 5 0 0.21 
5.5 81 4.15 4 4 0.83 2 5 1 0.20 
Section 6- Weaning  
6.1 96 4.49 5 5 0.73 1 5 1 0.16 
6.2 94 4.39 4 4 0.60 3 5 1 0.14 
6.3 96 4.51 5 5 0.64 2 5 1 0.14 
6.4 98 4.53 5 5 0.54 3 5 1 0.12 
6.5 86 4.33 5 5 0.82 2 5 1 0.19 
Section 7- Physiologic targets 
7.1 94 4.33 4 4 0.65 2 5 1 0.15 
7.2 98 4.43 4 4 0.54 3 5 1 0.12 
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7.3 98 4.51 5 5 0.54 3 5 1 0.12 
7.4 88 4.24 4 5 0.93 1 5 1 0.22 
7.5 84 4.08 4 4 0.85 2 5 1 0.21 
7.6 86 4.18 4 4 0.85 1 5 1 0.20 
7.7 94 4.33 4 4 0.65 2 5 1 0.15 
Section 8- Monitoring 
8.1 98 4.71 5 5 0.58 2 5 1 0.12 
8.2 94 4.49 5 5 0.73 2 5 1 0.16 
8.3 84 4.34 4.5 5 0.75 3 5 1 0.17 
8.4 98 4.68 5 5 0.52 3 5 1 0.11 
8.5 92 4.47 5 5 0.64 3 5 1 0.14 
8.6 90 4.14 4 4 0.65 2 5 1 0.16 
8.7 96 4.37 4 4 0.56 3 5 1 0.13 
8.8 88 4.16 4 4 0.67 2 5 1 0.16 
8.9 96 4.39 4 4 0.57 3 5 1 0.13 
Section 9- General MV  
9.1 96 4.43 4 4 0.58 3 5 1 0.13 
9.2 90 4.27 4 4 0.75 2 5 1 0.18 
9.3 98 4.49 5 5 0.54 3 5 1 0.12 
9.4 87 4.24 4 4 0.67 3 5 1 0.16 
9.5 100 4.53 5 5 0.50 4 5 1 0.11 
9.6 88 4.24 4 4 0.66 3 5 1 0.15 
Section 10- Equipment adjuncts 
10.1 98 4.71 5 5 0.50 3 5 1 0.11 
10.2 94 4.45 5 5 0.86 1 5 1 0.19 
10.3 100 4.65 5 5 0.48 4 5 1 0.10 
10.4 71 3.88 4 4 1.02 2 5 2 0.26 
10.5 84 4.22 4 5 0.95 2 5 1 0.22 
The numbered statements in this table correspond to the statements in Round 2’s survey.  
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Supplementary Table 7 





Mean Median Mode Standard 
deviation 





1.6 92 4.37 5 5 0.81 2 5 1 0.19 
2.1 81 4.0 4 4 0.95 2 5 1 0.24 
2.2  98 4.31 4 4 0.51 3 5 1 0.12 
2.3 96 4.31 4 4 0.77 1 5 1 0.18 
2.4 93 4.17 4 4 0.61 2 5 1 0.15 
5.3 90 4.14 4 4 0.72 2 5 1 0.17 
5.4 84 4.03 4 4 0.76 1 5 0.5 0.19 
5.5 96 4.43 4 5 0.65 2 5 1 0.15 
9.7 100 4.65 5 5 0.48 4 5 1 0.10 
10.4 84 3.91 4 4 0.82 2 5 0 0.21 
10.5 94 4.33 4 4 0.66 2 5 1 0.15 
 
Supplementary Table 8 
Statements that were significantly different between subgroups, identified by the KWT (p<0.05). 
Subgroups 
1= ≤15 years 








2.1- Target tidal volumes in the physiologic range (5-8ml/kg ideal body weight) for pediatric 
patients >10kg with healthy lungs. Target tidal volumes 5-8ml/kg measured weight for 
pediatric patients ≤10kg with healthy lungs. 
1 4.32 4.09, 4.55 0.56  
0.04 2 3.95 3.63, 4.27 0.69 
4.4- Higher levels of PEEP (>10cmH2O) may be required for adequate lung recruitment in 
pediatric patients with moderate to severe ARDS. 
1 4.76 4.58, 4.96 0.44  
0.04 2 4.4 4.12, 4.68 0.60 
7.4- Target Spo2 92-99% in pediatric patients with healthy lungs, in the absence of disease. 
1 4.52 4.23, 4.81 0.71  
<0.01 2 3.9 3.42, 4.38 1.02 
8.1- Use of continuous Spo2 monitoring to assess oxygen saturation in all pediatric patients 
on invasive and non-invasive mechanical ventilation. 
1 4.88 4.74, 5.02 0.33  
<0.01 2 4.6 4.36, 4.84 0.50 
8.9- Aim to maintain normal pH, PCO2 and PaO2 in pulmonary hypertension and traumatic 
brain injury. Consider targeting normal-high pH and normal-low CO2 values. 
1 4.6 4.39, 4.81 0.5  
0.02 2 4.15 3.88, 4.42 0.59 
9.4- Use the Pediatric Acute Lung Injury Consensus Conference (2015) recommendations 
1 4.48 4.21, 4.75 0.65  
<0.01 2 3.9 3.64, 4.16 0.55 
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Supplementary table 9 
Open text feedback from Round 2 and 3  
 Recommendation statement from 
Round 2/ 3 
Original comments  
1- Non invasive ventilation (NIV) 
1.4 Consider the use of non-invasive 
ventilation in pediatric patients with 
moderate cardiorespiratory failure.  If 
not responsive to other medical 
management e.g. inotropes, diuretics 
 
• dual limb NIV with full face mask is used as the 
approach prior to intubation. NAVA recently 
discontinued at our facility due to poor success 
rate  
• NIV NAVA should not simply be used "if 
available" - this will lead to the unnecessary 
introduction of an invasive catheter (not to 
mention increased cost of equipment).  NIV 
NAVA should primarily be used "if required" to 
















Optimize patient ventilator synchrony. 
This includes adjusting trigger 
sensitivity and optimizing mask seal in 
any triggered NIV mode e.g. bilevel, 
S/T. 
 
If available, specialty modes of NIV 
such as NIV NAVA can be used to 
optimize patient ventilator synchrony.  
 
Consider the use of high flow nasal 
cannula (HFNC) oxygen therapy prior 
to NIV, to alleviate work of breathing.  
 
The use of HFNC and/or NIV should 
not delay inevitable intubation.  
 
• This [NIV] should not be a "first approach" - 
other approaches such as medications or HFNC 
should be considered first.  NIV should only be 
considered as a "second approach" should these 
more basic interventions fail 
• If you need to start NIV for cardiac or 
obstructive reasons such as an asthma attack, 
then don't waste time with HFNC 
• I don't feel all patients should try HFNC prior to 
NIV.  Consider, yes. But if not appropriate, 
move right to NIV. 
• HFNC should not be tried in patients when NIV 
has been proven effective in patients with certain 
sicknesses or disease processes. It just delays 
treatment 
• For certain cases, prioritizing the use of HFNC 
before NIV is not appropriate, like bronchiolitis 
on small babies: a lot of secretions is not 
compatible with HFNC, NIV is more 
comfortable for them and more effective 
treatment. 
• Simply because patient has increased WOB, 
should not try HFNC simply because.  Should 
assess work of breathing and reason causing it.  
If patient requires more support like pressure due 
to cardiopulmonary effects then NIV should be 
started verses increase in oxygen needs and work 
of breathing due to common respiratory 
infection.    
• There may be some role in early respiratory 
failure as dead space washout effects may reduce 
PCO2; this is not the same as ventilation and 
they should not be confused!  Similarly, it is not 
CPAP as the pressure is not constant! The 
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system provides positive pressure primarily on 
expiration. 
• HFNC can be used initially as a substitute to 
NIV depending on how severe the WOB/CO2 
retention. Often you will find the HFNC alone 
will reduce CO2 levels sufficiently, especially in 
smaller children. 
• I strongly agree that HFNC is not a substitute for 
NIV. And while yes, one should CONSIDER 
HFNC before NIV, I don't believe that one 
should automatically try it based on the fact that 
it a) is not a substitute, and b) should not delay 
or replace NIV if that is more appropriate. 
• some studies show that HFNC can be used as an 
alternative to NIV and that there is no statistical 
difference in intubation rates between the two. 
The tolerance of HFNC in the pediatric 
population tends to be much greater compared to 
NIV via facemask. This is also difficult to use a 
generalized statement for because the age range 
of pediatrics is very large, and the specific 
patient and situation can also be a factor to 
consider what the patient may tolerate better. 
• There are currently indications to provide HFNC 
prior to intubation, and immediately post op, 
post extubation in lieu of low flow. I agree it 
should not delay or replace NIV IF NIV is more 
appropriate 
• For such things as pulmonary edema OR pleural 
effusions, or anything you want some PEEP to 
be applied HFNC is not appropriate. But HFNC 
may be used for tachypnea or work of breathing. 
• HFNC and NIV are not interchangeable, and 
their application is suitable for different reasons. 
2- Tidal volumes and inspiratory pressures 
2.1 Round 2: 
Target tidal volumes in the physiologic 
range (5-8ml/kg ideal body weight) for 
pediatric patients >10kg with healthy 
lungs. Target tidal volumes 5-8ml/kg 
measured weights for patients ≤ 10kg 
with healthy lungs. 
 
Round 3: 
In pediatric patients >10kg, target tidal 
volumes in the physiologic range (5-8ml/kg 
ideal body weight). In pediatric patients 
≤10kg, target tidal volumes 5-8ml/kg 
measured weight.  
• The ped patients we use IBW are usually school 
age and up. 
• "Measured weight" may be inappropriate if the 
patient is greatly fluid overloaded.    
• We use measured weight until the patients are in 
teenage years or severely overweight then we 
convert to IBW. For patients less than 20 kg, for 
sure, we use actual measured weight. 
• Certain medical conditions (ie. CDH) may 
experience volutrauma if a global volume target 
of 5-8ml/kg is used.  Perhaps some caveat 
regarding "anatomically or functionally normal 
lungs" should be included.   
• For post cardiac surgeries (excluding PDA 
ligation), our approach is 7-9 ml/kg with a lower 
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respiratory rate and longer i-time to optimize 
venous return to the heart; this is done in our 
































For specific congenital cardiac patients 
requiring optimal venous return, higher 
tidal volumes (>8ml/kg ideal body 
weight) may be used if peak pressures 
are within safe range (< 25cmH2O). 
This would allow a lower set respiratory 
rate to minimize mean airway pressure. 
 
Round 3: 
If unable to achieve physiologic tidal 
volumes (5-8ml/kg) within pressure 
limits (30cmH2O), targeting ranges 
outside these limits should be  iscussed 
with the interprofessional team. For 
example, congenital lesions, congenital 
hypoplastic lung, severe PARDS. 
Similarly, there may be circumstances 
where tidal volumes >8ml/kg may be 
cautiously used, but should not be 
routinely used. 
 
For all pediatric patients on pressure-
limited modes, aim to achieve optimal 
tidal volume in the physiological range 
(5-8ml/kg ideal body weight) with 
minimal delta pressure (PIP-PEEP). 
 
In absence of transpulmonary pressure 
measurements, the inspiratory plateau 
pressure should be limited to 30cmH2O 
in pediatric patients. Site specific limits 
should be within 28 to 32 cmH2O. 
• I agree with statement but disagree that delta 
pressure is PIP-PEEP.  I think this is better 
represented as Pplat- PEEP, whenever Pplat can 
be obtained. 
• Targeting Vt as low as 4ml/kg seems reasonable.  
Goals to limit Pplats to <25 cmH2O as much as 
possible seems reasonable, and default to a 
lower Vt rather than accepting higher Pplats, 
depending on pathophysiology. 
• PPlat <28 cmH2O as goal, allowable up to <32 
cmH2O given specific poor compliance patient 
conditions 
• I agree that the Pplat should be limited to less 
than 30 cmH2O unless you have measurements 
that you can follow to provide safe ventilation, 
electrical impedence tomography (EIT) can be 
used as well.  There are patients where 
maintaining low Pplats is not possible.  I would 
like to see it as 'attempt to limit' or something 
like that.  And the driving pressure is what will 
be important, rather than just a Pplat.  
• In my opinion I think the part about "site 
specific limits..." is a bit confusing.  I would 
suggest instead of writing specific targets for 
specific sites that it could just read specific sites 
may have variability in targets however should 
be around 30 cmH20. 
• Goals to limit Pplats to <25 cmH2O as much as 
possible seems reasonable, and default to a 
lower Vt rather than accepting higher Pplats, 
depending on pathophysiology. 
• I would be more comfortable with stating 
"appropriate Vt” rather than a specific number. 
3- Respiratory Rates and inspiratory time  
3.3 To maintain minute ventilation, increase 
the set respiratory rate when tidal 
volumes and/or PIP are reaching 
limits. Ensure there is sufficient 
expiratory time to avoid air-trapping. 
• to optimize alveolar ventilation, there is a 
physical limit to how high the rate can be - 
irrespective of the I:E ratio. A rate of 60 
breaths/minute cannot allow for laminar flow 
and alveolar gas exchange.  At this point a small 
increase in Vt, is indicated.   (the exception may 
be for patients with congenital diaphragmatic 
hernia, as it is imperative to use a lung protective 
strategy).    
• To maintain minute volume, increase the set 
respiratory rate when Vt ARE LOW and when 
Pplat is approaching limit (<30 cmH2O)  
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• to related to previous statements; OR if Vt are 
within range yet (PCO2) needs to be lower, or 
pH higher 
4- PEEP and FiO2 
4.1 Set a minimum PEEP of 5-6cmH2O, to 
prevent alveolar collapse in all pediatric 
patients. 
• Peep levels of 5-6cmH2O are used in most 
instances except cardiac pts (who may need 
lower) and the other cases mentioned in the 
further questions (ARDS, bronchomalacia).  
• there will always be a singular case where PEEP 
is contraindicated; perhaps it is a status 
asthmaticus scenario, or some other type of 
obstructive process. or extreme hemodynamic 
instability. If the statement was that the goal 
should be to prevent alveolar collapse in all 
ventilated patients this is more general and 
encompassing. I do not think religious 
application of PEEP to all pediatric patients 
regardless of disease process is a good idea 
• Post op Glen and Fontan will have PEEP of 
4cmH2O usually. 
• A min PEEP of 5-6 cmH2O in not to prevent 
collapse but to maintain an appropriate FRC 
• We have set PEEP at 4 (or even 3 cmH2O) on 
rare occasions where RV failure is a 
consideration, with good effect.   
4.3 For patients with challenging 
oxygenation needs (e.g. ARDS) 
titrate PEEP incrementally while 
assessing tidal volumes, oxygen 
saturation, hemodynamic stability and 
chest x-ray findings. 
  
• The use of oxygenation is not a good parameter 
to set PEEP, setting PEEP using oxygenation 
can cause significant regional over distension. 
Mechanics such as Compliance or driving 
pressure are more appropriate. Also, if assessing 
Vt with PEEP changes you are assuming a 
pressure mode of ventilation. Compliance would 
be a better parameter or also include driving 
pressure. 
4.5 Higher levels of PEEP (>10cmH2O) 
may be required to stabilize airways in 
pediatric patients with tracheomalacia 
and/or bronchomalacia. 
• an ENT consultation with flexible laryngoscopy 
is typically utilized to determine the optimal 
PEEP needed to stabilize airways in pediatric 
patients with moderate-to-severe tracheomalacia 
and/or bronchomalacia.   
4.6 Optimize PEEP to allow for the lowest 
possible FiO2 (to maintain target 
oxygen saturation goals), while 
maintaining adequate hemodynamic 
status. 
• PEEP should not be set/targeted based upon 
oxygenation alone. 
• The goal should not be to achieve the "lowest 
possible FiO2", regardless of PEEP.  FiO2 of 
0.21 and PEEP of 15, for example, would not be 





5- Advanced modes of Ventilation 
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5.3 Round 2:  
Consider the use of other advanced 
ventilation techniques to optimize 
patient-ventilator interactions, 
acknowledging that each has unique 
benefits and/or limitations. 
These modes include NAVA, Airway 
Pressure Release Ventilation (APRV), 
Proportional Assist Ventilation (PAV), 
high frequency jet ventilation (HFJV), 
automated weaning etc. 
 
Round 3: 
When conventional mechanical 
ventilation and/or HFOV has failed for 
pediatric patients, consider the use of 
other advanced modes, acknowledging 
that each has unique benefits and / or 
limitations. These modes include high 
frequency jet ventilation (HFJV) and 
Airway Pressure Release Ventilation 
(APRV) and severe oxygenation and/or 
ventilation failure. These advanced 
modes should not substitute or delay 
inevitable ECLS, if appropriate. 
 
Other advanced ventilation techniques 
may optimize patient-ventilator 
interactions. Consider their use while 
acknowledging that each has unique 
benefits and/or limitations. These 
modes include Neurally Adjusted 
Ventilatory Assist (NAVA), 
Proportional Assist Ventilation (PAV), 
automated weaning etc. 
• APRV is prohibited for use by RTs as agreed by 
the intensivists' team at the [name removed] 
PICU due to lack of evidence 
• Advanced therapies such as JET and HFOV may 
be beneficial if used as a protective strategy on 
certain pts versus being used as a rescue 
therapies. 
• APRV is available but prohibited to use as 
agreed by the PICU physician team due to the 
lack of pediatric evidence.  PAV is not available 
therefore not practiced 
• NAVA was previously trialed but not found 
effective therefore being phased out. PAV is not 
available to use in the [name removed] PICU 
• We currently don't use NAVA or PAV. (Have 
used NAVA in the, past, but not consistently or 
well. Will likely use PAV with our incoming 
fleet of new vents.) 
• NAVA was previously used but often 
inappropriately (didn't meet indications or not 
ideal candidate etc) or used off recommendation 
(indicators and reading interpreted but not used 
for weaning or escalation of care due to various 
MRP reasoning) and as result is no longer 
available at our center 
5.4 Round 2: 
Strongly consider Extracorporeal life 
support (ECLS) such as NovaLung, or 
extracorporeal membrane oxygenation. 
Use ECLS in pediatric patients with 
reversible diseases, if available within 
the facility, not contraindicated, and/or 
when conventional and/or high 
frequency oscillatory ventilation has 
failed. Follow guidelines (e.g. 
extracorporeal life support 
organizations) for specific criteria. 
Early consultation with an ECLS center 
should be considered if this therapy is 
not available within the facility. 
 
• Perhaps there should be a 
recommendation/statement regarding early 
consultation to a higher level of care for sites 
that do not have advanced therapies such as 
HFOV, jet ventilation, novalung, ECMO etc., 
available... in order to ensure earlier and safer 
transports for these patients?   
• I would rewrite to read "Strongly consider ECLS 
such as extracorporeal membrane oxygenation 
(ECMO)".  Remove NovaLung as this is a brand 
name of a device and the pediatric use of this 
device is very limited.  In its truest configuration 
(femoral artery to femoral vein) as the device 
was intended, would not be able to be used in 
patients less than 20-30 kg as would be unable to 
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Round 3: 
When conventional mechanical 
ventilation and/ or HFOV has failed, 
consider the use of Extracorporeal life 
support (ECLS) in pediatric patients 
with reversible diseases, if available 
within the facility and not 
contraindicated. Follow guidelines (e.g. 
ECLS organizations) for more specific 
criteria. Consider early consultation 
with an ECLS center when ECLS is not 
available within the facility. 
generate sufficient driving pressure to prevent 
clotting of the device over time.  The most 
common approach for supporting these patients 
would be VV ECMO if they were large enough 
for double lumen cannula or two site VV 
ECMO.  If they are small infants, the approach is 
VA ECMO.  There is still small usage of 
NovaLung device for bridge to lung transplant 
pediatric patients > 20 kg with pulmonary 
hyptertension who are centrally cannulated from 
PA to LA as a means to offload right heart to 
prevent RV failure.  However this is a very 
specific subset of pediatric patients with a 
specific respiratory disease.    Otherwise agree 
with rest of statement. 
• Consider the use of iNO in the instances where 
patient has oxygenation, PHTN or RV 
dysfunction prior to considering ECLS. 
6- Weaning  
6.3 Consider pressure support ventilation 
when adequate respiratory drive is 
present and disease trajectory is 
improving. This allows the pediatric 
patient to breathe spontaneously to 
maximize comfort, and avoid 
asynchrony/muscle atrophy 
• it does not appear to be clear how long one can 
leave a patient breathing on PSV who is not 
ready for extubation; in my practice, patients 
with minimal WOB and otherwise good 
indicators of gas exchange may stay on PSV as 
long as they're tolerating it, with a minimal delta 
P to compensate for ETT resistance (ie 5-10 
cmH2O) 
• Important to know what their drive is, but I 
typically would not leave a patient on PS 
ventilation for days on end as they recover, 
unless I am unable to achieve good synchrony 
and comfort in other modes. 












Target SpO2 92-99% in pediatric 
patients with healthy lungs, in the 
absence of disease. 
 
Target SpO2 92-97% when PEEP is less 
than 10cmH2O in pediatric patients 
who meet the pediatric ARDS criteria 
(as described in the PALICC 
guidelines). 
 
Target SpO2 88-92% when PEEP is 
10cmH2O or higher in pediatric patients 
who meet the pediatric ARDS criteria 
(as described in the PALICC 
guidelines). 
• We should not target an SpO2 of 99%, unless on 
room air [healthy lungs]. I don't know if the 
statement is referring to a non-intubated patient, 
invasively or non.  As it reads, it could include 
patients ventilated for other reasons than 
respiratory disease (post op).   
• PALs Post-rosc guidelines state SpO2 94-99%. 
• should just state >or = 92% if on room air and 
minimum PEEP and spo2 can be 100% [healthy 
lungs] 
• I don't like mixing PEEP value with oxygenation 
definitely.  Depending on body habitus of the 
patient, we could be using higher PEEPs 
regardless of ARDS status.  We should treat the 
patients as individuals.  For a patient with a BMI 
near ideal, I agree with the statement, but not for 
all patients. 
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• We tolerate 88%-92% if ABG and lactate are 
stable [even with PEEP <10cmH2O] 
• SpO2 targets in ARDS should not be based upon 
PEEP alone. PEEP setting alone will not identify 
the severity of their ARDS nor their arterial 
content requirements. For example, obese or 
morbidly obese patients may require a PEEP 
>10 to maintain EELV but this doesn't indicate 
the severity of the patient's lung pathology or 
ability to safely oxygenate. 
8- Monitoring  
8.2 Use CO2 monitoring (preferably end-
tidal CO2) in all pediatric patients on 
invasive mechanical ventilation. 
• preferably inline CO2 monitoring, preferably 
through the vent so volumetric data is available.   
• ETCO2 would be inappropriate for a patient 
ventilated using HFOV. 
8.6 Cautiously use peripheral venous PCO2 
measurements to provide estimates and 
trends of ventilatory gas exchange, 
when arterial/ central lines are not 
available. 
• Use capillary blood gas tests when 
arterial/central lines are not available. Capillary 
should be a first line test versus venous. 
8.8 Use pH as a tool to modify the 
pulmonary vascular resistance for 
specific disease conditions, e.g. 
pulmonary hypertension, single 
ventricle heart disease. 
• We also aim for adequate oxygenation, and use 
iNO. By omitting these other principles, it is a 
bit misleading 
9- General MV  
9.1 
9.2 
Routinely assess patients to allow for 
spontaneous breathing, except for 
severely ill pediatric patients requiring 
intermittent neuromuscular blockade 
and sedation. 
 
Routinely monitor and assess the 
impacts of muscle relaxants and 
sedation on mechanical ventilation 
(respiratory rate, tidal volumes, minute 
ventilation). 
• I would not only assess but encourage. Perhaps a 
statement to include the concept of: "when 
patients are heavily sedated and not breathing 
(without reason), discuss with the 
interprofessional team to decrease sedatives 
safely." 
• wouldn't routinely give NMB to assess how it 
affects the other variables, unless indicated.  
However I would assess if NMB is continuing to 
be beneficial to the patient if being used 
routinely. 
10- Equipment Adjuncts  
10.2 For all pediatric patients on invasive 
mechanical ventilation, provide active 
airway humidification at 100% relative 
humidity at 37°C. 
• Reword to say, for patients on NIV, provide 
active airway humidification in the range of 31-
37C, titrated to avoid excessive rainout in the 
interface.  
• Addendum - we routinely use 37°C for our 
HFNC patients as well. 
• For the majority of NIV patients at [name 
removed], the humidifier is kept at 37 degrees C 
to optimize gas humidification.  Rain out has not 
been found to be an issue in most cases. 
10.4 Round 2: • proximal flow sensors are of limited utility in 
larger Vts, in our practice we're using proximal 
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Use a proximal flow sensor for accurate 
tidal volume measurements in small 
patients (< 10kg) or patients with small 
tidal volumes (< 10mL). Follow the 
specific ventilator's recommendations 
on its use. 
 
Round 3: 
Proximal flow sensors are not routinely 
used for pediatric patients. Follow the 
specific ventilator's recommendations 
on proximal flow sensor use. In the 
absence of specific ventilator 
recommendations, use a proximal flow 
sensor for small tidal volumes (< 
10mL). 
flow for kids 4kg and less who would 
correspond (at 5mL/kg) to tidal volumes of 
20mL and less. 
• Not all proximal flow is created equal obviously 
and some ventilators will have bias against the 
proximal flow sensor to compensate for this. The 
technology used for proximal flow affects how 
much I trust it as well; heated wire anemometers 
appear to be far more accurate in my experience 
than pressure differential flow sensors. 
• "Consider" use of a proximal flow sensor.  It 
may not be required unless there is concern 
about the accuracy of vent-derived 
measurements.  Also consider the impact of 
added dead space without observable benefit.     
• Reword to make the principal idea to follow the 
specific ventilator recommendations on proximal 
flow sensor use.... in the absence of available 
recommendations, consider flow sensor use in 
small patients (insert limits).    
• We use proximal flow sensors for all patients 
less than 10 kg in both our ICUs (PICU and 
NICU)   
• we use proximal flow sensors on all our 
pediatric and neonatal patients 
• we use proximal flow sensors for up to 5kg 
babies i.e: up to 50mL tidal volumes 
10.5 Round 2:  
Avoid routine use of manual hand-
ventilation to minimize frequent circuit 
disconnects. If manual hand-ventilation 
is required, pressure manometers, 
pressure relief valves and PEEP valves 




Minimize routine use of manual 
ventilation to avoid circuit disconnects. 
Manual ventilation may be used to 
augment pulmonary hygiene as part of 
chest physiotherapy. Manual 
resuscitation devices should be capable 
of maintaining PEEP, limiting and 
monitoring pressures. 
• We try to avoid the use of manual hand-
ventilation especially when PEEP levels are 
higher but we occasionally use hand-ventilation 
to help take off the secretions in combination 
with respiratory physiotherapy 
• take out self-inflating or flow inflating bags, as 
PEEP valves are not used with flow inflating 
bags. Change it to read "if manual ventilation is 
required, a method of monitoring pressures, 
limiting excessive pressures and providing PEEP 
should be used with hand ventilation". 
• we use flow inflating bags with no pressure 
relief valves, and no PEEP valves. Agree that we 
should avoid routine hand ventilation. 
• We do "Open bag suction" osmose of our 
patients with bad secretion management. We 
also had started using "Flusso" valves before it 
went Backordered. 
• It is prudent to minimize circuit disconnection, 
but I would not go so far as to say "avoid" it. 
COVID precautions notwithstanding, manual 
ventilation is often necessary in pediatric 
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patients to assess compliance and for effective 
pulmonary toilet. 
• Avoid routine use "if patient condition allows".  
Some critically-ill patients will require routine 
manual ventilation to assist with secretion 
clearance or for post-suction re-recruitment. 
• Individual assessment may be required in order 
to optimize pulmonary hygiene 
• For patients requiring higher PEEP levels, we 
tend to clamp the ETT prior to disconnecting 
from the ventilator and reconnecting to the 
manual resuscitator in order not to de-recruit 
alveoli; flow-inflating bags are preferred to self-
inflating ones as they maintain PEEP better 
• Patients often suctioned, using cough assist or 
have frequent disconnect due to moves or 
transports get recruited post disconnect as 
tolerated 
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8.2 – Consent form 
 
 
Consent to Participate in a Research Study 
Participant Consent 
 
Study Title: The Pediatric Mechanical Ventilation in Canada (PeMViC) Study: A Delphi 
Survey of Pediatric Mechanical Ventilation Practices by Canadian Respiratory Therapists   
 
Shortened Title: A Survey of Pediatric Mechanical Ventilation Practices 
 
Principal Investigator:  
Mika L. Nonoyama, Registered Respiratory Therapist (RRT), PhD 
SickKids: Department of Respiratory Therapy, contact number 416-813-7654 x228064 
Ontario Tech University: Faculty of Health Sciences, contact number 905-721-8668 x5329 
 
Co-Principal Investigator:  
Shirley Quach, RRT, MHSc (c) 
SickKids: Department of Respiratory Therapy 
Ontario Tech University: Faculty of Health Sciences, contact number 416-720-6588 
 
Co-Investigator(s):  
Katherine Reise, RRT, MScCH (c) 
Department of Respiratory Therapy, Contact number 416-813-7654 x201530 
 
Efrosini Papaconstantinou, PhD, Registered Nurse 
Ontario Tech University: Faculty of Health Sciences, contact number 905-721-8668 x3736 
 
Carolyn McGregor, PhD 
Ontario Tech University: Faculty of Health Sciences, contact number 905-721-8668 x3697 
 
Research Contact: Shirley Quach, 416-720-6588 
 
Study Sponsor or Funder: Mika L. Nonoyama Ontario Tech University Research Funds 
  
Conflict of Interest: None of the study team members have a conflict of interest to declare 
 
Introduction 
We would like to invite you to take part in our research study. This consent form describes the research study 
and what it means to participate. This consent form may have words that you do not understand. Please ask 
the study staff to explain anything that you do not understand. Please take as much time as you need to think 
about your decision to participate or not, and ask any questions you have.  If it is helpful to you, you are 
encouraged to discuss the study with family, friends, other health professionals, or any members of your 
community that you trust. All participation is voluntary and you are not under any obligation to participate. 
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Why am I being asked to participate? 
You are being invited to participate in this study because you are a registered respiratory 
therapist in Canada, working in pediatric critical care for more than five years, and in a 
leadership position. 
 
Why is this study being done?  
The best way to provide and manage respiratory life support (mechanical ventilation [MV]) for 
children is not known. Treatment plans for MV can differ widely based on the child’s size, how 
they grow, and the illness they have. These plans also can vary based on the healthcare 
professional’s experience and opinion. In Europe, a group of medical experts have created a set 
of guiding principles for healthcare providers on children’s MV management. These guidelines 
are at times vague because the best way to provide care is often not described in previous 
research. In Canada, respiratory therapists (RTs) play a vital role in making decisions about a 
child’s MV treatment. The perspectives and experiences of RTs are not known, but can offer 
important information on the best way to manage children’s MV. 
 
This study is being done because we want to create Canadian guidelines for the management of 
MV in children, based on the perspectives and expertise of RTs who work with children. 
 
How long will the study take? 
Your participation in this study will be for 1.5 to 2 hours. You will be asked to complete 3 
surveys. Each survey is expected to take about 30 to 45 minutes. 
 
The overall study should take about 6 to 8 months (August 2020) to complete and the final 
results should be known in about 10 months (October 2020). 
 
How many participants will be in this study? 
This is a multi-centre study being done in various centres in Canada. It is anticipated that about 
45 people (RTs) will participate in this study throughout Canada. About three people (RTs) will 
participate in this study at SickKids. 
 
What will happen if I join this study? 
Your participation in this study will involve three surveys, about 30 to 45 minutes in length, with 
the option to leave the survey and complete it later. We may contact you to ask you to complete 
additional surveys depending on the responses received in the first three surveys. The overall 
study will take about 1.5 to 2 hours (with additional time added if you choose to complete 
additional surveys). 
 
We will use a survey method called the “Delphi Method” that aims to get a set of experts (like 
yourself) to agree on statements by the end of the surveys. There will be at least fifteen expert 
RTs in the study with at least five years’ experience working at a children’s critical care hospital 
in Canada. You will go through several rounds of questionnaires; your opinions will be collected 
and de-identified prior to analysis. The data will be summarized and sent back to the participant 
group with the next questionnaire. Each round aims to move the group closer to agreement on 
the statements, which will make up the guideline. We will consider agreement reached when at 
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least three-quarters or more of survey responses agree with each other, which is expected after 
three rounds. 
 
The surveys will be completed electronically on REDCap (a secure web application system). 
Hard copies of the survey can be provided if you prefer. The survey items for our Delphi survey 
will be based on this European MV treatment plan: 
Kneyber MCJ, de Luca D, Calderini E, et al. Recommendations for mechanical 
ventilation of critically ill children from the Paediatric Mechanical Ventilation Consensus 
Conference (PEMVECC). Intensive Care Med. Dec 2017;43(12):1764-1780. 
 
First survey round (R1): 
1. For R1, you will review and reflect on a shortened version of the European MV treatment 
plans based on their own personal practice and experiences. You will be asked to provide 
feedback in a maximum of 500 characters. Your feedback will be used to create a survey 
for the second round (R2). 
 
2. You will also be asked to complete a demographic questionnaire that includes 
descriptions of your personal characteristics (e.g. age, sex), individual practice (e.g. years 
of pediatric critical care experience), and practice location (e.g. number of beds for 
pediatric critical care). 
Second and third survey rounds (R2, R3) 
1. For R2 you will rate your agreement or disagreement on each survey item using a 5-point 
Likert scale: 1=strongly disagree, 2=disagree, 3=no opinion, 4=agree, 5=strongly agree. 
Results will be analyzed, and if consensus is reached, the study will be complete. If 
consensus is not reached, the survey items that did not reach consensus, will be 
reassessed and rephrased for the next round (R3). 
 
2. For R3 (if necessary) you will review and rate your agreement or disagreement with the 
same 5-point Likert scale used in R2. Results will be analyzed in the same way as R2. If 
consensus is not reached in R3 another round will be necessary. 
 
Please note for each round, a reminder email to complete the survey if a completed survey has 
been received in 8 days, again on Day 15, and again on day 20. 
 
Paper questionnaires are available upon request. If this is your preference, we will require your 
mailing address.  
 
Determining the Consensus 
Individual Survey Items. For each survey item, responses will be categorized into 3 groups: agree 
(score 4 or 5), no opinion (score 3) or disagree (score 1 or 2). We will consider consensus 
reached for a statement when ≥75% of expert participants’ responses fall within one of the three 
categorized groups. 
 
Overall Consensus. To consider consensus reached for the overall Delphi survey, ≥75% of all 
the survey items in the last round must reach consensus.  
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What are the risks, harms or discomforts of the study? 
We don’t know of any risks or harms associated with participating in this study. During the 
questionnaires and/or the interview, you may experience some anxiety, emotional and/or 
psychological distress due to the nature of the questions. You can skip questions, take a break or 
stop answering at any time. 
 
If your responses indicate that there is a serious risk of harm to yourself or others, confidentiality 
will be broken in order to protect you or another person. If we feel that you need urgent care as 
result of participating in this research study, we will intervene according to routine clinical care 
practices. 
 
There is an inconvenience of time. Each study visit will take about 30 to 45 minutes, for a total 
of 1.5 to 2 hours for the entire research study. If more survey rounds are necessary, this may be 
longer. You will have the option to leave the survey and complete it later. 
 
Despite protections being in place, there is a risk of unintentional release of information. Even 
though the risk of identifying you from the study data is very small, it can never be completely 
eliminated. 
 
Are there benefits from being in the study? 
There are no direct benefits to you for participating in this research study. However, we hope that 
the information learned from this study can be used in the future, to benefit future pediatric 
mechanical ventilation practices in Canada. 
 
Can I choose to leave the study? 
It is your choice to take part in this study, participation is voluntary. You can change your mind 
at any time during the research study. The study team may ask why you are withdrawing for 
reporting purposes, but you do not need to give a reason to withdraw from the study if you do not 
want to. Withdrawal from the study will not have any effect on your employment at your 
workplace. If you decide to leave the study, you can contact the Principal Investigator or a 
member of the study team to let them know. 
 
If you no longer want your study information to be used in this research you can request your 
data to be withdrawn and destroyed. Please note that any study data that has been included as 
part of the analysis or that has been shared cannot be withdrawn. 
 
Will I be paid and/or reimbursed if I join this study? 
To compensate for your time, you will be reimbursed with a $10 gift card (e.g. Amazon, 
Chapters, Starbucks, or Tim Horton’s) for each completed survey round. 
 
In recognition of your time, you will also be given a certificate of participation that includes 
number of volunteer hours, and 1.0 Canadian Society of Respiratory Therapists (CSRT) 
Continuing Education/Continuing Professional Development (CE/CPD) credits for each 
completed survey round. 
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How will my privacy be protected? 
We will respect your privacy. No information about you will be given to anyone or be published 
without your permission, unless the law requires us to do this. The Hospital for Sick Children, 
and Ontario Tech University are also committed to respecting your privacy.  
 
If you decide to participate in this study, the research team (study investigators, coordinators, 
nurses, and delegates) will collect personal information about you, including things learned from 
the study procedures. They will collect only the information they need for this study. The 
research team will also collect your information (e.g. name, phone number, and email) for the 
purposes of contacting you. This personal information will not be shared outside of the SickKids 
and Ontario Tech University research teams. “Personal information” is information about you 
that could identify you.  
 
All information collected about you will be “de-identified” by replacing your identifiable 
information (i.e., name) with a “study number”. Only the “study code key” can connect the 
information collected about you to your identity. The study code key will be safeguarded by the 
research team. Even though the risk of identifying you from the study data is very small, it can 
never be completely eliminated. 
 
The following people may look at your personal information to check that the information 
collected for the study is correct and to make sure the study followed the required laws and 
guidelines:  
• Representatives of the SickKids Research Ethics Board and/or Research Quality and 
Risk Management team 
• Representatives of the Ontario Tech University Research Ethics Board 
 
The research team will keep any personal health information about you in a secure and 
confidential location for seven years and then destroy it according to SickKids policy.  
 
How will I be informed about new information? 
We may learn new information during the study that you may need to know. We may also learn 
about things that might make you want to stop participating in the study. If this happens, you will 
be notified about any new information in a timely manner.  You may also be asked to sign a new 
consent form that describes these new findings if you decide to continue in the research study. 
 
What are my rights when participating in a research study? 
You have the right to receive all information that could help you make a decision about 
participating in this study. You also have the right to ask questions about this study at any time 
and to have them answered to your satisfaction. Your rights to privacy are legally protected by 
federal and provincial laws that require safeguards to ensure that your privacy is respected. 
 
By signing this form, you do not give up any of your legal rights against the study team, or 
involved institutions for compensation, nor does this form relieve the study team or their agents 
of their legal and professional responsibilities. 
 




Will I receive study results?  
Research results will be shared through academic conferences, journal publications, and health 
profession webinars. When the results of this study are shared, your identity will not be 
disclosed. You have the right to be informed of the results of this study once the entire study is 
complete.  
 
If you would like to be informed of the results of this study, please contact the study team. You 
will only be provided with overall study results (aggregate results from all participants). This 
means you will not know the results as they relate to you specifically. 
 
Who can I call if I have questions about the study? 
If you have any questions during your participation in this research study you can contact the 
Principal Investigator, Mika Nonoyama at 416-813-7654 x228064 or 905-721-8668 x5329; or 
the research team members listed at the beginning of this consent form. 
 
Research Ethics Board Contact Information 
The study protocol and consent form have been reviewed by the SickKids Research Ethics Board 
(REB). If you have any questions regarding your rights as a research participant, you may 
contact the SickKids Office of the Research Ethics Board at 416-813-8279, and/or the Ontario 
Tech Office of the Research Ethics Board at 905-721-8668 x3693 or by email, 
researchethics@uoit.ca during business hours. 
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Consent to Participate in a Research Study 
 
Study Title: The Pediatric Mechanical Ventilation in Canada (PeMViC) Study: A Delphi Survey 
of Pediatric Mechanical Ventilation Practices by Canadian Respiratory Therapists 
 
By signing this research consent form, I understand and confirm that: 
1. All of my questions have been answered, 
2. I understand the information within this informed consent form, 
3. I do not give up any of my legal rights by signing this consent form, 
4. I have been told I will be given a signed and dated copy of this consent form. 
5. I agree to take part in this study. 
 
I consent to participate in this study.  
     
 
                     
                 






Printed Name of person 
who obtained consent 
 Role of person 
obtaining consent 






8.3- Recruitment materials  
8.31- Recruitment poster 
 
Join our study on pediatric 
mechanical ventilation practices
Study title: The Pediatric 
Mechanical Ventilation in 
Canada (PeMViC) Study: 
A Delphi Survey of 
Pediatric Mechanical 















Are you a respiratory therapist (RT) 
working in pediatric critical care? 
Consider participating in our study:
What is the study about?
This study is being done because we want to 
create Canadian mechanical ventilation 
recommendations for all children, based on the 
expertise of experienced RTs.
Who can participate?
We are looking for registered RTs in Canada, 
working in pediatric critical care for more than 
five years, and in a leadership (or equivalent) 
position.
What’s involved?
Three online surveys, about 30 to 45 minutes 
each.
Are there benefits to participating?
There are no direct benefits to participants, but 
it may help future pediatric mechanical 
ventilation healthcare practices.
Participants will be given a gift certificate, 
participation certificate & 3.0 CSRT CE/CPD 
credits in recognition of their contribution.
This study has been reviewed by the University of 
Ontario Institute of Technology (Ontario Tech 
University) (#15636) and SickKids Research 










Dear [name of organization], 
We are requesting your assistance in distributing our advertisement to recruit participants for our 
study: The Pediatric Mechanical Ventilation in Canada (PeMViC) Study: A Delphi Survey 
of Pediatric Mechanical Ventilation Practices by Canadian Respiratory Therapists. The 
European Society of Pediatric and Neonatal Intensive Care (ESPNIC) outlined best pediatric 
mechanical ventilation (MV) management strategies (1). ESPNIC consisted of a European and 
physician-exclusive perspective but was the first to establish consensus recommendations on 
many aspects of pediatric MV management.  
 
Because Respiratory therapists (RRTs) do not exist in Europe, the recommendations published 
by ESPNIC may not represent Canadian pediatric MV practices. This study will help standardize 
Canadian pediatric MV management and facilitate future research to understand their clinical 
impact on patient outcomes. 
 
We have attached our recruitment poster in this message. If you would kindly distribute this to 
your Listserv, it will be greatly appreciated. 
 





Shirley Quach, RRT 






Mika Nonoyama, RRT, PhD 
Assistant professor, Ontario Tech U 
Mika.nonoyama@ontariotechu.net  
 
1. Kneyber MCJ, de Luca D, Calderini E, Jarreau P-H, Javouhey E, Lopez-Herce J, et al. 
Recommendations for mechanical ventilation of critically ill children from the Paediatric 









Subject line: Invitation to Participate in Research: Pediatric Mechanical Ventilation Survey 
 
Dear [participant’s name] 
 
We are a research team from the Respiratory Therapy Department at The Hospital for Sick Children 
(SickKids) and Ontario Tech University. You are invited to participate in our research study called “The 
Pediatric Mechanical Ventilation in Canada (PeMViC) Study: A Delphi Survey of Pediatric Mechanical 
Ventilation Practices by Canadian Respiratory Therapists.” 
 
Why am I being asked to participate? 
You are a candidate for this research because you are a respiratory therapist (RT) working in a pediatric 
critical care hospital, with over 5 years of clinical experience in Canada. The goal of the research study is to 
create Canadian guidelines for the management of mechanical ventilation in children, based on the 
perspective and expertise in RTs.  
 
Your contact information was obtained from [describe where/from whom contact information was obtained]. 
 
What will happen if I join this study? 
We will use a survey method called the “Delphi Method” that aims to get a set of experts (like yourself) to 
provide feedback on statements through a series of surveys. Your voluntary participation in this study will 
involve three surveys, about 30 to 45 minutes in length, with the option to leave the survey and complete it 
later. We may contact you to ask you to complete additional surveys depending on the responses received in 
the first three surveys. The overall study will take about 1.5 to 2 hours (with additional time added if you 
choose to complete additional surveys). 
 
Surveys will be distributed and completed online. If you prefer, we can provide you with a hard copy of the 
survey, and a pre-stamped return envelope.  
 
Your participation is voluntary, and you may opt to leave the study at any time. If you decide to participate, 
we will reimburse you for your time. You will receive a $10 gift card after you complete each survey. In 
addition, our study is approved by the Canadian Society of Respiratory Therapists (CSRT) for Continuing 
Education (CE) credits. The time spent on completing each survey is eligible for 1.0 CE credit, and the entire 
study is eligible for 3.0 CE credits.  
 
How can I find out more information? 
We are attaching the Participant Consent Form, which contains more details about the study. If you have 
questions, and/or would like to participate please reply to this email, or telephone any of the investigators 
below. Signed Participant Consent Forms can be emailed, completed verbally over the phone, or we can send 
you a pre-stamped return envelope to be mailed. 
 




If we have not heard from you in 7 business days, a research team member will get in touch with you again.  
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Thank you for your consideration in participating in our study. Your participation is crucial to us, and 




Principal Investigator:  
Mika L. Nonoyama, Registered Respiratory Therapist (RRT), PhD 
SickKids: Department of Respiratory Therapy, contact number 416-813-7654 x228064 
Ontario Tech University: Faculty of Health Sciences, contact number 905-721-8668 x5329 
 
Co-Principal Investigator:  
Shirley Quach, RRT, MHSc (c) 
SickKids: Department of Respiratory Therapy 
Ontario Tech University: Faculty of Health Sciences, contact number 416-720-6588 
 
Co-Investigator(s):  
Katherine Reise, RRT, MScCH (c) 
Department of Respiratory Therapy, Contact number 416-813-7654 x201530 
 
Efrosini Papaconstantinou, PhD, Registered Nurse 
Ontario Tech University: Faculty of Health Sciences, contact number 905-721-8668 x3736 
 
Carolyn McGregor, PhD 










Subject line: Pediatric Mechanical Ventilation Survey 
Dear [Participants name], 
Thank you for participating in this study titled “The Pediatric Mechanical Ventilation in Canada 
(PeMViC) Study: A Delphi Survey of Pediatric Mechanical Ventilation Practices by Canadian 
Respiratory Therapists”. 
Your participation is critical because we want to create Canadian mechanical ventilation 
guidelines for all children, based on the expertise of experienced respiratory therapists (RTs) like 
yourself. It involves completing two to three surveys, each about 45 to 60 minutes in length, with 
the option to leave the survey and complete it later.  
To compensate for your time, you will be reimbursed with a $10 gift card a certificate of 
participation that includes number of volunteer hours, and 1.0 Canadian Society of Respiratory 
Therapists (CSRT) CE/CPD credits for each completed survey round. 
Your participation is voluntary, and you may opt to leave the study at any time.  
In about a week, we will send you a friendly reminder email if you have not completed the 
survey. If you have any questions about the survey, or have any challenges before then please 
call or leave a message with Mika Nonoyama at 416-813-7654 x228064 or email 
mika.nonoyama@sickkids.ca or mika.nonoyama@ontariotechu.ca. 
As always, your responses are confidential, and only aggregate data will be reported. 
[Content for Round 1] 
For this first survey, we will ask you some questions on your individual practice (e.g. years of 
pediatric critical care experience), and practice location (e.g. number of beds for pediatric critical 
care). We will then ask you will review and reflect on a series of pediatric mechanical ventilation 
recommendations based on your own personal practice and experiences.  
Please complete the entire survey and submit your responses by clicking “submit” on the last 
page of the form. Remember you have the option to leave and complete it later. Here is the 
WebAccess-protected survey: REDCap URL. 
[Content for Subsequent Rounds 2, 3] 
For the second survey (R2/ R3), we ask you to rate your agreement or disagreement to an item. 
Please complete the entire survey and submit your responses by clicking “submit” on the last 
page of the form. Remember you have the option to leave and complete it later. Here is the 
WebAccess-protected R2 [R3 if necessary] survey: REDCap URL. 
 
Thank you very much for your help. 
The PeMViC Research team: Mika Nonoyama, Shirley Quach, Katie Reise, Efrosini 
Papaconstantinou, and Carolyn McGregor 
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SECOND EMAIL: sent to non-responders on Day 8 
 
Subject line: REMINDER 1: Pediatric Mechanical Ventilation Survey 
Dear [Participants name], 
About a week ago we sent you an email regarding your participation in the study titled “The 
Pediatric Mechanical Ventilation in Canada (PeMViC) Study: A Delphi Survey of Pediatric 
Mechanical Ventilation Practices by Canadian Respiratory Therapists”. We noticed you have 
not yet responded. Your response is greatly appreciated. We kindly ask that you fill out the 
survey at this time. Here is the WebAccess-protected survey: REDCap URL. 
As you recall this study is being done because we want to create Canadian mechanical 
ventilation guidelines for all children, based on the expertise of experienced respiratory 
therapists (RTs) like yourself. This study involves getting a group opinion by surveying experts, 
which is why we really need your response. It involves completing two to three surveys, about 
45 to 60 minutes in length each, with the option to leave the survey and complete it later. To 
compensate for your time, you will be reimbursed with a $10 gift card a certificate of 
participation that includes number of volunteer hours, and 1.0 CSRT CE/CPD credits for 
each completed survey round.. 
Your participation is voluntary, and you may opt to leave the study at any time.  
If you have any questions or wish to leave the study please call or leave a message with Mika 
Nonoyama at 416-813-7654 x228064 or email mika.nonoyama@sickkids.ca or 
mika.nonoyama@ontariotechu.ca. 
As always, your responses are confidential, and only aggregate data will be reported. 
[Content for Round 1] 
For this first survey, we will ask you some questions on your individual practice (e.g. years of 
pediatric critical care experience), and practice location (e.g. number of beds for pediatric critical 
care). We will then ask you will review and reflect on a series of pediatric mechanical ventilation 
recommendations based on your own personal practice and experiences.  
Please complete the entire survey and submit your responses by clicking “submit” on the last 
page of the form. Remember you have the option to leave and complete it later. Here is the 
WebAccess-protected R1 survey: REDCap URL. 
[Content for Subsequent Rounds] 
For the second survey (R2/ R3), we ask you to rate your agreement or disagreement to an item. 
Please complete the entire survey and submit your responses by clicking “submit” on the last 
page of the form. Remember you have the option to leave and complete it later. Here is the 
WebAccess-protected R2 [R3 if necessary] survey: REDCap URL. 
 
Thank you very much for your help. 
The PeMViC Research team: Mika Nonoyama, Shirley Quach, Katie Reise, Efrosini 





SECOND EMAIL: sent to partial responders on Day 8 
 
Subject line: REMINDER 1: Pediatric Mechanical Ventilation Survey 
Dear [Participants name], 
About a week ago we sent you an email regarding your participation in the study titled “The 
Pediatric Mechanical Ventilation in Canada (PeMViC) Study: A Delphi Survey of Pediatric 
Mechanical Ventilation Practices by Canadian Respiratory Therapists”. You started to fill in 
our survey, but we noticed that you have not finished. Would you please take the time to 
complete the rest of the survey? Your response is greatly appreciated. 
As you recall this study is being done because we want to create Canadian mechanical 
ventilation guidelines for all children, based on the expertise of experienced respiratory 
therapists (RTs) like yourself. To compensate for your time, you will be reimbursed with a 
$10 gift card a certificate of participation that includes number of volunteer hours, and 1.0 
CSRT CE/CPD credits for each completed survey round. 
Your participation is voluntary, and you may opt to leave the study at any time.  
If you have any questions or wish to leave the study please call or leave a message with Mika 
Nonoyama at 416-813-7654 x228064 or email mika.nonoyama@sickkids.ca or 
mika.nonoyama@ontariotechu.ca. 
As always, your responses are confidential, and only aggregate data will be reported. 
[Content for Round 1] 
By following the WebAccess-protected link [REDCap URL] you will return to the survey where 
you stopped. Please complete the entire survey and submit your responses by clicking “submit” 
on the last page of the form. You can always return to the survey where you stopped if you only 
have short periods of time to work at completing the survey.  
[Content for Subsequent Rounds. R2/R3] 
By following the WebAccess-protected link [REDCap URL] you will return to the survey where 
you stopped. Please complete the entire survey and submit your responses by clicking “submit” 
on the last page of the form.  
 
Thank you very much for your help. 
The PeMViC Research team: Mika Nonoyama, Shirley Quach, Katie Reise, Efrosini 





THIRD EMAIL: sent to non-responders on Day 15 
 
Subject line: REMINDER 2: Pediatric Mechanical Ventilation Survey 
Dear [Participants name], 
About a week ago we sent you an email regarding your participation in the study titled “The 
Pediatric Mechanical Ventilation in Canada (PeMViC) Study: A Delphi Survey of Pediatric 
Mechanical Ventilation Practices by Canadian Respiratory Therapists”. We noticed you have 
not yet responded. Your response is greatly appreciated. We kindly ask that you fill out the 
survey at this time. If it is easier to receive a paper copy of this survey, we will be happy to mail 
it to you, along with a postage-paid return envelope. 
As you recall this study is being done because we want to create Canadian mechanical 
ventilation guidelines for all children, based on the expertise of experienced respiratory 
therapists (RTs) like yourself. This study involves getting a group opinion by surveying experts. 
It involves completing two to three surveys, about 45 to 60 minutes in length each, with the 
option to leave the survey and complete it later.  To compensate for your time, you will be 
reimbursed with a $10 gift card a certificate of participation that includes number of 
volunteer hours, and 1.0 CSRT CE/CPD credits for each completed survey round. 
Your participation is voluntary, and you may opt to leave the study at any time.  
If you have any questions, wish to receive a paper copy of the survey, or wish to leave the study 
please call or leave a message with Mika Nonoyama at 416-813-7654 x228064 or email 
mika.nonoyama@sickkids.ca or mika.nonoyama@ontariotechu.ca. 
As always, your responses are confidential, and only aggregate data will be reported. 
[Content for Round 1] 
For this first survey, we will ask you some questions on your individual practice (e.g. years of 
pediatric critical care experience), and practice location (e.g. number of beds for pediatric critical 
care). We will then ask you will review and reflect on a series of pediatric mechanical ventilation 
recommendations based on your own personal practice and experiences.  
Please complete the entire survey and submit your responses by clicking “submit” on the last 
page of the form. Remember you have the option to leave and complete it later. Here is the 
WebAccess-protected R1 survey: REDCap URL. 
[Content for Subsequent Rounds] 
For the second survey (R2/ R3), we ask you to rate your agreement or disagreement to an item. 
Please complete the entire survey and submit your responses by clicking “submit” on the last 
page of the form. Remember you have the option to leave and complete it later. Here is the 
WebAccess-protected R2 [R3 if necessary] survey: REDCap URL. 
 
Thank you very much for your help. 
The PeMViC Research team: Mika Nonoyama, Shirley Quach, Katie Reise, Efrosini 




THIRD EMAIL: sent to partial responders on Day 15 
 
Subject line: REMINDER 2: Pediatric Mechanical Ventilation Survey 
Dear [Participants name], 
About a week ago we sent you an email regarding your participation in the study titled “The 
Pediatric Mechanical Ventilation in Canada (PeMViC) Study: A Delphi Survey of Pediatric 
Mechanical Ventilation Practices by Canadian Respiratory Therapists”. You started to fill in 
our survey, but you did not finish it. Would you please take the time to complete the rest of 
the survey? Your response is greatly appreciated. If it is easier to receive a paper copy of this 
survey, we will be happy to mail it to you (with your partial responses), along with a postage-
paid return envelope. 
As you recall this study is being done because we want to create Canadian mechanical 
ventilation guidelines for all children, based on the expertise of experienced respiratory 
therapists (RTs) like yourself. To compensate for your time, you will be reimbursed with a 
$10 gift card a certificate of participation that includes number of volunteer hours, and 1.0 
CSRT CE/CPD credits for each completed survey round. 
Your participation is voluntary, and you may opt to leave the study at any time.  
If you have any questions, wish to receive a paper copy of the survey, or wish the leave the 
study, please call or leave a message with Mika Nonoyama at 416-813-7654 x228064 or email 
mika.nonoyama@sickkids.ca or mika.nonoyama@ontariotechu.ca. 
As always, your responses are confidential, and only aggregate data will be reported. 
[Content for Round 1] 
By following the WebAccess-protected link [REDCap URL] you will return to the survey where 
you stopped. Please complete the entire survey and submit your responses by clicking “submit” 
on the last page of the form. You can always return to the survey where you stopped if you only 
have short periods of time to work at completing the survey.  
 [Content for Subsequent Rounds] 
By following the WebAccess-protected link [REDCap URL] you will return to the survey where 
you stopped. Please complete the entire survey and submit your responses by clicking “submit” 
on the last page of the form.  
 
Thank you very much for your help. 
The PeMViC Research team: Mika Nonoyama, Shirley Quach, Katie Reise, Efrosini 





FOURTH AND FINAL EMAIL: sent to non-responders on Day 20 
 
Subject line: FINAL REMINDER: Pediatric Mechanical Ventilation Survey 
Dear [Participants name], 
About a week ago we sent you an email regarding your participation in the study titled “The 
Pediatric Mechanical Ventilation in Canada (PeMViC) Study: A Delphi Survey of Pediatric 
Mechanical Ventilation Practices by Canadian Respiratory Therapists”. We noticed you have 
not yet responded. Your response is greatly appreciated. We kindly ask that you fill out the 
survey at this time. If it is easier to receive a paper copy of this survey, we will be happy to mail 
it to you, along with a postage-paid return envelope. 
As you recall this study is being done because we want to create Canadian mechanical 
ventilation guidelines for all children, based on the expertise of experienced respiratory 
therapists (RTs) like yourself. This study involves getting a group opinion by surveying experts. 
It involves completing two to three surveys, about 45 to 60 minutes in length each, with the 
option to leave the survey and complete it later. To compensate for your time, you will be 
reimbursed with a $10 gift card a certificate of participation that includes number of 
volunteer hours, and 1.0 CSRT CE/CPD credits for each completed survey round. 
Your participation is voluntary, and you may opt to leave the study at any time.  
If you have any questions,  wish to receive a paper copy of the survey, or wish to leave the study 
please call or leave a message with Mika Nonoyama at 416-813-7654 x228064 or email 
mika.nonoyama@sickkids.ca or mika.nonoyama@ontariotechu.ca. 
As always, your responses are confidential, and only aggregate data will be reported. 
 [Content for Round 1] 
For this first survey, we will ask you some questions on your individual practice (e.g. years of 
pediatric critical care experience), and practice location (e.g. number of beds for pediatric critical 
care). We will then ask you will review and reflect on a series of pediatric mechanical ventilation 
recommendations based on your own personal practice and experiences.  
Please complete the entire survey and submit your responses by clicking “submit” on the last 
page of the form. Remember you have the option to leave and complete it later. Here is the 
WebAccess-protected R1 survey: REDCap URL. 
[Content for Subsequent Rounds] 
For the second survey (R2/ R3), we ask you to rate your agreement or disagreement to an item. 
Please complete the entire survey and submit your responses by clicking “submit” on the last 
page of the form. Remember you have the option to leave and complete it later. Here is the 
WebAccess-protected R2 [R3 if necessary] survey: REDCap URL. 
 
Thank you very much for your help. 
The PeMViC Research team: Mika Nonoyama, Shirley Quach, Katie Reise, Efrosini 




FOURTH AND FINAL EMAIL: sent to partial responders on Day 
20 
 
Subject line: FINAL REMINDER: Pediatric Mechanical Ventilation Survey 
Dear [Participants name], 
About a week ago we sent you an email regarding your participation in the study titled “The 
Pediatric Mechanical Ventilation in Canada (PeMViC) Study: A Delphi Survey of Pediatric 
Mechanical Ventilation Practices by Canadian Respiratory Therapists”. You started to fill in 
our survey, but you did not finish it. Would you please take the time to complete the rest of 
the survey? Your response is greatly appreciated. If it is easier to receive a paper copy of this 
survey, we will be happy to mail it to you (with your partial responses), along with a postage-
paid return envelope. 
As you recall this study is being done because we want to create Canadian mechanical 
ventilation guidelines for all children, based on the expertise of experienced respiratory 
therapists (RTs) like yourself. This study involves something called a “Delphi Survey”, getting a 
group opinion or decision by surveying experts like yourself. It involves completing two to three 
“Rounds” of surveys, about 30 to 45 minutes in length each, with the option to leave the survey 
and complete it later. To compensate for your time, you will be reimbursed with a $10 gift 
card a certificate of participation that includes number of volunteer hours, and 1.0 CSRT 
CE/CPD credits for each completed survey round. 
Your participation is voluntary, and you may opt to leave the study at any time.  
If you have any questions before then, wish to receive a paper copy of the survey, or wish to 
leave the study please call or leave a message with Mika Nonoyama at 416-813-7654 x228064 or 
email mika.nonoyama@sickkids.ca or mika.nonoyama@ontariotechu.ca. 
As always, your responses are confidential, and only aggregate data will be reported. 
[Content for Round 1] 
For this first survey Round (R1) you reviewed and reflected on some of the European pediatric 
mechanical ventilation recommendations based on your own personal practice and experiences. 
For this session only, we also ask you to complete a demographic questionnaire that includes 
questions on your personal characteristics (e.g. age, gender), individual practice (e.g. years of 
pediatric critical care experience), and practice location (e.g. number of beds for pediatric critical 
care). 
By following the WebAccess-protected link [REDCap URL] you will return to the R1 survey 
where you stopped. Please complete the entire survey and submit your responses by clicking 
“submit” on the last page of the form. Remember you have the option to leave and complete it 
later. Here is the WebAccess-protected R2 [R3 if necessary] survey: REDCap URL. 
[Content for Subsequent Rounds] 
For the second survey (R2/ R3), we ask you to rate your agreement or disagreement to an item. 
By following the WebAccess-protected link [REDCap URL] you will return to the survey where 
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you stopped. Please complete the entire survey and submit your responses by clicking “submit” 
on the last page of the form. Remember you have the option to leave and complete it later. Here 
is the WebAccess-protected R2 [R3 if necessary] survey: REDCap URL. 
 
Thank you very much for your help. 
The PeMViC Research team: Mika Nonoyama, Shirley Quach, Katie Reise, Efrosini 
Papaconstantinou, and Carolyn McGregor 
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8.9 - Participation certificate 
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Pediatric Mechanical Ventilation in Canada (PeMViC) 
Summary: All Recommendations 
 
Thank you for taking the time to provide us with your feedback on all Rounds of the Delphi 
Survey. The following document describes all the finalized recommendations, percent rankings, 
and original feedback (if received) from participants.  
 
The rankings were categorized into 3 different groups: 
1. Strongly disagree (SD) + Disagree (D) 
2. Neutral 
3. Strongly agree (SA) + Agree (A) 
 
Consensus was achieved when any category 1, 2, or 3 achieved over 75% of responses. For all 
the statements, consensus was achieved in the “strongly agree + agree” category.  
 
The number of participants who selected “0 - No comment” is reported for each recommendation 
statement. “0 - No comment” was selected if a participant’s location of practice did not use/ 
practice a certain recommendation.  
 
A list of abbreviations is available at the end of the document.  
 
Original feedback from participants can be found at the end of the document. 
 
All the “patients” in this document are Pediatric patients. 
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Section 1: Non-invasive ventilation (NIV) Recommendations 
Non-invasive ventilation (NIV) refers to any positive pressure ventilation that is provided via a 
headgear, face mask or nasal interface. This includes CPAP or BiLevel non-invasive support e.g. 
NIV, spontaneous timed (ST), pressure control (PC), pressure support (PS), proportional assist 
ventilation (PAV), non-invasive neurally adjusted ventilatory assist (NIV-NAVA). 
 
1. Consider the use of NIV in patients with mild to moderate cardiorespiratory failure, if not 
responsive to or in combination with other medical management (e.g. inotropes, diuretics).  
 
2. Consider the use of NIV to reduce work of breathing and decrease afterload for patients with 
left ventricular failure, if not responsive to or in combination with other medical management 
(e.g. inotropes, diuretics).  
 
3. For patients on NIV, aim to use interfaces with minimal leak and appropriate for their size, 
age and skin integrity. Monitor leaks within an acceptable range to optimize patient comfort, 
compliance, patient ventilator synchrony, and to preserve patient trigger sensitivity.  
 
4. Optimize patient ventilator synchrony. This includes adjusting trigger sensitivity and 
optimizing mask seal in any triggered non-invasive ventilation mode (e.g. bilevel, S/T).  
 
4a. If available, specialty modes of NIV such as NIV-NAVA can be used to optimize 
patient-ventilator synchrony.  
 
5. High flow nasal cannula oxygen therapy (a form of oxygen therapy) is not a substitute for 
NIV. Consider the use of high flow nasal cannula oxygen therapy prior to NIV, to alleviate 
work of breathing. However, the use of high flow oxygen therapy should not delay or replace 
the use of NIV, if NIV is more appropriate.  
 
6. Consider the use of NIV prior to intubation, in patients with mixed diseases (decreased 
compliance and/or increased resistance), unless contraindicated. Common contraindications 
are decreased level of consciousness, impending respiratory failure/arrest, airway 
compromise, decreased respiratory drive, and poor skin integrity (e.g. burns, contusions). 
 
7. The use of HFNC and/or NIV should not delay inevitable intubation.  
 














1.1 0 0 0 4% 56% 40% 96% 
1.2 0 0 0 2% 44% 54% 98% 
1.3 0 0 0 2% 26% 72% 98% 
1.4 0 0 0 0 26% 74% 100% 
1.4a 12 0 2.5% 13% 44% 41% 85% 
1.5 0 0 6% 2% 41% 51% 92% 
1.6 0 0 4% 2% 36% 58% 94% 
1.7 0 0 0 0 24% 76% 100% 
* Participants are supposed to select 0 if their location of practice did not use/ practice a certain recommendation 
 262 
Section 2: Tidal Volume & Inspiratory Pressure Recommendations 
1. Aim to achieve a tidal volume in the physiologic range (5-8ml/kg ideal body weight) in 
patients <10kg. Alternatively, aim to achieve tidal volumes of 5-8ml/kg measured weight in 
patients ≤10kg.  
 
2. Aim to achieve tidal volume in the physiological range (5-8ml/kg ideal body weight) with 
minimal driving pressure (PIP-PEEP) in patients on pressure limited modes.  
 
3. Aim to limit inspiratory plateau pressure (Pplat) to approximately 30cmH2O, in the absence 
of transpulmonary pressure measurements. Limits should be between 28 to 32 cmH2O. 
 
4. If unable to achieve physiologic tidal volumes (5-8ml/kg) within plateau pressure limits 
(30cmH2O), targeting ranges outside these limits should be discussed with the 
interprofessional team. There may be circumstances where tidal volumes < 5mL/kg and 
>8ml/kg may be cautiously, but not routinely used. 
 














2.1 1 0 13% 6% 50% 31% 81% 
2.2 1 2% 2% 0% 55% 26% 96% 
2.3 0 0 2% 4% 67% 26% 93% 
2.4 4 0 0 2% 65% 33% 98% 
* Participants are supposed to select 0 if their location of practice did not use/ practice a certain recommendation 
 
Section 3: Respiratory Rate and Inspiratory Time Recommendations 
1. Set inspiratory time and respiratory rate based on the patient’s age, respiratory mechanics 
(including waveforms), and clinical data (e.g. blood gases, vital signs) in controlled 
ventilation modes. This will allow for full exhalation (acceptable I:E ratio), optimized patient 
synchrony and ventilation.  
 
2. Set the trigger setting and cycling setting on the ventilator to achieve the above goals 
(Recommendation 3.1) in all spontaneous ventilation modes.  
 
3. Increase the set respiratory rate when tidal volumes and/or PIP are reaching limits to 
maintain minute ventilation. Ensure there is sufficient expiratory time to avoid air-trapping.  
 














3.1 0 0 0 2% 32% 66% 98% 
3.2 0 0 0 2% 34% 64% 98% 
3.3 0 2% 4% 2% 44% 48% 92% 
* Participants are supposed to select 0 if their location of practice did not use/ practice a certain recommendation 
 
Section 4: PEEP and FiO2 Recommendations  
1. Set a minimum PEEP of 5-6cmH2O, to prevent alveolar collapse, in all patients.  
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2. Set PEEP to maintain end expiratory lung volume, and an optimal balance between 
hemodynamic stability and oxygenation, in all patients.  
 
3. Titrate PEEP incrementally while assessing lung compliance, oxygen saturation, 
hemodynamic stability and chest x-ray findings for patients with challenging oxygenation 
needs (e.g. PARDS).  
 
4. Higher levels of PEEP (>10cmH2O) may be required for adequate lung recruitment in 
patients with moderate to severe ARDS. 
 
5. Higher levels of PEEP (>10cmH2O) may be required to stabilize airways in patients with 
tracheomalacia and/or bronchomalacia.  
 
6. Titrate PEEP to allow for the lowest possible FiO2 (to maintain target oxygenation goals), 
while maintaining adequate hemodynamic status.  
 














4.1 0 4% 8% 2% 28% 58% 86% 
4.2 0 0 0 0 38% 62% 100% 
4.3 0 2% 0 2% 44% 52% 96% 
4.4 0 0 0 2% 36% 62% 98% 
4.5 0 0 2% 4% 48% 46% 94% 
4.6 0 4% 0 2% 44% 50% 94% 




Section 5: Advanced Mechanical Ventilation Recommendations 
All forms of advanced mechanical ventilation should only be used by trained and experienced 
practitioners. Availability of devices may vary across different institutions/units, reflecting when 
they are used.   
 
1. Consider the use of high frequency oscillatory ventilation (HFOV) in patients with restrictive 
or mixed diseases and severe oxygenation and/ or ventilation failure. 
 
2. Consider the use of HFOV in patients with cardiac issues and severe respiratory failure. 
Cautious use of increased mean airway pressure is advised in patients with passive 
pulmonary blood flow or right ventricular dysfunction. 
 
3. Consider the use of other advanced modes (such as HFJV or APRV) when conventional 
mechanical ventilation and/or HFOV has failed. Consider the unique benefits and/or 
limitations for each of these advanced modes. These advanced modes should not substitute or 
delay inevitable ECLS, if appropriate. 
 
4. Consider the use of other advanced ventilation modes/techniques (such as NAVA, PAV, or 
automated weaning) to optimize patient-ventilator interactions. The unique benefits and/or 
limitations for each of these advanced modes must be acknowledged. 
 
5. Consider the use of ECLS in patients with reversible diseases when conventional mechanical 
ventilation and/ or HFOV has failed, if available within the facility, and not contraindicated. 
Follow guidelines (e.g. ECLS organizations) for more specific criteria. Consider early 
consultation with an ECLS center when ECLS is not available within the facility. 














5.1 0 0 5% 5% 62% 29% 91% 
5.2 0 0 0 14% 50% 36% 86% 
5.3 16 0 5% 5% 62% 29% 90% 
5.4 4 0 5% 11% 59% 24% 84% 
5.5  3 0 2% 2% 47% 49% 96% 




Section 6: Weaning Recommendations  
 
1. Routinely assess all patients, with the aim to wean ventilator settings as early and often as 
possible.  
 
2. Use weaning principles guided by respiratory mechanics, pathologies and disease trajectory 
in patients with complex presentations (e.g. restrictive, obstructive, mixed or cardiac 
diseases). 
 
3. Consider pressure support ventilation when adequate respiratory drive is present and disease 
trajectory is improving. This allows the patient to breathe spontaneously to maximize 
comfort and avoid asynchrony/muscle atrophy.  
 
4. Routinely assess the pressure support level, rise time and sensitivity of flow cycling to 
maintain patient comfort/synchrony and physiologic tidal volumes (5-8ml/kg) in patients on 
pressure support ventilation.  
 
5. Routine daily assessment for weaning and extubation readiness should be performed in all 
patients.  
 














6.1 0 2% 0 2% 38% 58% 96% 
6.2 0 0 0 6% 48% 46% 94% 
6.3 0 0 2% 2%5 38% 58% 96% 
6.4 0 0 0 2% 42% 56% 98% 
6.5 0 0 4% 10% 34% 52% 86% 
* Participants are supposed to select 0 if their location of practice did not use/ practice a certain recommendation 
 
Section 7: Physiologic Target Recommendations 
1. Physiological targets should be guided by patient respiratory mechanics, and both respiratory 
and non-respiratory pathologies and disease trajectories.  
 
2. Target normal arterial CO2 levels for patients with healthy lungs (i.e. no respiratory disease). 
If arterial CO2 is not available, target normal venous and capillary CO2 levels. 
 
3. Permissive hypercapnia (pH ≥ 7.25) may be acceptable for acute patients, unless specific 
disease conditions dictate otherwise (e.g. pulmonary hypertension, traumatic brain injury). 
 
4. Target a SpO2 92-99% in patients with healthy lungs, in the absence of respiratory disease. If 
the patient is post-resuscitation, follow the Heart and Stroke PALS recommendations of 
SpO2 94-99%. 
 
5. Target SpO2 92-97% when PEEP is < 10cmH2O in patients who meet the PARDS criteria (as 
described in the PALICC guidelines).  
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6. Target SpO2 88-92% when PEEP is ≥10cmH2O in patients who meet the PARDS criteria (as 
described in the PALICC guidelines).  
 
7. Target SpO2 75-85% (or as recommended by the interprofessional collaborative team), for 
patients with cyanotic cardiac lesions (e.g. fixed Right to Left shunts). 
 














7.1 0 0 2% 4% 52% 42% 94% 
7.2 0 0 0 2% 52% 46% 98% 
7.3 0 0 0 2% 44% 54% 98% 
7.4 0 2% 6% 4% 42% 88% 88% 
7.5 1 0 8% 8% 51% 32% 84% 
7.6 0 2% 2% 10% 47% 39% 86% 
7.7 0 0 2% 4% 52% 42% 94% 
* Participants are supposed to select 0 if their location of practice did not use/ practice a certain recommendation 
 
Section 8: Monitoring Recommendations 
1. Use continuous SpO2 monitoring to assess oxygen saturation in all patients on invasive and 
non-invasive mechanical ventilation. 
 
2. Use CO2 monitoring (preferably end-tidal CO2) in all patients on invasive mechanical 
ventilation. 
 
3. Consider the use of transcutaneous CO2 in patients on advanced forms of mechanical 
ventilation, (e.g. HFOV, HFJV). These monitoring options should be frequently assessed for 
its correlation to the blood gases.  
 
4. Use arterial lines for accurate pH, PaO2, and lactate measurements, in moderate to severely 
ill patients on mechanical ventilation. 
 
5. Use central venous saturation (SvO2) and lactate measurements to assess oxygen extraction 
and/or cardiac output, in cardiac and/or severely ill patients on mechanical ventilation.  
 
6. Cautiously use peripheral venous PCO2 measurements to provide estimates and trends of 
ventilatory gas exchange, when arterial/ central lines are not available.  
 
7. Consider the use of capillary gases to assess gas exchange in mechanically ventilated patients 
with good perfusion and with mild diseases. They may be used to provide estimates or trends 
when arterial/central lines are not available.   
 
8. Use pH as a tool to modify the pulmonary vascular resistance for specific disease conditions, 
(e.g. pulmonary hypertension, single ventricle heart disease).  
 
9. Aim to maintain normal pH, PCO2  and PaO2 in pulmonary hypertension and traumatic brain 
injury. Consider targeting normal-high pH and normal-low CO2 values. 
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8.1 0 0 2% 0 22% 76% 98% 
8.2 0 0 4% 2% 45% 60% 94% 
8.3 0 0 0 16% 33% 51% 84% 
8.4 0 0 0 8% 28% 70% 98% 
8.5 0 0 0 8% 36% 56% 92% 
8.6 0 0 2% 8% 63% 27% 90% 
8.7 0 0 4% 4% 54% 42% 96% 
8.8 0 0 2% 10% 58% 30% 88% 
8.9 0 0 0 4% 52% 44% 96% 
* Participants are supposed to select 0 if their location of practice did not use/ practice a certain recommendation 
 
Section 9: Other General Recommendations 
1. Routinely assess patients to allow for spontaneous breathing, except for severely ill patients 
requiring intermittent neuromuscular blockade and sedation. 
 
2. Routinely monitor and assess the impacts of muscle relaxants and sedation on mechanical 
ventilation (respiratory rate, tidal volumes, minute ventilation) when they are in use for the 
patient’s clinical management.  
 
3. Routinely assess ventilator waveforms (e.g. flow volume loops, pressure volume loops) as 
they provide real-time data about patient-ventilator interactions such as breath-by-breath 
ventilation status, response to therapies, and lung mechanics.   
 
4. Use The Pediatric Acute Lung Injury Consensus Conference (2015) recommendations on nitric 
oxide, neuromuscular blockade, prone position and surfactant use, if safe to do so. 
 
5. Reduce the risk of Ventilator acquired pneumonia (VAP) by following the VAP bundles 
published by safety groups (e.g. Safer Healthcare Now!, Canadian Institute for Health Information, 
Solutions to Patient Safety). Elements include: 1) elevate the head of the bed 30-45 degrees 
(15-30 degrees in infants), unless specific disease or conditions dictate otherwise, 2) perform 
consistent oral hygiene, 3) minimize unnecessary circuit disconnects, and 4) perform daily 




6. Different Organization and Working Group guidelines and recommendations may be 
incorporated into practice and may include, but are not limited to: Pediatric Acute Lung Injury 
Care Conference (PALICC), National Heart, Lung, and Blood Institute (NHLBI) ARDS Network 
Protocol, Pediatric Advanced Life Support (PALS), Neonatal Resuscitation Program (NRP), 
Extracorporeal Life Support Organization (ELSO). 
 
7. Mechanical ventilation management and anticipated plans should be discussed as an 
interprofessional (IP) team at minimum on a daily basis. Any changes in the patients’ 
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trajectory or mechanical ventilation needs should be communicated between all members of 
the IP team.  
 














9.1 0 0 0 4% 48% 48% 96% 
9.2 0 0 4% 6% 48% 42% 90% 
9.3 0 0 0 2% 46% 52% 98% 
9.4 5 0 0 13% 49% 38% 87% 
9.5 0 0 0 0 46% 54% 100% 
9.6 0 0 0 12% 51% 37% 88% 
9.7 0 0 0 0 34% 65% 100% 
* Participants are supposed to select 0 if their location of practice did not use/ practice a certain recommendation 
 
Section 10: Equipment adjuncts recommendations 
1. Use dual-limb, heated, filtered circuits with active airway humidity for invasive mechanical 
ventilation.  
 
2. Use active airway humidification at 100% relative humidity at 37°C in patients on invasive 
mechanical ventilation. Use active airway humidification in the range of 31- 37°C, and titrate 
to avoid excessive rain out in the interface in patients on NIV. 
 
3. Minimize the use of apparatuses or connectors that add dead space to ventilator circuits, 
whenever possible. 
 
4. Do not routinely use proximal flow sensors, or follow the specific ventilator’s 
recommendations on proximal flow sensor use. In the absence of specific ventilator 
recommendations, use a proximal flow sensor for small tidal volumes (<10mL).  
 
5. Minimize routine use of manual ventilation to avoid circuit disconnects. Manual ventilation 
may be used to augment pulmonary hygiene as part of chest physiotherapy. Manual 


















10.1 0 0 0 2% 26% 72% 98% 
10.2 0 2% 4% 0 36% 58% 94% 
10.3 0 0 0 0 36% 64% 100% 
10.4 3 0 11% 4% 67% 18% 97% 
10.5 0 0 2% 4% 53% 41% 84% 




List of abbreviations 
 
APRV  Airway Pressure Release Ventilation 
CO2  carbon dioxide  
ECLS  Extracorporeal Life Support 
ECMO  Extracorporeal membrane oxygenation  
FiO2  Fraction of inspired oxygen 
HFJV  High frequency jet ventilation 
HFNC  High flow nasal cannula 
HFJV  High frequency jet ventilation  
HFOV  High frequency oscillation ventilation 
IBW  Ideal body weight  
NAVA  Neurally adjusted ventilatory assist 
NIV-NAVA Non-invasive neurally ventilatory assist 
PaO2  Arterial partial pressure of oxygenation  
PALICC Pediatric Acute Lung injury Consensus conference 
PALS  Pediatric Advanced Life Support 
PARDS Pediatric acute respiratory distress syndrome 
PAV  Proportional Assist ventilation 
PCO2  Partial pressure of carbon dioxide 
PEEP  Positive end expiratory pressure  
PICU  Pediatric intensive care unit 
PIP  Peak inspiratory pressure 
Pplat  Plateau pressure 
PSV  Pressure support ventilation  
SpO2  oxygen saturation   
SvO2  Venous saturation  
VAP  Ventilator acquired pneumonia  
WOB  Work of breathing 
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OPEN TEXT FEEDBACK FOR ROUND 2-3 
*The following are free text responses from participants and were not revised 
Section 1: Non-invasive ventilation (NIV) Recommendations 
Recommendation 1.4 (all Rounds) 
• dual limb NIV with full face mask is used as the approach prior to intubation. NAVA recently 
discontinued at our facility due to poor success rate  
• NIV NAVA should not simply be used "if available" - this will lead to the unnecessary 
introduction of an invasive catheter (not to mention increased cost of equipment).  NIV NAVA 
should primarily be used "if required" to correct insufficient patient-vent synchrony. 
Recommendation 1.5, 1.6, 1.7 
• This [NIV] should not be a "first approach" - other approaches such as medications or HFNC 
should be considered first.  NIV should only be considered as a "second approach" should these 
more basic interventions fail 
• If you need to start NIV for cardiac or obstructive reasons such as an asthma attack, then don't 
waste time with HFNC 
• I don't feel all patients should try HFNC prior to NIV.  Consider, yes. But if not appropriate, move 
right to NIV. 
• HFNC should not be tried in patients when NIV has been proven effective in patients with certain 
sicknesses or disease processes. It just delays treatment 
• For certain cases, prioritizing the use of HFNC before NIV is not appropriate, like bronchiolitis on 
small babies: a lot of secretions is not compatible with HFNC, NIV is more comfortable for them 
and more effective treatment. 
• Simply because patient has increased WOB, should not try HFNC simply because.  Should assess 
work of breathing and reason causing it.  If patient requires more support like pressure due to 
cardiopulmonary effects then NIV should be started verses increase in oxygen needs and work of 
breathing due to common respiratory infection.    
• There may be some role in early respiratory failure as dead space washout effects may reduce 
PCO2; this is not the same as ventilation and they should not be confused!  Similarly, it is not 
CPAP as the pressure is not constant! The system provides positive pressure primarily on 
expiration. 
• HFNC can be used initially as a substitute to NIV depending on how severe the WOB/CO2 
retention. Often you will find the HFNC alone will reduce CO2 levels sufficiently, especially in 
smaller children. 
• I strongly agree that HFNC is not a substitute for NIV. And while yes, one should CONSIDER 
HFNC before NIV, I don't believe that one should automatically try it based on the fact that it a) is 
not a substitute, and b) should not delay or replace NIV if that is more appropriate. 
• some studies show that HFNC can be used as an alternative to NIV and that there is no statistical 
difference in intubation rates between the two. The tolerance of HFNC in the pediatric population 
tends to be much greater compared to NIV via facemask. This is also difficult to use a generalized 
statement for because the age range of pediatrics is very large, and the specific patient and situation 
can also be a factor to consider what the patient may tolerate better. 
• There are currently indications to provide HFNC prior to intubation, and immediately post op, post 
extubation in lieu of low flow. I agree it should not delay or replace NIV IF NIV is more 
appropriate 
• For such things as pulmonary edema OR pleural effusions, or anything you want some PEEP to be 
applied HFNC is not appropriate. But HFNC may be used for tachypnea or work of breathing. 
• HFNC and NIV are not interchangeable, and their application is suitable for different reasons. 
Section 2: Tidal Volume & Inspiratory Pressure Recommendations 
Recommendation 2.1 (all Rounds) 
 271 
• The ped patients we use IBW are usually school age and up. 
• "Measured weight" may be inappropriate if the patient is greatly fluid overloaded.    
• We use measured weight until the patients are in teenage years or severely overweight then we 
convert to IBW. For patients less than 20 kg, for sure, we use actual measured weight. 
• Certain medical conditions (ie. CDH) may experience volutrauma if a global volume target of 5-
8ml/kg is used.  Perhaps some caveat regarding "anatomically or functionally normal lungs" should 
be included.   
• For post cardiac surgeries (excluding PDA ligation), our approach is 7-9 ml/kg with a lower 
respiratory rate and longer i-time to optimize venous return to the heart; this is done in our PICU 
patients   
Recommendation 2.2, 2.3, and 2.4 (All Rounds) 
• I agree with statement but disagree that delta pressure is PIP-PEEP.  I think this is better 
represented as Pplat- PEEP, whenever Pplat can be obtained. 
• Targeting Vt as low as 4ml/kg seems reasonable.  Goals to limit Pplats to <25 cmH2O as much as 
possible seems reasonable, and default to a lower Vt rather than accepting higher Pplats, depending 
on pathophysiology. 
• PPlat <28 cmH2O as goal, allowable up to <32 cmH2O given specific poor compliance patient 
conditions 
• I agree that the Pplat should be limited to less than 30 cmH2O unless you have measurements that 
you can follow to provide safe ventilation, electrical impedence tomography (EIT) can be used as 
well.  There are patients where maintaining low Pplats is not possible.  I would like to see it as 
'attempt to limit' or something like that.  And the driving pressure is what will be important, rather 
than just a Pplat.  
• In my opinion I think the part about "site specific limits..." is a bit confusing.  I would suggest 
instead of writing specific targets for specific sites that it could just read specific sites may have 
variability in targets however should be around 30 cmH20. 
• Goals to limit Pplats to <25 cmH2o as much as possible seems reasonable, and default to a lower 
Vt rather than accepting higher Pplats, depending on pathophysiology. 
• I would be more comfortable with stating "appropriate Vt” rather than a specific number. 
 
Section 3: Respiratory Rate and Inspiratory Time Recommendations 
Recommendation 3.3 (Round 2) 
• to optimize alveolar ventilation, there is a physical limit to how high the rate can be - irrespective 
of the I:E ratio. A rate of 60 breaths/minute cannot allow for laminar flow and alveolar gas 
exchange.  At this point a small increase in Vt, is indicated.   (the exception may be for patients 
with congenital diaphragmatic hernia, as it is imperative to use a lung protective strategy).    
• To maintain minute volume, increase the set respiratory rate when Vt ARE LOW and when Pplat is 
approaching limit (<30 cmH2O) - to related to previous statements; OR if Vt are within range yet 
(PCO2) needs to be lower, or pH higher 
 
Section 4: PEEP and FiO2 Recommendations  
Recommendation 4.1 (Round 2) 
• Peep levels of 5-6cmH20 are used in most instances except cardiac pts (who may need lower) and 
the other cases mentioned in the further questions (ARDS, bronchomalacia).  
• there will always be a singular case where PEEP is contraindicated; perhaps it is a status 
asthmaticus scenario, or some other type of obstructive process. or extreme hemodynamic 
instability. If the statement was that the goal should be to prevent alveolar collapse in all ventilated 
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patients this is more general and encompassing. I do not think religious application of PEEP to all 
pediatric patients regardless of disease process is a good idea 
• Post op Glen and Fontan will have PEEP of 4cmH2O usually. 
• A min PEEP of 5-6 cmH2O in not to prevent collapse but to maintain an appropriate FRC 
• We have set PEEP at 4 (or even 3 cmH2O) on rare occasions where RV failure is a consideration, 
with good effect.   
Recommendation 4.3 (Round 2) 
• The use of oxygenation is not a good parameter to set PEEP, setting PEEP using oxygenation can 
cause significant regional over distension. Mechanics such as Compliance or driving pressure are 
more appropriate. Also, if assessing Vt with PEEP changes you are assuming a pressure mode of 
ventilation. Compliance would be a better parameter or also include driving pressure. 
Recommendation 4.5 (Round 2) 
• an ENT consultation with flexible laryngoscopy is typically utilized to determine the optimal PEEP 
needed to stabilize airways in pediatric patients with moderate-to-severe tracheomalacia and/or 
bronchomalacia.   
Recommendation 4.6 (Round 2) 
• PEEP should not be set/targeted based upon oxygenation alone. 
• The goal should not be to achieve the "lowest possible FiO2", regardless of PEEP.  FiO2 of 0.21 
and PEEP of 15, for example, would not be an appropriate way of maintaining target O2 saturation 
(spO2). 
 
Section 5: Advanced Mechanical Ventilation Recommendations 
Recommendation 5.1 (All Rounds) 
• APRV is prohibited for use by RTs as agreed by the intensivists' team at the [name removed] PICU 
due to lack of evidence 
Recommendation 5.3 (all Rounds) 
• Advanced therapies such as JET and HFO may be beneficial if used as a protective strategy on 
certain pts versus being used as a rescue therapies. 
• APRV is available but prohibited to use as agreed by the PICU physician team due to the lack of 
pediatric evidence.  PAV is not available therefore not practiced 
• NAVA was previously trialed but not found effective therefore being phased out. PAV is not 
available to use in the [name removed] PICU 
• We currently don't use NAVA or PAV. (Have used NAVA in the, past, but not consistently or 
well. Will likely use PAV with our incoming fleet of new vents.) 
• NAVA was previously used but often inappropriately (didn't meet indications or not ideal 
candidate etc) or used off recommendation (indicators and reading interpreted but not used for 
weaning or escalation of care due to various MRP reasoning) and as result is no longer available at 
our center 
Recommendation 5.4 (All Rounds) 
• Perhaps there should be a recommendation/statement regarding early consultation to a higher level 
of care for sites that do not have advanced therapies such as HFOV, jet ventilation, novalung, 
ECMO etc., available... in order to ensure earlier and safer transports for these patients?   
• I would rewrite to read "Strongly consider ECLS such as extracorporeal membrane oxygenation 
(ECMO)".  Remove NovaLung as this is a brand name of a device and the pediatric use of this 
device is very limited.  In its truest configuration (femoral artery to femoral vein) as the device was 
intended, would not be able to be used in patients less than 20-30 kg as would be unable to 
generate sufficient driving pressure to prevent clotting of the device over time.  The most common 
approach for supporting these patients would be VV ECMO if they were large enough for double 
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lumen cannula or two site VV ECMO.  If they are small infants, the approach is VA ECMO.  There 
is still small usage of NovaLung device for bridge to lung transplant pediatric patients > 20 kg with 
pulmonary hyptertension who are centrally cannulated from PA to LA as a means to offload right 
heart to prevent RV failure.  However this is a very specific subset of pediatric patients with a 
specific respiratory disease.    Otherwise agree with rest of statement. 
• Consider the use of iNO in the instances where patient has oxygenation, PHTN or RV dysfunction 
prior to considering ECLS. 
 
Section 6: Weaning Recommendations  
Recommendation 6.3 
• it does not appear to be clear how long one can leave a patient breathing on PSV who is not ready 
for extubation; in my practice, patients with minimal WOB and otherwise good indicators of gas 
exchange may stay on PSV as long as they're tolerating it, with a minimal delta P to compensate 
for ETT resistance (ie 5-10 cmH2O) 
• Important to know what their drive is, but I typically would not leave a patient on PS ventilation 
for days on end as they recover, unless I am unable to achieve good synchrony and comfort in 
other modes. 
 
Section 7: Physiologic Target Recommendations 
Recommendation 7.4, 7.5, and 7.6 (Round 2) 
• We should not target an SpO2 of 99%, unless on room air [healthy lungs]. I don't know if the 
statement is referring to a non-intubated patient, invasively or non.  As it reads, it could include 
patients ventilated for other reasons than respiratory disease (post op).   
• PALs Post-rosc guidelines state SpO2 94-99%. 
• should just state >or = 92% if on room air and minimum PEEP and spo2 can be 100% [healthy 
lungs] 
• I don't like mixing PEEP value with oxygenation definitely.  Depending on body habitus of the 
patient, we could be using higher PEEPs regardless of ARDS status.  We should treat the 
patients as individuals.  For a patient with a BMI near ideal, I agree with the statement, but not 
for all patients. 
• We tolerate 88%-92% if ABG and lactate are stable [even with PEEP <10cmH2O] 
• SpO2 targets in ARDS should not be based upon PEEP alone. PEEP setting alone will not 
identify the severity of their ARDS nor their arterial content requirements. For example, obese 
or morbidly obese patients may require a PEEP >10 to maintain EELV but this doesn't indicate 
the severity of the patient's lung pathology or ability to safely oxygenate. 
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Section 8: Monitoring Recommendations 
Recommendation 8.2 (Round 2) 
• preferably inline CO2 monitoring, preferably through the vent so volumetric data is available.   
• ETCO2 would be inappropriate for a patient ventilated using HFO. 
Recommendation 8.6 (Round 2) 
• Use capillary blood gas tests when arterial/central lines are not available. Capillary should be a first 
line test versus venous. 
Recommendation 8.8 (round 2) 
• We also aim for adequate oxygenation, and use iNO. By omitting these other principles, it is a bit 
misleading 
 
Section 9: Other General Recommendations 
Recommendation 9.1 (Round 2) 
• I would not only assess but encourage. Perhaps a statement to include the concept of: "when 
patients are heavily sedated and not breathing (without reason), discuss with the interprofessional 
team to decrease sedatives safely."  
Recommendation 9.2 
• wouldn't routinely give NMB to assess how it affects the other variables, unless indicated.  
However I would assess if NMB is continuing to be beneficial to the patient if being used 
routinely.  
Recommendation 9.7 
• I agree with the statement, other than the entire IP team.  Physio, pharmacy, dietary staff, social 
work and others, generally do not need to be included in discussions on mechanical ventilation, just 




Section 10: Equipment adjuncts recommendations 
Recommendation 10.2 (Round 2) 
• Reword to say, for patients on NIV, provide active airway humidification in the range of 31-37C, 
titrated to avoid excessive rainout in the interface.  
• Addendum - we routinely use 37°C for our HFNC patients as well. 
• For the majority of NIV patients at [name removed], the humidifier is kept at 37 degrees C to 
optimize gas humidification.  Rain out has not been found to be an issue in most cases. 
Recommendation 10.4 (All Rounds) 
• proximal flow sensors are of limited utility in larger Vts, in our practice we're using proximal flow 
for kids 4kg and less who would correspond (at 5mL/kg) to tidal volumes of 20mL and less. 
• Not all proximal flow is created equal obviously and some ventilators will have bias against the 
proximal flow sensor to compensate for this. The technology used for proximal flow affects how 
much I trust it as well; heated wire anemometers appear to be far more accurate in my experience 
than pressure differential flow sensors. 
• "Consider" use of a proximal flow sensor.  It may not be required unless there is concern about the 
accuracy of vent-derived measurements.  Also consider the impact of added dead space without 
observable benefit.     
• Reword to make the principal idea to follow the specific ventilator recommendations on proximal 
flow sensor use.... in the absence of available recommendations, consider flow sensor use in small 
patients (insert limits).    
• We use proximal flow sensors for all patients less than 10 kg in both our ICUs (PICU and NICU)   
• we use proximal flow sensors on all our pediatric and neonatal patients 
• we use proximal flow sensors for up tp 5kg babies i.e: up to 50mL tidal volumes 
Recommendation 10.5 (All Rounds) 
• We try to avoid the use of manual hand-ventilation especially when PEEP levels are higher but we 
occasionally use hand-ventilation to help take off the secretions in combination with respiratory 
physiotherapy 
• take out self-inflating or flow inflating bags, as PEEP valves are not used with flow inflating bags. 
Change it to read "if manual ventilation is required, a method of monitoring pressures, limiting 
excessive pressures and providing PEEP should be used with hand ventilation". 
• we use flow inflating bags with no pressure relief valves, and no PEEP valves. Agree that we 
should avoid routine hand ventilation. 
• We do "Open bag suction" osmose of our patients with bad secretion management. We also had 
started using "Flusso" valves before it went Backordered. 
• It is prudent to minimize circuit disconnection, but I would not go so far as to say "avoid" it. 
COVID precautions notwithstanding, manual ventilation is often necessary in pediatric patients to 
assess compliance and for effective pulmonary toilet. 
• Avoid routine use "if patient condition allows". Some critically-ill patients will require routine 
manual ventilation to assist with secretion clearance or for post-suction re-recruitment. 
• Individual assessment may be required in order to optimize pulmonary hygiene 
• For patients requiring higher PEEP levels, we tend to clamp the ETT prior to disconnecting from 
the ventilator and reconnecting to the manual resuscitator in order not to de-recruit alveoli; flow-
inflating bags are preferred to self-inflating ones as they maintain PEEP better 
• Patients often suctioned, using cough assist or have frequent disconnect due to moves or transports 
get recruited post disconnect as tolerated 
 
 
 
